0001428336-21-000035.txt : 20210909 0001428336-21-000035.hdr.sgml : 20210909 20210909160301 ACCESSION NUMBER: 0001428336-21-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20210731 FILED AS OF DATE: 20210909 DATE AS OF CHANGE: 20210909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 211244426 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 10-Q 1 hqy-20210731.htm 10-Q hqy-20210731
00014283361/312022Q2FALSE00014283362021-02-012021-07-31xbrli:shares00014283362021-08-31iso4217:USD00014283362021-07-3100014283362021-01-31iso4217:USDxbrli:shares0001428336us-gaap:ServiceMember2021-05-012021-07-310001428336us-gaap:ServiceMember2020-05-012020-07-310001428336us-gaap:ServiceMember2021-02-012021-07-310001428336us-gaap:ServiceMember2020-02-012020-07-310001428336us-gaap:FinancialServiceOtherMember2021-05-012021-07-310001428336us-gaap:FinancialServiceOtherMember2020-05-012020-07-310001428336us-gaap:FinancialServiceOtherMember2021-02-012021-07-310001428336us-gaap:FinancialServiceOtherMember2020-02-012020-07-310001428336us-gaap:CreditAndDebitCardMember2021-05-012021-07-310001428336us-gaap:CreditAndDebitCardMember2020-05-012020-07-310001428336us-gaap:CreditAndDebitCardMember2021-02-012021-07-310001428336us-gaap:CreditAndDebitCardMember2020-02-012020-07-3100014283362021-05-012021-07-3100014283362020-05-012020-07-3100014283362020-02-012020-07-3100014283362021-04-3000014283362020-04-3000014283362020-01-310001428336us-gaap:CommonStockMember2021-04-300001428336us-gaap:CommonStockMember2020-04-300001428336us-gaap:CommonStockMember2021-01-310001428336us-gaap:CommonStockMember2020-01-310001428336us-gaap:CommonStockMember2020-02-012020-07-310001428336us-gaap:CommonStockMember2020-05-012020-07-310001428336us-gaap:CommonStockMember2021-07-310001428336us-gaap:CommonStockMember2020-07-310001428336us-gaap:AdditionalPaidInCapitalMember2021-04-300001428336us-gaap:AdditionalPaidInCapitalMember2020-04-300001428336us-gaap:AdditionalPaidInCapitalMember2021-01-310001428336us-gaap:AdditionalPaidInCapitalMember2020-01-310001428336us-gaap:AdditionalPaidInCapitalMember2021-05-012021-07-310001428336us-gaap:AdditionalPaidInCapitalMember2020-05-012020-07-310001428336us-gaap:AdditionalPaidInCapitalMember2021-02-012021-07-310001428336us-gaap:AdditionalPaidInCapitalMember2020-02-012020-07-310001428336us-gaap:AdditionalPaidInCapitalMember2021-07-310001428336us-gaap:AdditionalPaidInCapitalMember2020-07-310001428336us-gaap:RetainedEarningsMember2021-04-300001428336us-gaap:RetainedEarningsMember2020-04-300001428336us-gaap:RetainedEarningsMember2021-01-310001428336us-gaap:RetainedEarningsMember2020-01-310001428336us-gaap:RetainedEarningsMember2021-05-012021-07-310001428336us-gaap:RetainedEarningsMember2020-05-012020-07-310001428336us-gaap:RetainedEarningsMember2021-02-012021-07-310001428336us-gaap:RetainedEarningsMember2020-02-012020-07-310001428336us-gaap:RetainedEarningsMember2021-07-310001428336us-gaap:RetainedEarningsMember2020-07-3100014283362020-07-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2021-02-012021-07-310001428336us-gaap:ComputerSoftwareIntangibleAssetMember2020-02-012020-07-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-02-012021-07-310001428336hqy:AcquiredHSAIntangibleAssetsMember2020-02-012020-07-310001428336hqy:FollowOnEquityOfferingMember2021-02-012021-04-300001428336hqy:FollowOnEquityOfferingMember2021-04-300001428336hqy:LuumAcquisitionMember2021-03-082021-03-08xbrli:pure0001428336hqy:LuumAcquisitionMember2021-03-080001428336srt:MaximumMemberhqy:LuumAcquisitionMember2021-03-080001428336hqy:LuumAcquisitionMember2021-07-310001428336us-gaap:CustomerRelationshipsMemberhqy:LuumAcquisitionMember2021-03-082021-03-080001428336us-gaap:DevelopedTechnologyRightsMemberhqy:LuumAcquisitionMember2021-03-082021-03-080001428336us-gaap:TrademarksAndTradeNamesMemberhqy:LuumAcquisitionMember2021-03-082021-03-080001428336us-gaap:LeaseholdImprovementsMember2021-07-310001428336us-gaap:LeaseholdImprovementsMember2021-01-310001428336us-gaap:FurnitureAndFixturesMember2021-07-310001428336us-gaap:FurnitureAndFixturesMember2021-01-310001428336us-gaap:ComputerEquipmentMember2021-07-310001428336us-gaap:ComputerEquipmentMember2021-01-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-07-310001428336us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2021-01-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-07-310001428336hqy:AcquiredHSAIntangibleAssetsMember2021-01-310001428336us-gaap:CustomerRelationshipsMember2021-07-310001428336us-gaap:CustomerRelationshipsMember2021-01-310001428336us-gaap:DevelopedTechnologyRightsMember2021-07-310001428336us-gaap:DevelopedTechnologyRightsMember2021-01-310001428336us-gaap:TradeNamesMember2021-07-310001428336us-gaap:TradeNamesMember2021-01-310001428336hqy:FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember2021-04-012021-04-30hqy:hsaMember0001428336hqy:FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember2021-04-300001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember2021-04-012021-04-300001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember2021-04-300001428336hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMemberus-gaap:SubsequentEventMember2021-09-092021-09-0900014283362021-04-012021-04-300001428336hqy:WageWorksInc.Member2021-07-310001428336hqy:WageWorksInsurersMember2021-07-31hqy:lawsuit00014283362018-09-062018-09-0600014283362018-06-222018-06-220001428336hqy:TermLoanFacilityMember2021-07-310001428336hqy:TermLoanFacilityMember2021-01-310001428336us-gaap:RevolvingCreditFacilityMember2021-07-310001428336us-gaap:RevolvingCreditFacilityMember2021-01-310001428336hqy:TermLoanFacilityMemberus-gaap:SecuredDebtMemberhqy:CreditAgreementMember2021-02-012021-07-310001428336hqy:TermLoanFacilityMemberus-gaap:SecuredDebtMemberhqy:CreditAgreementMember2021-07-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-02-012021-07-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-07-310001428336srt:MinimumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-02-012021-07-310001428336srt:MaximumMemberus-gaap:LondonInterbankOfferedRateLIBORMember2021-02-012021-07-310001428336srt:MinimumMemberus-gaap:BaseRateMember2021-02-012021-07-310001428336srt:MaximumMemberus-gaap:BaseRateMember2021-02-012021-07-310001428336hqy:CreditAgreementMemberus-gaap:LineOfCreditMember2021-07-310001428336srt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2021-02-012021-07-310001428336srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2021-02-012021-07-310001428336hqy:DebtCovenantPeriodTwoMember2021-07-310001428336hqy:DebtCovenantPeriodFourMember2021-07-310001428336us-gaap:CostOfSalesMember2021-05-012021-07-310001428336us-gaap:CostOfSalesMember2020-05-012020-07-310001428336us-gaap:CostOfSalesMember2021-02-012021-07-310001428336us-gaap:CostOfSalesMember2020-02-012020-07-310001428336hqy:SalesandMarketingMember2021-05-012021-07-310001428336hqy:SalesandMarketingMember2020-05-012020-07-310001428336hqy:SalesandMarketingMember2021-02-012021-07-310001428336hqy:SalesandMarketingMember2020-02-012020-07-310001428336hqy:TechnologyandDevelopmentMember2021-05-012021-07-310001428336hqy:TechnologyandDevelopmentMember2020-05-012020-07-310001428336hqy:TechnologyandDevelopmentMember2021-02-012021-07-310001428336hqy:TechnologyandDevelopmentMember2020-02-012020-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2021-05-012021-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2020-05-012020-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2021-02-012021-07-310001428336us-gaap:GeneralAndAdministrativeExpenseMember2020-02-012020-07-310001428336us-gaap:OtherExpenseMember2021-05-012021-07-310001428336us-gaap:OtherExpenseMember2020-05-012020-07-310001428336us-gaap:OtherExpenseMember2021-02-012021-07-310001428336us-gaap:OtherExpenseMember2020-02-012020-07-310001428336hqy:IncentivePlanMember2021-07-3100014283362020-02-012021-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2021-01-310001428336us-gaap:RestrictedStockMember2021-01-310001428336us-gaap:RestrictedStockUnitsRSUMember2021-02-012021-07-310001428336us-gaap:RestrictedStockMember2021-02-012021-07-310001428336us-gaap:RestrictedStockUnitsRSUMember2021-07-310001428336us-gaap:RestrictedStockMember2021-07-310001428336hqy:PerformanceRestrictedStockUnitsMember2021-02-012021-07-310001428336hqy:PerformanceRestrictedStockUnitsMember2021-07-310001428336srt:MinimumMemberhqy:PerformanceRestrictedStockUnitsMember2021-02-012021-07-310001428336srt:MaximumMemberhqy:PerformanceRestrictedStockUnitsMember2021-02-012021-07-310001428336hqy:ContingentConsiderationMember2021-01-310001428336hqy:ContingentConsiderationMember2021-02-012021-07-310001428336hqy:ContingentConsiderationMember2021-07-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Form 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-36568
HEALTHEQUITY, INC.
(Exact name of registrant as specified in its charter)
Delaware52-2383166
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(Address of principal executive offices) (Zip code)

(801) 727-1000
(Registrant's telephone Number, including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
 Emerging growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 31, 2021, there were 83,508,975 shares of the registrant's common stock outstanding.



HealthEquity, Inc. and subsidiaries
Form 10-Q quarterly report

Table of contents
Page
Part I. FINANCIAL INFORMATION
Item 1.
Item 2.
Item 3.
Item 4.
Part II. OTHER INFORMATION
Item 1.
Item 1A.
Item 6.


-2-


Part I. Financial information
Item 1. Financial statements

HealthEquity, Inc. and subsidiaries
Condensed consolidated balance sheets
(in thousands, except par value)July 31, 2021January 31, 2021
(unaudited)
Assets
Current assets
Cash and cash equivalents$753,754 $328,803 
Accounts receivable, net of allowance for doubtful accounts of $5,824 and $4,239 as of July 31, 2021 and January 31, 2021, respectively
74,223 72,767 
Other current assets32,637 58,607 
Total current assets860,614 460,177 
Property and equipment, net27,382 29,106 
Operating lease right-of-use assets83,768 89,508 
Intangible assets, net770,329 767,003 
Goodwill1,363,568 1,327,193 
Other assets42,973 37,420 
Total assets$3,148,634 $2,710,407 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$4,696 $1,614 
Accrued compensation40,154 50,670 
Accrued liabilities49,098 75,880 
Current portion of long-term debt78,125 62,500 
Operating lease liabilities13,051 14,037 
Total current liabilities185,124 204,701 
Long-term liabilities
Long-term debt, net of issuance costs895,449 924,217 
Operating lease liabilities, non-current69,998 74,224 
Other long-term liabilities20,091 8,808 
Deferred tax liability115,306 119,729 
Total long-term liabilities1,100,844 1,126,978 
Total liabilities1,285,968 1,331,679 
Commitments and contingencies (see Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively
  
Common stock, $0.0001 par value, 900,000 shares authorized, 83,608 and 77,168 shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively
8 8 
Additional paid-in capital1,648,743 1,158,372 
Accumulated earnings213,915 220,348 
Total stockholders’ equity1,862,666 1,378,728 
Total liabilities and stockholders’ equity$3,148,634 $2,710,407 
See accompanying notes to condensed consolidated financial statements.

-3-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations and
comprehensive income (loss) (unaudited)
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2021202020212020
Revenue
Service revenue$109,182 $103,805 $211,716 $215,076 
Custodial revenue48,776 46,909 95,754 93,808 
Interchange revenue31,145 25,325 65,835 57,166 
Total revenue189,103 176,039 373,305 366,050 
Cost of revenue
Service costs67,334 65,246 137,966 136,259 
Custodial costs4,824 4,998 9,833 10,043 
Interchange costs4,974 4,011 10,419 9,890 
Total cost of revenue77,132 74,255 158,218 156,192 
Gross profit111,971 101,784 215,087 209,858 
Operating expenses
Sales and marketing15,476 12,167 29,562 23,622 
Technology and development37,898 30,654 73,367 61,732 
General and administrative22,812 20,493 43,499 39,491 
Amortization of acquired intangible assets20,289 19,077 40,103 37,779 
Merger integration16,371 10,365 25,178 23,135 
Total operating expenses112,846 92,756 211,709 185,759 
Income (loss) from operations(875)9,028 3,378 24,099 
Other expense
Interest expense(7,254)(8,895)(13,943)(21,158)
Other income (expense), net344 (824)(3,286)(1,588)
Total other expense(6,910)(9,719)(17,229)(22,746)
Income (loss) before income taxes(7,785)(691)(13,851)1,353 
Income tax benefit(3,967)(543)(7,418)(325)
Net income (loss) and comprehensive income (loss)$(3,818)$(148)$(6,433)$1,678 
Net income (loss) per share:
Basic$(0.05)$0.00 $(0.08)$0.02 
Diluted$(0.05)$0.00 $(0.08)$0.02 
Weighted-average number of shares used in computing net income (loss) per share:
Basic83,481 72,343 82,628 71,669 
Diluted83,481 72,343 82,628 72,971 
See accompanying notes to condensed consolidated financial statements.
-4-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of stockholders’ equity (unaudited)
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Total stockholders' equity, beginning balance$1,848,270 $1,040,650 $1,378,728 $1,030,295 
Common stock:
Beginning balance8 7 8 7 
Issuance of common stock upon exercise of stock options, and for restricted stock— — —  
Other issuance of common stock— 1 — 1 
Ending balance8 8 8 8 
Additional paid-in capital:
Beginning balance1,630,529 827,303 1,158,372 818,774 
Issuance of common stock upon exercise of stock options, and for restricted stock2,599 1,618 5,315 2,751 
Other issuance of common stock(2)286,777 456,640 286,777 
Stock-based compensation15,617 11,438 28,416 18,834 
Ending balance1,648,743 1,127,136 1,648,743 1,127,136 
Accumulated earnings
Beginning balance217,733 213,340 220,348 211,514 
Net income (loss)(3,818)(148)(6,433)1,678 
Ending balance213,915 213,192 213,915 213,192 
Total stockholders' equity, ending balance$1,862,666 $1,340,336 $1,862,666 $1,340,336 
See accompanying notes to condensed consolidated financial statements.

-5-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
Six months ended July 31,
(in thousands)20212020
Cash flows from operating activities:
Net income (loss)$(6,433)$1,678 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization64,819 56,106 
Stock-based compensation28,416 18,834 
Amortization of debt issuance costs2,482 2,533 
Change in fair value of contingent consideration1,011  
Other non-cash items(752)1,145 
Deferred taxes(4,051)(568)
Changes in operating assets and liabilities:
Accounts receivable, net(230)628 
Other assets20,636 (3,187)
Operating lease right-of-use assets6,060 5,563 
Accrued compensation(10,639)(13,854)
Accounts payable, accrued liabilities, and other current liabilities(30,213)30 
Operating lease liabilities, non-current(4,556)(5,723)
Other long-term liabilities1,616 5,477 
Net cash provided by operating activities68,166 68,662 
Cash flows from investing activities:
Acquisitions, net of cash acquired(49,533) 
Purchases of software and capitalized software development costs(32,097)(21,787)
Purchases of property and equipment(6,352)(8,987)
Acquisition of intangible member assets(2,653)(24,922)
Proceeds from sale of equity securities2,367  
Net cash used in investing activities(88,268)(55,696)
Cash flows from financing activities:
Proceeds from follow-on equity offering, net of payments for offering costs456,642 287,318 
Principal payments on long-term debt(15,625)(215,625)
Settlement of client-held funds obligation, net(2,636)(10,292)
Proceeds from exercise of common stock options6,672 2,817 
Net cash provided by financing activities445,053 64,218 
Increase in cash and cash equivalents424,951 77,184 
Beginning cash and cash equivalents328,803 191,726 
Ending cash and cash equivalents$753,754 $268,910 
See accompanying notes to condensed consolidated financial statements.
-6-


HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
Six months ended July 31,
(in thousands)20212020
Supplemental cash flow data:
Interest expense paid in cash$9,838 $17,659 
Income tax payments (refunds), net(5,545)798 
Supplemental disclosures of non-cash investing and financing activities:
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation4,077 1,262 
Purchases of property and equipment included in accounts payable or accrued liabilities357 1,104 
Contingent consideration recognized at acquisition8,147  
Exercise of common stock options receivable119 66 
Purchases of intangible member assets 58 
Additions to goodwill due to measurement period adjustments 1,177 
Follow-on equity offering costs accrued during the period 540 
See accompanying notes to condensed consolidated financial statements.
-7-

Table of Contents

HealthEquity, Inc. and subsidiaries
Notes to condensed consolidated financial statements
Note 1. Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2021 and for the three and six months ended July 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Follow-on equity offering
In the first quarter of fiscal year 2022, the Company closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. The Company received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million. The Company used $50.2 million of the net proceeds from the offering to acquire 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum, and intends to use the remaining net proceeds from the offering for general corporate purposes, which may include prepayments under its term loan facility or potential acquisitions, including the acquisitions of Further and the Fifth Third Bank HSA portfolio.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
-8-

Table of Contents


Note 2. Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2021202020212020
Numerator (basic and diluted):
Net income (loss)$(3,818)$(148)$(6,433)$1,678 
Denominator (basic):
Weighted-average common shares outstanding83,481 72,343 82,628 71,669 
Denominator (diluted):
Weighted-average common shares outstanding83,481 72,343 82,628 71,669 
Weighted-average dilutive effect of stock options and restricted stock units   1,302 
Diluted weighted-average common shares outstanding83,481 72,343 82,628 72,971 
Net income (loss) per share:
Basic $(0.05)$0.00 $(0.08)$0.02 
Diluted$(0.05)$0.00 $(0.08)$0.02 
For the three months ended July 31, 2021 and 2020, 1.9 million and 2.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
For the six months ended July 31, 2021 and 2020, approximately 2.0 million and 0.6 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
Note 3. Business combination
Acquisition of Luum
On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). Luum provides employers with a suite of commute tools as well as real-time commute data to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits. The aggregate purchase price consisted of $50.2 million in cash, and up to $20.0 million in additional payments which are contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. The Company recorded an $8.1 million liability representing its best estimate of the fair value of the contingent consideration as of the acquisition date. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs and will be remeasured to fair value quarterly, with any changes in the fair value recorded as other income (expense), net, in the condensed consolidated statement of operations and comprehensive income (loss). As of July 31, 2021, the fair value of the contingent consideration liability was $9.2 million.
The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to adjustment during the measurement period (up to one year from the acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
-9-

Table of Contents


The following table summarizes the Company's current allocation of the consideration paid:
(in thousands)Estimated fair value
Cash and cash equivalents$626 
Other current assets1,469 
Intangible assets23,900 
Goodwill36,374 
Other assets100 
Current liabilities(597)
Deferred tax liability(3,566)
Total consideration paid$58,306 
The Luum Acquisition resulted in $36.4 million of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational, and financial benefits expected from the Luum Acquisition, including an expanded commuter offering beyond traditional pre-tax commuter benefits and additional cross-selling opportunities. The goodwill created in the Luum Acquisition is not expected to be deductible for tax purposes.
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.

The pro forma effects of the Luum Acquisition would not materially impact the Company's reported results for any period presented, and as a result no pro forma financial information is presented.
Note 4. Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Property and equipment
Property and equipment consisted of the following as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Leasehold improvements$20,604 $22,271 
Furniture and fixtures9,014 9,230 
Computer equipment33,927 28,592 
Property and equipment, gross63,545 60,093 
Accumulated depreciation(36,163)(30,987)
Property and equipment, net$27,382 $29,106 
Depreciation expense for the three months ended July 31, 2021 and 2020 was $3.5 million and $4.1 million, respectively, and $7.4 million and $8.0 million for the six months ended July 31, 2021 and 2020, respectively.
Contract balances
The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of July 31, 2021 and January 31, 2021, the balance of deferred revenue was $4.0 million and $4.1 million, respectively. The balances are related to cash received in advance for an interchange revenue arrangement, other up-front fees and other commuter deferred revenue, and are generally recognized within twelve months, with the
-10-

exception of the interchange arrangement, which is recognized over a term of approximately ten years. During the three and six months ended July 31, 2021, approximately $0.5 million and $1.1 million of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2021.
Leases
The components of operating lease costs were as follows:
Three months ended July 31,Six months ended July 31,
(in thousands)
2021202020212020
Operating lease expense$3,498 $3,925 $7,809 $8,249 
Sublease income(450)(450)(900)(900)
Net operating lease expense$3,048 $3,475 $6,909 $7,349 
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Interest income$533 $76 $941 $676 
Acquisition gains (costs), net(1,665)28 (7,604)(66)
Other income (expense), net1,476 (928)3,377 (2,198)
Total other income (expense), net$344 $(824)$(3,286)$(1,588)
Supplemental cash flow information related to the Company's operating leases was as follows:
Six months ended July 31,
(in thousands)20212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,261 $6,468 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$320 $17,480 
Note 5. Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$161,134 $127,005 
Acquired HSA portfolios127,794 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,023,434 962,752 
Accumulated amortization(253,105)(195,749)
Amortizable intangible assets, net$770,329 $767,003 
Amortization expense for the three months ended July 31, 2021 and 2020 was $29.5 million and $24.5 million, respectively, and $57.4 million and $48.1 million for the six months ended July 31, 2021 and 2020, respectively.
Goodwill
During the six months ended July 31, 2021, goodwill increased by $36.4 million due to the Luum Acquisition. For further information, see Note 3—Business combination. There were no other changes to the carrying value of goodwill during the six months ended July 31, 2021.
-11-

Table of Contents

Note 6. Commitments and contingencies
Commitments
Contingent acquisition consideration. In connection with the Luum Acquisition, the Company agreed to pay up to $20.0 million in additional payments which are contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. For further information, see Note 3—Business combination.
Fifth Third Bank HSA portfolio acquisition. In April 2021, the Company entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition custodianship of Fifth Third’s HSA portfolio to HealthEquity. The definitive agreement contemplates a $60.8 million dollar purchase price for a transfer of approximately 149,000 HSA members and their approximately $477.0 million of HSA assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA assets actually transferred. The transaction is subject to satisfaction of certain customary closing conditions and is expected to close by the end of the Company's fiscal third quarter.
Further acquisition. In April 2021, the Company entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 550,000 HSAs and $1.7 billion of HSA assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto for, which is anticipated to close on January 31, 2022 for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021, and (2) an amended agreement to acquire the remainder of the Further business for $455 million, with a target closing date on November 1, 2021. The transactions are subject to satisfaction of certain customary closing conditions.
Lease termination. In April 2021, the Company exercised its right to terminate an operating lease that had not yet commenced with aggregate undiscounted lease payments of $63.1 million and a term of approximately 11 years following the landlord's failure to fulfill its obligations under the lease agreement. The Company's right to terminate the lease agreement is disputed by the landlord. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease.
Other commitments. The Company’s other commitments consist primarily of a term loan facility, operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. Except for the items noted above, there were no material changes during the three and six months ended July 31, 2021, outside of the ordinary course of business, in our commitments from those disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Contingencies
As described above, the Company's right to terminate an operating lease agreement with aggregate undiscounted lease payments of $63.1 million is disputed by the landlord.
In the normal course of business, the Company enters into contracts and agreements that contain a variety of covenants, representations, and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against the Company's subsidiary WageWorks, Inc. ("WageWorks"), its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleged claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering. The class action settled for $30.0 million. During the quarter ended July 31, 2021, WageWorks
-12-

Table of Contents

contributed $5.0 million and its insurers paid the remaining $25.0 million. The court granted final approval of the settlement and entered a final judgment on August 20, 2021.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages, fees and costs. Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint. On June 24, 2020, the court granted the defendants’ motion to dismiss the amended complaint. The plaintiffs subsequently filed a notice of appeal. The District Court action is currently stayed.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense fees and costs of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Except with respect to the Securities Class Action, which has been settled, the Company does not believe, based on currently available information, that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
Note 7. Income taxes
The Company follows Accounting Standards Codification ("ASC") 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income (loss) to determine the interim benefit or provision for income taxes. For the three and six months ended July 31, 2021, the Company recorded an income tax benefit of $4.0 million and $7.4 million, respectively. This resulted in an effective income tax benefit rate of 50.8% and 53.6% for the three and six months ended July 31, 2021, respectively, compared with an effective income tax benefit rate of 78.6% and 24.0% for the three and six months ended July 31, 2020, respectively. For the three and six months ended July 31, 2021, discrete tax items had an effective tax rate benefit of 25.6% and 28.9%, respectively, compared with an effective tax rate benefit of 62.9% and 57.4% for the three and six months ended July 31, 2020, respectively, primarily due to excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
As of July 31, 2021 and January 31, 2021, the Company’s total gross unrecognized tax benefit was $10.7 million and $10.2 million, respectively. If recognized, $9.9 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2021.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and in the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2001.

-13-

Table of Contents
Note 8. Indebtedness
Long-term debt consisted of the following:
(in thousands)July 31, 2021January 31, 2021
Term loan facility$987,500 $1,003,125 
Less: unamortized loan issuance costs (1)13,926 16,408 
Long-term debt, net of issuance costs$973,574 $986,717 
(1)In addition to the $13.9 million and $16.4 million of unamortized issuance costs related to the term loan facility as of July 31, 2021 and January 31, 2021, respectively, $4.3 million and $5.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the condensed consolidated balance sheets as of July 31, 2021 and January 31, 2021, respectively.
The Company is party to a credit facility (the "Credit Agreement”) that provides for:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion; and
(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350.0 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of July 31, 2021.
Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of July 31, 2021, the stated interest rate was 1.84% and the effective interest rate was 2.37%. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 4.50 to 1.00 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100.0 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of July 31, 2021, and for the period then ended.
The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and Fort Effect Corp and are secured by security interests in substantially all assets of HealthEquity and the guarantors, subject to certain customary exceptions.





-14-

Note 9. Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Cost of revenue$3,068 $2,065 $5,471 $3,528 
Sales and marketing2,660 1,818 4,848 2,776 
Technology and development3,693 2,493 6,706 5,410 
General and administrative6,196 5,062 11,391 7,120 
Other expense (1)  342  
Total stock-based compensation expense$15,617 $11,438 $28,758 $18,834 
(1)Equity-based awards exchanged for cash in connection with the Luum Acquisition.
Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2021, 7.5 million shares were available for grant under the Incentive Plan.
Stock options
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20211,674 
$1.25 - 82.39
$31.46 5.00$87,164 
Exercised(225)
$1.25 - 44.53
$23.69 
Outstanding as of July 31, 20211,449 
$1.25 - 82.39
$32.66 4.40$60,083 
Vested and expected to vest as of July 31, 20211,449 $32.66 4.40$60,083 
Exercisable as of July 31, 20211,352 $29.95 4.20$59,645 
Restricted stock units and restricted stock awards
A summary of RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20211,832 $60.41 193 $61.77 
Granted1,265 72.47   
Vested(383)57.64 (116)61.77 
Forfeited(103)60.43 (73)61.77 
Outstanding as of July 31, 20212,611 $66.66 4 $61.72 
Performance restricted stock units. During the first quarter of fiscal year 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million.
-15-

Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.
Note 10. Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of July 31, 2021 due to the short-term nature of these instruments.
Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.
The contingent consideration liability resulting from the Luum Acquisition was determined using a Monte Carlo valuation model based on Level 3 inputs. The estimate of fair value of the contingent consideration obligation requires subjective assumptions to be made regarding revenue growth rates, discount rates, peer revenue volatilities, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of achieving certain revenue targets. The fair value measurement is based on inputs unobservable in the market and thus represents a level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation. For further information, see Note 3—Business combination.
The following table reconciles the change in the fair value of the contingent consideration during the period presented:
(in thousands)Carrying Amount
Balance as of January 31, 2021$ 
Contingent consideration recognized at acquisition8,147 
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)1,011 
Balance as of July 31, 2021$9,158 
-16-

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The following discussion and analysis contains forward-looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Statements that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. Such statements include, but are not limited to, statements concerning our ability to close the acquisition of Further, the impact of the ongoing COVID-19 pandemic on the Company, the anticipated synergies and other benefits of the acquisitions of WageWorks and Further, health savings accounts and other tax-advantaged consumer-directed benefits, tax and other regulatory changes, market opportunity, our future financial and operating results, our investment and acquisition strategy, our sales and marketing strategy, management’s plans, beliefs and objectives for future operations, technology and development, economic and industry trends or trend analysis, expectations about seasonality, opportunity for portfolio purchases and other acquisitions, operating expenses, anticipated income tax rates, capital expenditures, cash flows and liquidity. These statements are based on the beliefs and assumptions of our management based on information currently available to us. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, this Quarterly Report on Form 10-Q, and our other reports filed with the SEC. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such events.

Overview
We are a leader and an innovator in providing technology-enabled services that empower consumers to make healthcare saving and spending decisions. We use our innovative technology to manage consumers' tax-advantaged health savings accounts ("HSAs") and other consumer-directed benefits ("CDBs") offered by employers, including flexible spending accounts and health reimbursement arrangements (“FSAs” and “HRAs”), and to administer Consolidated Omnibus Budget Reconciliation Act (“COBRA”), commuter and other benefits. As part of our services, we and our subsidiaries provide consumers with healthcare bill evaluation and payment processing services, personalized benefit information including information on treatment options and comparative pricing, access to remote and telemedicine benefits, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings.
The core of our offerings is the HSA, a financial account through which consumers spend and save long-term for healthcare expenses on a tax-advantaged basis. As of July 31, 2021, we administered 6.0 million HSAs, with balances totaling $15.5 billion, which we call HSA Assets. Also, as of July 31, 2021, we administered 7.2 million complementary CDBs. We refer to the aggregate number of HSAs and other CDBs that we administer as Total Accounts, of which we had 13.1 million as of July 31, 2021.
We reach consumers primarily through relationships with their employers, which we call Clients. We reach Clients primarily through a sales force that calls on Clients directly, relationships with benefits brokers and advisors, and integrated partnerships with a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan recordkeepers, which we call Network Partners.
We have increased our share of the growing HSA market from 4% in calendar year 2010 to 16% in 2020, measured by HSA Assets. According to Devenir, today we are the largest HSA provider by accounts and second largest by assets. In addition, we believe we are the largest provider of other CDBs. We seek to differentiate ourselves through our proprietary technology, product breadth, ecosystem connectivity, and service-driven culture. Our proprietary
-17-

technology allows us to help consumers optimize the value of their HSAs and other CDBs and gain confidence and skills in managing their healthcare costs as part of their financial security.
Our ability to assist consumers is enhanced by our capacity to securely share data in both directions with others in the health, benefits, and retirement ecosystems. Our commuter benefits offering also leverages connectivity to an ecosystem of mass transit, ride hailing, and parking providers. These strengths reflect our “DEEP Purple” culture of remarkable service to customers and teammates, achieved by driving excellence, ethics, and process into everything we do.
We earn revenue primarily from three sources: service, custodial, and interchange. We earn service revenue mainly from fees paid by Clients on a recurring per-account per-month basis. We earn custodial revenue mainly from HSA Assets held at our members’ direction in federally insured cash deposits, insurance contracts or mutual funds, and from investment of Client-held funds. We earn interchange revenue mainly from fees paid by merchants on payments that our members make using our physical payment cards and on our virtual payment system. See “Key components of our results of operations” for additional information on our sources of revenue, including the adverse impacts caused by the ongoing COVID-19 pandemic.
WageWorks Acquisition
On August 30, 2019, we completed the acquisition of WageWorks, Inc. (the "WageWorks Acquisition") and paid approximately $2.0 billion in cash to WageWorks stockholders, financed through net borrowings of approximately $1.22 billion under a new term loan facility and approximately $816.9 million of cash on hand. As a result of the WageWorks Acquisition, WageWorks Inc. became a wholly owned subsidiary of HealthEquity, Inc.
The key strategy of the WageWorks Acquisition was to enable us to increase the number of our employer sales opportunities, the conversion of these opportunities to Clients, and the value of Clients in generating members, HSA Assets and complementary CDBs. WageWorks’ historic strength of selling to employers directly and through health benefits brokers and advisors complemented our distribution through Network Partners. With WageWorks’ CDB capabilities, we provide employers with a single partner for both HSAs and other CDBs, which is preferred by the vast majority of employers according to research conducted for us by Aite Group. For Clients that partner with us in this way, we believe we can produce more value by encouraging both CDB participants to contribute to HSAs and HSA-only members to take advantage of tax savings available through other CDBs. Accordingly, we believe that there are significant opportunities to expand the scope of services that we provide to our Clients.
We are continuing our multi-year integration effort that we expect will produce long-term cost savings and revenue synergies. We have identified opportunities of approximately $80 million in annualized ongoing net synergies to be achieved by the end of fiscal year 2022, of which approximately $70 million were achieved as of July 31, 2021. Furthermore, we anticipate generating additional revenue synergies over the longer-term as our combined distribution channels and existing client base take advantage of the broader service offerings and as we continue to drive member engagement. We estimate non-recurring costs to achieve these synergies of approximately $100 million resulting from investment in technology we use to provide our services, and to run our back-office systems, and from integration of technology, as well as rationalization of cost of operations. Merger integration expenses attributable to the WageWorks Acquisition are expected to be completed by the end of fiscal year 2022, with the exception of ongoing lease expense related to certain WageWorks offices that have been permanently closed, less any related sublease income. As of July 31, 2021, we had incurred a total of $96 million of non-recurring merger integration costs related to the WageWorks Acquisition.
Luum Acquisition
In March 2021, we bolstered our commuter offering by acquiring 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition") for an aggregate purchase price consisting of $50.2 million in cash and up to $20.0 million in contingent payments payable during the two-year period following the closing of the Luum Acquisition. Luum provides employers with a suite of commute tools as well as real-time commute data, to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits.
Fifth Third Bank HSA portfolio acquisition
In April 2021, we entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition custodianship of Fifth Third’s HSA portfolio to HealthEquity. The definitive agreement contemplates a $60.8 million dollar purchase price for a transfer of approximately 149,000 HSA members and their approximately $477.0 million of HSA Assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA Assets actually transferred. The transaction is subject to satisfaction of certain customary closing conditions and is expected to close by the end of our fiscal third quarter.
-18-

Further Acquisition
In April 2021, we entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 550,000 HSAs and $1.7 billion of HSA Assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto for, which is anticipated to close on January 31, 2022 for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021, and (2) an amended agreement to acquire the remainder of the Further business for $455 million, with a target closing date on November 1, 2021. The transactions are subject to satisfaction of certain customary closing conditions.
Key factors affecting our performance
We believe that our future performance will be driven by a number of factors, including those identified below. Each of these factors presents both significant opportunities and significant risks to our future performance. See also "Results of operations - Revenue" for information relating to the ongoing COVID-19 pandemic and also the section entitled “Risk factors” included in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021, this Quarterly Report on Form 10-Q, and our other reports filed with the SEC.
Structural change in U.S. health insurance
We derive revenue primarily from healthcare-related saving and spending by consumers in the U.S., which are driven by changes in the broader healthcare industry, including the structure of health insurance. The average premium for employer-sponsored health insurance has risen by 22% since 2015 and 55% since 2010, resulting in increased participation in HSA-qualified health plans and HSAs and increased consumer cost-sharing in health insurance more generally. We believe that continued growth in healthcare costs and related factors will spur continued growth in HSA-qualified health plans and HSAs and may encourage policy changes making HSAs or similar vehicles available to new populations such as individuals in Medicare. However, the timing and impact of these and other developments in U.S. healthcare are uncertain. Moreover, changes in healthcare policy, such as "Medicare for all" plans, could materially and adversely affect our business in ways that are difficult to predict.
Trends in U.S. tax law
Tax law has a profound impact on our business. Our offerings to members, Clients, and Network Partners consist primarily of services enabled, mandated, or advantaged by provisions of U.S. tax law and regulations. Changes in tax policy are speculative, and may affect our business in ways that are difficult to predict.
Our client base
Our business model is based on a B2B2C distribution strategy, whereby we work with Network Partners and Clients to reach consumers to increase the number of our members with HSA accounts and complementary CDBs. We believe that there are significant opportunities to expand the scope of services that we provide to our current Clients.
Broad distribution footprint
We believe we have a diverse distribution footprint to attract new Clients and Network Partners. Our sales force calls on enterprise and regional employers in industries across the U.S., as well as potential Network Partners from among health plans, benefits administrators, and retirement plan record keepers.
Product breadth
We are the largest custodian and administrator of HSAs (by number of accounts), as well as a market-share leader in each of the major categories of complementary CDBs, including FSAs and HRAs, COBRA and commuter benefits administration. Our Clients and their benefits advisors increasingly seek HSA providers that can deliver an integrated offering of HSAs and complementary CDBs. With our CDB capabilities, we can provide employers with a single partner for both HSAs and complementary CDBs, which is preferred by the vast majority of employers, according to research conducted for us by Aite Group. We believe that the combination of HSA and complementary CDB offerings significantly strengthens our value proposition to employers, health benefits brokers and consultants, and Network Partners as a leading single-source provider.
-19-

Our proprietary technology
We believe that innovations incorporated in our technology, which enable us to better assist consumers to make healthcare saving and spending decisions and maximize the value of their tax-advantaged benefits, differentiate us from our competitors and drive our growth. We are building on these innovations by combining our HSA offering with WageWorks' complementary CDB offerings, giving us a full suite of CDB products, and adding to our solutions set and leadership position within the HSA sector. We intend to continue to invest in our technology development to enhance our capabilities and infrastructure, while maintaining a focus on data security and the privacy of our customers' data. For example, we are making significant investments in the architecture and infrastructure of the technology that we use to provide our services to improve our transaction processing capabilities and support continued account and transaction growth, as well as in data-driven personalized engagement to help our members spend less, save more, and build wealth for retirement.
Our “DEEP Purple” service culture
The successful healthcare consumer needs education and guidance delivered by people as well as by technology. We believe that our "DEEP Purple" culture, which we define as driving excellence, ethics, and process while providing remarkable service, is a significant factor in our ability to attract and retain customers and to address nimbly, opportunities in the rapidly changing healthcare sector. We make significant efforts to promote and foster DEEP Purple within our workforce. We invest in and intend to continue to invest in human capital through technology-enabled training, career development, and advancement opportunities.
Interest rates
As a non-bank custodian, we contract with federally insured banks and credit unions, which we collectively call our Depository Partners, and also with insurance company partners, to hold custodial cash assets on behalf of our members. We earn a material portion of our total revenue from interest paid to us by these partners. The lengths of our agreements with Depository Partners typically range from three to five years and may have fixed or variable interest rate terms. The terms of new and renewing agreements may be impacted by the then-prevailing interest rate environment, which in turn is driven by macroeconomic factors and government policies over which we have no control. Such factors, and the response of our competitors to them, also determine the amount of interest retained by our members. We believe that diversification of Depository Partners, varied contract terms and other factors reduce our exposure to short-term fluctuations in prevailing interest rates and mitigate the short-term impact of sustained increases or declines in prevailing interest rates on our custodial revenue. Over longer periods, sustained shifts in prevailing interest rates affect the amount of custodial revenue we can realize on custodial assets and the interest retained by our members.
Although interest rates have improved somewhat, we expect our custodial revenue to continue to be adversely affected by the interest rate cuts by the Federal Reserve associated with the ongoing COVID-19 pandemic, the lack of demand from Depository Partners for deposits, and other market conditions that have caused the interest rates offered by our Depository Partners to decline significantly.
Interest on our long-term debt changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Our competition and industry
Our direct competitors are HSA custodians and other CDB providers. Many of these are state or federally chartered banks and other financial institutions for which we believe benefits administration services are not a core business. Some of our direct competitors (including healthcare service companies such as United Health Group's Optum, Webster Bank, and well-known retail investment companies, such as Fidelity Investments) are in a position to devote more resources to the development, sale, and support of their products and services than we have at our disposal. In addition, numerous indirect competitors, including benefits administration service providers, partner with banks and other HSA custodians to compete with us. Our Network Partners may also choose to offer competitive services directly, as some health plans have done. Our success depends on our ability to predict and react quickly to these and other industry and competitive dynamics.
As a result of the COVID-19 pandemic, we have seen an adverse impact on sales opportunities, with some opportunities delayed and most now being held virtually. As an increasing number of companies go out of business, the number of our Clients and potential Clients is adversely affected. Increased unemployment may mean that fewer of our members contribute to HSAs, FSAs, or other CDBs and reduce overall demand for our products. We have seen a significant decline in the use of commuter benefits due to many of our members working from home during the outbreak or other impacts from the outbreak, which has negatively impacted both our interchange revenue and service revenue, and this "work from home" trend may continue after the pandemic. We have also
-20-

seen a decline in interchange revenue across all other products. The extent to which the COVID-19 pandemic will negatively impact our business remains highly uncertain and cannot be accurately predicted.
Regulatory environment
Federal law and regulations, including the Affordable Care Act, the Internal Revenue Code, the Employee Retirement Income Security Act and Department of Labor regulations, and public health regulations that govern the provision of health insurance and provide the tax advantages associated with our services, play a pivotal role in determining our market opportunity. Privacy and data security-related laws such as the Health Insurance Portability and Accountability Act, or HIPAA, and the Gramm-Leach-Bliley Act, laws governing the provision of investment advice to consumers, such as the Investment Advisers Act of 1940, or the Advisers Act, the USA PATRIOT Act, anti-money laundering laws, and the Federal Deposit Insurance Act, all play a similar role in determining our competitive landscape. In addition, state-level regulations also have significant implications for our business in some cases. For example, our subsidiary HealthEquity Trust Company is regulated by the Wyoming Division of Banking, and several states are considering, or have already passed, new privacy regulations that can affect our business. Various states also have laws and regulations that impose additional restrictions on our collection, storage, and use of personally identifiable information. Privacy regulation in particular has become a priority issue in many states, including California, which in 2018 enacted the California Consumer Privacy Act broadly regulating California residents’ personal information and providing California residents with various rights to access and control their data, and the new California Privacy Rights Act. We have also seen an increase in regulatory changes related to our services due to government responses to the COVID-19 pandemic and may continue to see additional regulatory changes. Our ability to predict and react quickly to relevant legal and regulatory trends and to correctly interpret their market and competitive implications is important to our success.
On March 21, 2021, the American Rescue Plan Act of 2021 (“ARPA”) was signed into law. ARPA temporarily increased the dependent care flexible spending account contribution limit for the 2021 plan year. It also provided a temporary 100% subsidy of COBRA premium payments for eligible individuals who lost coverage due to an involuntary termination or a reduction of hours for up to 6 months.
Our acquisition strategy
We have a successful history of acquiring HSA portfolios and businesses that strengthen our service offerings. We seek to continue this growth strategy and are regularly engaged in evaluating different opportunities. We have developed an internal capability to source, evaluate, and integrate acquired HSA portfolios. We intend to continue to pursue acquisitions of complementary assets and businesses that we believe will strengthen our service offering, and our success depends in part on our ability to successfully integrate acquired businesses and HSA portfolios with our business in an efficient and effective manner.
-21-

Key financial and operating metrics
Our management regularly reviews a number of key operating and financial metrics to evaluate our business, determine the allocation of our resources, make decisions regarding corporate strategies and evaluate forward-looking projections and trends affecting our business. We discuss certain of these key financial metrics, including revenue, below in the section entitled “Key components of our results of operations.” In addition, we utilize other key metrics as described below.
Total Accounts
The following table sets forth our HSAs, CDBs, and Total Accounts as of and for the periods indicated:
(in thousands, except percentages)July 31, 2021July 31, 2020% ChangeJanuary 31, 2021
HSAs5,972 5,384 11 %5,782 
New HSAs from sales - Quarter-to-date180 108 67 %370 
New HSAs from sales - Year-to-date295 213 38 %687 
New HSAs from acquisitions - Year-to-date— — n/a— 
HSAs with investments402 284 42 %333 
CDBs7,171 7,090 %7,028 
Total Accounts13,143 12,474 %12,810 
Average Total Accounts - Quarter-to-date13,358 12,416 %12,659 
Average Total Accounts - Year-to-date13,114 12,602 %12,604 
The number of our HSAs and CDBs are key metrics because our revenue is driven by the amount we earn from them. The number of our HSAs increased by approximately 0.6 million, or 11%, from July 31, 2020 to July 31, 2021, due to further penetration into existing Network Partners and the addition of new Network Partners. The number of our CDBs increased by approximately 0.1 million, or 1%, from July 31, 2020 to July 31, 2021, driven by an increase in COBRA accounts, largely offset by a decrease in commuter benefit accounts that are currently suspended due to the COVID-19 pandemic and fewer workers being required to commute to an office. The suspended commuter accounts continue to be administered on our platform and can be reinstated at any time. We have excluded the suspended commuter accounts from our account totals because they are currently not generating revenue for the Company.
HSA Assets
The following table sets forth HSA Assets as of and for the periods indicated:
(in millions, except percentages)July 31, 2021July 31, 2020% ChangeJanuary 31, 2021
HSA cash with yield (1)$9,938 $8,626 15 %$9,875 
HSA cash without yield (2)90 344 (74)%244 
Total HSA cash10,028 8,970 12 %10,119 
HSA investments with yield (1)5,351 3,046 76 %4,078 
HSA investments without yield (2)92 195 (53)%138 
Total HSA investments5,443 3,241 68 %4,216 
Total HSA Assets15,471 12,211 27 %14,335 
Average daily HSA cash with yield - Year-to-date9,838 8,332 18 %8,599 
Average daily HSA cash with yield - Quarter-to-date$9,850 $8,380 18 %$9,060 
(1)HSA Assets that generate custodial revenue.
(2)HSA Assets that do not generate custodial revenue.
HSA Assets, which are our HSA members' assets for which we are the custodian or administrator, or from which we generate custodial revenue, consist of the following components: (i) HSA cash, which includes cash deposits with our Depository Partners or other custodians and cash placed in annuity contracts with our insurance company partners, and (ii) HSA investments in mutual funds through our custodial investment fund partners. We are continuing to transition HSA cash without yield to HSA cash with yield and expect to complete the transition in fiscal year 2022. Measuring HSA Assets is important because our custodial revenue is directly affected by average daily custodial balances for HSA Assets that are revenue generating.
-22-

Total HSA cash increased by $1.1 billion, or 12%, from July 31, 2020 to July 31, 2021, due primarily to HSA contributions, new HSAs, and decreased spending per HSA, partially offset by transfers to HSA investments.
HSA investments increased by $2.2 billion, or 68%, from July 31, 2020 to July 31, 2021, due primarily to transfers from HSA cash and appreciation of invested balances.
Total HSA Assets increased by $3.3 billion, or 27%, from July 31, 2020 to July 31, 2021, due primarily to HSA contributions, new HSAs, decreased spending per HSA, and appreciation of invested balances.
Client-held funds
(in millions, except percentages)July 31, 2021July 31, 2020% ChangeJanuary 31, 2021
Client-held funds (1)$810 $840 (4)%$986 
Average daily Client-held funds - Year-to-date (1)876 861 %847 
Average daily Client-held funds - Quarter-to-date (1)853 891 (4)%848 
(1) Client-held funds that generate custodial revenue.
Client-held funds are interest-earning deposits from which we generate custodial revenue. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of CDBs. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. Client-held funds fluctuate depending on the timing of funding and spending of CDB balances.
Adjusted EBITDA
We define Adjusted EBITDA, which is a non-GAAP financial metric, as adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, and certain other non-operating items. We believe that Adjusted EBITDA provides useful information to investors and analysts in understanding and evaluating our operating results in the same manner as our management and our board of directors because it reflects operating profitability before consideration of non-operating expenses and non-cash expenses, and serves as a basis for comparison against other companies in our industry.
The following table presents a reconciliation of net income (loss), the most comparable GAAP financial measure, to Adjusted EBITDA for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Net income (loss)$(3,818)$(148)$(6,433)$1,678 
Interest income(533)(76)(941)(676)
Interest expense7,254 8,895 13,943 21,158 
Income tax benefit(3,967)(543)(7,418)(325)
Depreciation and amortization12,762 9,522 24,716 18,327 
Amortization of acquired intangible assets20,289 19,077 40,103 37,779 
Stock-based compensation expense15,617 11,438 28,416 18,834 
Merger integration expenses16,371 10,365 25,178 23,135 
Acquisition costs (gains) (1)1,665 (28)7,604 66 
Gain on equity securities(1,677)— (1,677)— 
Other (2)1,552 1,500 999 3,034 
Adjusted EBITDA$65,515 $60,002 $124,490 $123,010 
(1)For the six months ended July 31, 2021, acquisition costs included $0.3 million of stock-based compensation.
(2)For the three months ended July 31, 2021 and 2020, other consisted of amortization of incremental costs to obtain a contract of $1.4 million and $0.6 million, respectively, and other costs, net, of $0.2 million and $0.9 million, respectively. For the six months ended July 31, 2021 and 2020, other consisted of amortization of incremental costs to obtain a contract of $2.6 million and $0.8 million, respectively, and other income of $1.6 million and other costs of $2.2 million, respectively.
-23-

The following table further sets forth our Adjusted EBITDA as a percentage of revenue:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Adjusted EBITDA$65,515 $60,002 $5,513 %$124,490 $123,010 $1,480 %
As a percentage of revenue35 %34 %33 %34 %
Our Adjusted EBITDA increased by $5.5 million, or 9%, from $60.0 million for the three months ended July 31, 2020 to $65.5 million for the three months ended July 31, 2021. The increase in Adjusted EBITDA was primarily driven by an increase in revenue related to COBRA benefits administration, which increased primarily due to the temporary COBRA subsidy available to eligible individuals under ARPA.
Our Adjusted EBITDA increased by $1.5 million, or 1%, from $123.0 million for the six months ended July 31, 2020 to $124.5 million for the six months ended July 31, 2021. The increase in Adjusted EBITDA was driven by the increase in revenue related to COBRA benefits administration, partially offset by a decrease in the number of commuter benefit accounts due to accounts being suspended as a result of the COVID-19 pandemic.
Our use of Adjusted EBITDA has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP.
Key components of our results of operations
Revenue
We generate revenue from three primary sources: service revenue, custodial revenue, and interchange revenue.
Service revenue.    We earn service revenue from the fees we charge our Network Partners, Clients, and members for the administration services we provide in connection with the HSAs and other CDBs we offer. With respect to our Network Partners and Clients, our fees are generally based on a fixed tiered structure for the duration of the relevant service agreement and are paid to us on a monthly basis. We recognize revenue on a monthly basis as services are rendered to our members and Clients.
Custodial revenue.    We earn custodial revenue primarily from HSA Assets deposited with our Depository Partners and with our insurance company partners, Client-held funds deposited with our Depository Partners, and recordkeeping fees we earn in respect of mutual funds in which our members invest. We deposit HSA cash with our Depository Partners pursuant to contracts that (i) typically have terms ranging from three to five years, (ii) provide for a fixed or variable interest rate payable on the average daily cash balances deposited with the relevant Depository Partner, and (iii) have minimum and maximum required deposit balances. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. We earn custodial revenue on HSA Assets and Client-held funds that is based on the interest rates offered to us by these Depository Partners and insurance company partners. In addition, once a member’s HSA cash balance reaches a certain threshold, the member is able to invest his or her HSA Assets in mutual funds through our custodial investment partner. We earn a recordkeeping fee, calculated as a percentage of custodial investments. We are continuing to transition HSA cash without yield to HSA cash with yield and expect to complete the transition in fiscal year 2022.
Interchange revenue.    We earn interchange revenue each time one of our members uses one of our physical payment cards or virtual platforms to make a purchase. This revenue is collected each time a member “swipes” our payment card to pay expenses. We recognize interchange revenue monthly based on reports received from third parties, namely, the card-issuing banks and card processors.
Cost of revenue
Cost of revenue includes costs related to servicing accounts, managing Client and Network Partner relationships and processing reimbursement claims. Expenditures include personnel-related costs, depreciation, amortization, stock-based compensation, common expense allocations (such as office rent, supplies, and other overhead expenses), new member and participant supplies, and other operating costs related to servicing our members. Other components of cost of revenue include interest retained by members on HSA cash and interchange costs incurred in connection with processing card transactions for our members.
Service costs.    Service costs include the servicing costs described above. Additionally, for new accounts, we incur on-boarding costs associated with the new accounts, such as new member welcome kits, the cost associated with issuance of new payment cards, and costs of marketing materials that we produce for our Network Partners.
-24-

Custodial costs.    Custodial costs are comprised of interest retained by our HSA members, in respect of HSA cash with yield, and fees we pay to banking consultants whom we use to help secure agreements with our Depository Partners. Interest retained by HSA members is calculated on a tiered basis. The interest rates retained by HSA members can change based on a formula or upon required notice.
Interchange costs.    Interchange costs are comprised of costs we incur in connection with processing payment transactions initiated by our members. Due to the substantiation requirement on FSA/HRA-linked payment card transactions, payment card costs are higher for FSA/HRA card transactions. In addition to fixed per card fees, we are assessed additional transaction costs determined by the amount of the transaction.
Gross profit and gross margin
Our gross profit is our total revenue minus our total cost of revenue, and our gross margin is our gross profit expressed as a percentage of our total revenue. Our gross margin has been and will continue to be affected by a number of factors, including interest rates, the amount we charge our Network Partners, Clients, and members, the mix of our sources of revenue, how many services we deliver per account, and payment processing costs per account.
Operating expenses
Sales and marketing.    Sales and marketing expenses consist primarily of personnel and related expenses for our sales and marketing staff, including sales commissions for our direct sales force, external agent/broker commission expenses, marketing expenses, depreciation, amortization, stock-based compensation, and common expense allocations.
Technology and development.    Technology and development expenses include personnel and related expenses for software development and delivery, information technology, data management, product, and security. Technology and development expenses also include software engineering services, the costs of operating our on-demand technology infrastructure, depreciation, amortization of capitalized software development costs, stock-based compensation, and common expense allocations.
General and administrative.    General and administrative expenses include personnel and related expenses of, and professional fees incurred by our executive, finance, legal, internal audit, corporate development, compliance, and people departments. They also include depreciation, amortization, stock-based compensation, and common expense allocations.
Amortization of acquired intangible assets.    Amortization of acquired intangible assets results primarily from intangible assets acquired in connection with business combinations. The assets include acquired customer relationships, acquired developed technology, and acquired trade names and trademarks, which we amortize over the assets' estimated useful lives, estimated to be 7-15 years, 2-5 years, and 3 years, respectively. We also acquired intangible HSA portfolios from third-party custodians. We amortize these assets over the assets’ estimated useful life of 15 years. We evaluate our acquired intangible assets for impairment annually, or at a triggering event.
Merger integration.    Merger integration expenses include personnel and related expenses, including severance, professional fees, legal expenses, and facilities and technology expenses directly related to integration activities to merge operations as a result of acquisitions.
Interest expense
Interest expense consists of accrued interest expense and amortization of deferred financing costs associated with our credit agreement. Interest on our long-term debt changes frequently due to variable interest rate terms, and as a result, our interest expense is expected to fluctuate based on changes in prevailing interest rates.
Other income (expense), net
Other income (expense), net, consists of acquisition costs, interest income earned on corporate cash and other miscellaneous income and expense.
Income tax provision (benefit)
We are subject to federal and state income taxes in the United States based on a January 31 fiscal year end. We use the asset and liability method to account for income taxes, under which current tax liabilities and assets are recognized for the estimated taxes payable or refundable on the tax returns for the current fiscal year. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, net operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted statutory
-25-

tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized or settled. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. As of July 31, 2021, we have recorded an overall net deferred tax liability on our condensed consolidated balance sheet.
Comparison of the three and six months ended July 31, 2021 and 2020
Revenue
The following table sets forth our revenue for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Service revenue$109,182 $103,805 $5,377 %$211,716 $215,076 $(3,360)(2)%
Custodial revenue48,776 46,909 1,867 %95,754 93,808 1,946 %
Interchange revenue31,145 25,325 5,820 23 %65,835 57,166 8,669 15 %
Total revenue$189,103 $176,039 $13,064 %$373,305 $366,050 $7,255 %
Service revenue. The $5.4 million, or 5%, increase in service revenue from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to an increase in revenue related to COBRA benefits administration, which increased primarily due to the temporary COBRA subsidy available to eligible individuals under ARPA.
The $3.4 million, or 2%, decrease in service revenue from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to the decrease in the number of commuter benefit accounts due to accounts being suspended as a result of the COVID-19 pandemic, partially offset the increase in revenue related to COBRA benefits administration.
Custodial revenue. The $1.9 million, or 4%, increase in custodial revenue from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to the $1.5 billion, or 18%, increase in the year-over-year average daily balance of HSA cash with yield. The increase was partially offset by a decrease in average annualized yield from 2.10% for the three months ended July 31, 2020 to 1.77% for the three months ended July 31, 2021, which was due in part to the interest rate cuts made by the Federal Reserve in response to the COVID-19 pandemic.
The $1.9 million, or 2%, increase in custodial revenue from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to the $1.5 billion, or 18%, increase in the year-over-year average daily balance of HSA cash with yield. The increase was partially offset by a decrease in average annualized yield from 2.11% for the six months ended July 31, 2020 to 1.78% for the six months ended July 31, 2021, which was due in part to the interest rate cuts made by the Federal Reserve in response to the COVID-19 pandemic.
We are continuing to transition HSA cash without yield to HSA cash with yield and expect to complete the transition in fiscal year 2022. This cash is being placed with our Depository Partners at prevailing interest rates, which we expect will generate additional custodial revenue.
Interchange revenue. The $5.8 million, or 23%, increase in interchange revenue from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to increased spend per account, as healthcare-related restrictions related to the COVID-19 pandemic have decreased.
The $8.7 million, or 15%, increase in interchange revenue from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to increased spend per account, as healthcare-related restrictions related to the COVID-19 pandemic have decreased, partially offset by a decrease in spend with respect to commuter benefit accounts partially attributable to the COVID-19 pandemic and fewer workers being required to commute to an office.
Total revenue. Total revenue increased $13.1 million, or 7%, from the three months ended July 31, 2020 to the three months ended July 31, 2021 due to the increases in interchange, service, and custodial revenues.
Total revenue increased $7.3 million, or 2%, from the six months ended July 31, 2020 to the six months ended July 31, 2021 due to the increases in interchange and custodial revenues, partially offset by the decrease in service revenue.
-26-

Impact of COVID-19. Our business has been adversely affected by the COVID-19 pandemic, and we expect that it will continue to be adversely affected by the COVID-19 pandemic, including as a result of the associated interest rate cuts by the Federal Reserve and other market conditions that have caused interest rates to decline significantly, which reduces the yield on funds placed with our Depository Partners in this environment. Sales opportunities have also been impacted, with some opportunities delayed and most now being held virtually. In addition, we are required to support our Clients' open enrollment activities virtually. We may be unable to meet our service level commitments to our Clients as a result of disruptions to our work force and disruptions to third party contracts that we rely on to provide our services. Our financial results related to certain of our products have also been adversely affected, such as commuter benefits, due to many of our members working from home during the outbreak and other impacts from the outbreak, and the "work from home" trend may continue after the pandemic. In particular, the recent increased spread of COVID-19 and the associated decisions by employers to delay return-to-office plans for their employees will further delay the recovery of use of these commuter benefits. During the initial stages of the COVID-19 pandemic, we saw a negative impact on our members' spend on healthcare, which negatively impacted both our interchange revenue and service revenue. If the current increase in COVID-19 cases results in new lockdowns or restrictions on elective medical procedures, our interchange revenue and service revenue could again be negatively impacted. The extent to which the COVID-19 pandemic will continue to negatively impact our business remains highly uncertain and as a result may have a material adverse impact on our business and financial results.
Cost of revenue
The following table sets forth our cost of revenue for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Service costs$67,334 $65,246 $2,088 %$137,966 $136,259 $1,707 %
Custodial costs4,824 4,998 (174)(3)%9,833 10,043 (210)(2)%
Interchange costs4,974 4,011 963 24 %10,419 9,890 529 %
Total cost of revenue$77,132 $74,255 $2,877 %$158,218 $156,192 $2,026 %
Service costs. The $2.1 million, or 3%, increase in service costs from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to an increase in costs related to COBRA benefits administration, which increased primarily due to efforts to implement the offering of the temporary COBRA subsidy available to eligible individuals under ARPA.
The $1.7 million, or 1%, increase in service costs from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to an increase in costs related to COBRA benefits administration, which increased primarily due to efforts to implement the offering of the temporary COBRA subsidy available to eligible individuals under ARPA.
Custodial costs. The $0.2 million, or 3%, decrease in custodial costs from the three months ended July 31, 2020 to the three months ended July 31, 2021 was due to a lower average annualized rate of interest retained by HSA members on HSA cash with yield, which decreased from 0.20% for the three months ended July 31, 2020 to 0.16% for the three months ended July 31, 2021, partially offset by an increase in the average daily balance of HSA cash with yield, which increased from $8.4 billion for the three months ended July 31, 2020 to $9.9 billion for the three months ended July 31, 2021.
The $0.2 million, or 2%, decrease in custodial costs from the six months ended July 31, 2020 to the six months ended July 31, 2021 was due to a lower average annualized rate of interest retained by HSA members on HSA cash with yield, which decreased from 0.20% for the six months ended July 31, 2020 to 0.17% for the six months ended July 31, 2021, partially offset by an increase in the average daily balance of HSA cash with yield, which increased from $8.3 billion for the six months ended July 31, 2020 to $9.8 billion for the six months ended July 31, 2021.
Interchange costs. The $1.0 million, or 24%, increase in interchange costs from the three months ended July 31, 2020 to the three months ended July 31, 2021 was due to higher card spend volumes, as healthcare-related restrictions related to the COVID-19 pandemic have decreased.
The $0.5 million, or 5%, increase in interchange costs from the six months ended July 31, 2020 to the six months ended July 31, 2021 was due to higher card spend volumes, as healthcare-related restrictions related to the COVID-19 pandemic have decreased.
-27-

Total cost of revenue. As we continue to add Total Accounts, we expect that our cost of revenue will increase in dollar amount to support our Network Partners, Clients, and members. Cost of revenue will continue to be affected by a number of different factors, including our ability to scale our service delivery, Network Partner implementation, account management functions, realized synergies, and the impact of the COVID-19 pandemic.
Operating expenses
The following table sets forth our operating expenses for the periods indicated:
Three months ended July 31,Six months ended July 31,
(in thousands, except percentages)20212020$ Change% Change20212020$ Change% Change
Sales and marketing$15,476 $12,167 $3,309 27 %$29,562 $23,622 $5,940 25 %
Technology and development37,898 30,654 7,244 24 %73,367 61,732 11,635 19 %
General and administrative22,812 20,493 2,319 11 %43,499 39,491 4,008 10 %
Amortization of acquired intangible assets20,289 19,077 1,212 %40,103 37,779 2,324 %
Merger integration16,371 10,365 6,006 58 %25,178 23,135 2,043 %
Total operating expenses$112,846 $92,756 $20,090 22 %$211,709 $185,759 $25,950 14 %
Sales and marketing. The $3.3 million, or 27%, increase in sales and marketing expense from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to an increase in marketing expenses from increased team member and partner commissions, staffing, and marketing materials.
The $5.9 million, or 25%, increase in sales and marketing expense from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to an increase in marketing expenses from increased staffing and marketing collateral and increases in team member and partner commissions.
We expect our sales and marketing expenses to increase for the foreseeable future as we focus on our cross-selling program and marketing campaigns. On an annual basis, we expect our sales and marketing expenses to continue to increase as a percentage of our total revenue. However, our sales and marketing expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our sales and marketing expenses.
Technology and development. The $7.2 million, or 24%, increase in technology and development expense from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to increases in amortization, stock-based compensation, and personnel-related expenses.
The $11.6 million, or 19%, increase in technology and development expense from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to increases in amortization, stock-based compensation, and personnel-related expenses.
We expect our technology and development expenses to increase for the foreseeable future as we continue to invest in the development and security of our proprietary technology. On an annual basis, we expect our technology and development expenses to continue to increase as a percentage of our total revenue pursuant to our growth initiatives. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our technology and development expenses.
General and administrative. The $2.3 million, or 11%, increase in general and administrative expense from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to increases in credit losses on trade receivables and stock-based compensation, partially offset by decreases in personnel-related expenses and professional fees.
The $4.0 million, or 10%, increase in general and administrative expense from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to increases in credit losses on trade receivables and stock-based compensation, partially offset by decreases in personnel-related expenses and professional fees.
We expect our general and administrative expenses to continue to increase for the foreseeable future due to the additional demands on our legal, compliance, accounting, and insurance functions that we incur as we continue to grow our business. On an annual basis, we expect our general and administrative expenses to remain relatively steady as a percentage of our total revenue over the near term pursuant to our growth initiatives. Our general and
-28-

administrative expenses may fluctuate as a percentage of our total revenue from period to period due to the seasonality of our total revenue and the timing and extent of our general and administrative expenses.
Amortization of acquired intangible assets. The $1.2 million, or 6%, increase in amortization of acquired intangible assets from the three months ended July 31, 2020 to the three months ended July 31, 2021 was primarily due to the inclusion of amortization related to identified intangible assets acquired through the Luum Acquisition. The remainder of the increase was due to amortization of acquired HSA portfolios.
The $2.3 million, or 6%, increase in amortization of acquired intangible assets from the six months ended July 31, 2020 to the six months ended July 31, 2021 was primarily due to the inclusion of amortization related to identified intangible assets acquired through the Luum Acquisition commencing March 8, 2021. The remainder of the increase was due to amortization of acquired HSA portfolios.
Merger integration. The $16.4 million and $25.2 million in merger integration expense for the three and six months ended July 31, 2021, respectively, was primarily due to personnel and related expenses, including expenses incurred in conjunction with the migration of accounts, severance, professional fees, technology-related, and facilities expenses directly related to the WageWorks Acquisition and additional integration expenses incurred related to the acquisition of Further. We expect integration expenses totaling approximately $100 million and $55 million in the aggregate for the WageWorks and Further acquisitions, respectively. Merger integration expenses attributable to the WageWorks Acquisition are expected to be completed by the end of fiscal year 2022, with the exception of ongoing lease expense related to certain WageWorks offices that have been permanently closed, less any related sublease income. As of July 31, 2021, we had incurred a total of approximately $103 million of non-recurring merger integration costs related to the WageWorks Acquisition and the Further acquisition.
Interest expense
The $7.3 million and $13.9 million in interest expense for the three and six months ended July 31, 2021, respectively, consisted primarily of interest accrued under our term loan facility and amortization of financing costs. We expect interest expense to decrease as a result of the principal repayments under our term loan facility and to fluctuate based on changes in prevailing interest rates.
Other income (expense), net
The $1.2 million change in other income (expense), net, from expense of $0.8 million during the three months ended July 31, 2020 to income of $0.4 million during the three months ended July 31, 2021 was due to a $2.9 million increase in interest income and other income, partially offset by a $1.7 million increase in acquisition costs.
The $1.7 million increase in other expense, net, from $1.6 million during the six months ended July 31, 2020 to $3.3 million during the six months ended July 31, 2021 was due to a $7.5 million increase in acquisition costs, partially offset by a $5.8 million increase in interest income and other income.
Income tax benefit
Income tax benefit for the three and six months ended July 31, 2021 was $4.0 million and $7.4 million, respectively, compared to an income tax benefit of $0.5 million and $0.3 million for the three and six months ended July 31, 2020, respectively. The $3.5 million and $7.1 million increase in the income tax benefit for the three and six months ended July 31, 2021 compared to the three and six months ended July 31, 2020 was primarily due to a decrease in pre-tax book income and an increase in excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
Seasonality
Seasonal concentration of our growth combined with our recurring revenue model create seasonal variation in our results of operations. Revenue results are seasonally impacted due to ancillary service fees, timing of HSA contributions, and timing of card spend. Cost of revenue is seasonally impacted as a significant number of new and existing Network Partners bring us new HSAs and CDBs beginning in January of each year concurrent with the start of many employers’ benefit plan years. Before we realize any revenue from these new accounts, we incur costs related to implementing and supporting our new Network Partners and new accounts. These costs of services relate to activating accounts and hiring additional staff, including seasonal help to support our member support center. These expenses begin to ramp up during our third fiscal quarter, with the majority of expenses incurred in our fourth fiscal quarter.
-29-

Liquidity and capital resources
Cash and cash equivalents overview
Our principal sources of liquidity are our current cash and cash equivalents balances, collections from our service, custodial, and interchange revenue activities, and availability under our revolving credit facility described below. We rely on cash provided by operating activities to meet our short-term liquidity requirements, which primarily relate to the payment of corporate payroll and other operating costs, payments under our term loan facility, and capital expenditures.
As of July 31, 2021 and January 31, 2021, cash and cash equivalents were $753.8 million and $328.8 million, respectively. Cash and cash equivalents as of July 31, 2021 included $456.6 million of net proceeds we received from our follow-on public offering in the first quarter of fiscal year 2022 from the sale of 5,750,000 shares of our common stock, partially offset by $50.2 million used for the Luum Acquisition.
Capital resources
We routinely maintain a “shelf” registration statement on Form S-3 on file with the SEC. A shelf registration statement, which includes a base prospectus, allows us at any time to offer any combination of securities described in the prospectus in one or more offerings. Unless otherwise specified in a prospectus supplement accompanying the base prospectus, we would use the net proceeds from the sale of any securities offered pursuant to the shelf registration statement for general corporate purposes, including, but not limited to, working capital, sales and marketing activities, general and administrative matters, capital expenditures, and repayment of indebtedness, and if opportunities arise, for the acquisition of, or investment in, assets, technologies, solutions or businesses that complement our business. Pending such uses, we may invest the net proceeds in interest-bearing securities. In addition, we may conduct concurrent or other financings at any time.
In the first quarter of fiscal year 2022, we closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. We received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million.
Our credit agreement includes a five-year senior secured revolving credit facility in an aggregate principal amount of up to $350.0 million, which may be used for working capital and general corporate purposes, including the financing of acquisitions and other investments. For a description of the terms of the credit agreement, refer to Note 8—Indebtedness. We were in compliance with all covenants under the credit agreement as of July 31, 2021, and for the period then ended.
Use of cash
We used $50.2 million of the net proceeds from the follow-on public offering for the Luum Acquisition, with the remaining proceeds to be used for general corporate purposes, which may include prepayments under our term loan facility or potential acquisitions, including the acquisitions of Further and the Fifth Third Bank HSA portfolio.
Capital expenditures for the six months ended July 31, 2021 and 2020 were $38.4 million and $30.8 million, respectively. We expect to continue our current level of increased capital expenditures for the remainder of the fiscal year ending January 31, 2022 as we continue to devote a significant amount of our capital expenditures to improving the architecture and functionality of our proprietary systems. Costs to improve the architecture of our proprietary systems include computer hardware, personnel and related costs for software engineering and outsourced software engineering services.
We believe our existing cash, cash equivalents, and revolving credit facility will be sufficient to meet our operating and capital expenditure requirements for at least the next 12 months. To the extent these current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to raise additional funds through public or private equity or debt financing. In the event that additional financing is required, we may not be able to raise it on favorable terms, if at all.
-30-

The following table shows our cash flows from operating activities, investing activities, and financing activities for the stated periods:
Six months ended July 31,
(in thousands)20212020
Net cash provided by operating activities$68,166 $68,662 
Net cash used in investing activities(88,268)(55,696)
Net cash provided by financing activities445,053 64,218 
Increase in cash and cash equivalents424,951 77,184 
Beginning cash and cash equivalents328,803 191,726 
Ending cash and cash equivalents$753,754 $268,910 
Cash flows from operating activities. Net cash provided by operating activities during the six months ended July 31, 2021 resulted from net loss of $6.4 million, plus depreciation and amortization expense of $64.8 million, stock-based compensation expense of $28.4 million, amortization of debt issuance costs of $2.5 million, and an increase in the fair value of contingent consideration of $1.0 million, partially offset by other non-cash items and working capital changes totaling $22.1 million.
Net cash provided by operating activities during the six months ended July 31, 2020 resulted from net income of $1.7 million, plus depreciation and amortization expense of $56.1 million, stock-based compensation expense of $18.8 million, and amortization of debt issuance costs of $2.5 million, partially offset by other non-cash items and working capital changes totaling $10.5 million.
Cash flows from investing activities. Cash used in investing activities for the six months ended July 31, 2021 resulted from the Luum Acquisition for $49.5 million, net of cash acquired, $32.1 million in software and capitalized software development, $6.4 million in purchases of property and equipment, and $2.7 million in acquisitions of intangible member assets, partially offset by $2.4 million of proceeds from the sale of equity securities associated with a long-term capital investment.
Net cash used in investing activities for the six months ended July 31, 2020 resulted from $21.8 million in software and capitalized software development, $9.0 million in purchases of property and equipment, and $24.9 million in acquisitions of intangible member assets.
Cash flows from financing activities. Net cash provided by financing activities during the six months ended July 31, 2021 resulted from $456.6 million of net proceeds from our follow-on public offering of 5,750,000 shares of common stock and the exercise of stock options of $6.7 million. These items were partially offset by $15.6 million of principal payments on our long-term debt and $2.6 million used in the settlement of Client-held funds obligation.

Net cash provided by financing activities during the six months ended July 31, 2020 resulted primarily from $287.3 million of net proceeds from our follow-on public offering of 5,290,000 shares of common stock, which does not include accrued offering costs of $0.5 million, and the exercise of stock options of $2.8 million, partially offset by $215.6 million of principal payments on our long-term debt and $10.3 million used in the settlement of Client-held funds obligation.
Contractual obligations
See Note 6—Commitments and contingencies for information about our contractual obligations.
Off-balance sheet arrangements
As of July 31, 2021, other than outstanding letters of credit issued under our revolving credit facility, we did not have any off-balance sheet arrangements. The majority of the standby letters of credit expire within one year. However, in the ordinary course of business, we will continue to renew or modify the terms of the letters of credit to support business requirements. The letters of credit are contingent liabilities, supported by our revolving credit facility, and are not reflected on our condensed consolidated balance sheets.
-31-

Critical accounting policies and significant management estimates
Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.
Our significant accounting policies are more fully described in Note 1 of the accompanying unaudited condensed consolidated financial statements and in Note 1 to our audited consolidated financial statements contained in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021. There have been no significant or material changes in our critical accounting policies during the six months ended July 31, 2021, as compared to those disclosed in “Management’s discussion and analysis of financial condition and results of operations – Critical accounting policies and significant management estimates” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Recent accounting pronouncements
See Note 1—Summary of business and significant accounting policies within the interim financial statements included in this Form 10-Q for further discussion.
Item 3. Qualitative and quantitative disclosures about market risk
Market risk
Concentration of market risk. We derive a substantial portion of our revenue from providing services to tax-advantaged healthcare account holders. A significant downturn in this market or changes in state and/or federal laws impacting the preferential tax treatment of healthcare accounts such as HSAs could have a material adverse effect on our results of operations. During the six months ended July 31, 2021 and 2020, no one customer accounted for greater than 10% of our total revenue. We monitor market and regulatory changes regularly and make adjustments to our business if necessary.
Inflation. Inflationary factors may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of expenses as a percentage of revenue if our revenue does not correspondingly increase with inflation.
Concentration of credit risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents. We maintain our cash and cash equivalents in bank and other depository accounts, which frequently may exceed federally insured limits. Our cash and cash equivalents as of July 31, 2021 were $753.8 million, the vast majority of which was not covered by federal depository insurance. We have not experienced any material losses in such accounts and believe we are not exposed to any significant credit risk with respect to our cash and cash equivalents. Our accounts receivable balance as of July 31, 2021 was $74.2 million. We have not experienced any significant write-offs to our accounts receivable and believe that we are not exposed to significant credit risk with respect to our accounts receivable; however, the extent to which the ongoing COVID-19 pandemic will negatively impact our credit risk remains highly uncertain and cannot be accurately predicted. We continue to monitor our credit risk and place our cash and cash equivalents with reputable financial institutions.
Interest rate risk
HSA Assets and Client-held funds. HSA Assets consist of custodial HSA funds we hold in custody on behalf of our members. As of July 31, 2021, we held in custody HSA Assets of approximately $15.5 billion. As a non-bank custodian, we contract with our Depository Partners and insurance company partners to hold custodial cash assets on behalf of our members, and we earn a significant portion of our total revenue from interest paid to us by these partners. The contract terms with our Depository Partners typically range from three to five years and have either fixed or variable interest rates. As HSA Assets increase and existing contracts with Depository Partners expire, we seek to enter into new contracts with Depository Partners, the terms of which are impacted by the then-prevailing interest rate environment. The diversification of HSA Assets placed among our Depository Partners and insurance
-32-

company partners, and varied contract terms, substantially reduces our exposure to short-term fluctuations in prevailing interest rates and mitigates the short-term impact of a sustained increase or decline in prevailing interest rates on our custodial revenue. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the interest rate yield, or yield, available to us and thus the amount of the custodial revenue we can realize. Conversely, a sustained increase in prevailing interest rates can increase our yield. An increase in our yield would increase our custodial revenue as a percentage of total revenue. In addition, if our yield increases, we expect the spread to also increase between the interest offered to us by our Depository Partners and insurance company partners and the interest retained by our members, thus increasing our profitability. However, we may be required to increase the interest retained by our members in a rising prevailing interest rate environment. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control, such as the interest rate cuts by the Federal Reserve associated with the ongoing COVID-19 pandemic.
Client-held funds are interest earning deposits from which we generate custodial revenue. As of July 31, 2021, we held Client-held funds of approximately $810.0 million. These deposits are amounts remitted by Clients and held by us on their behalf to pre-fund and facilitate administration of our other CDBs. These deposits are held with Depository Partners. We deposit the Client-held funds with our Depository Partners in interest-bearing, demand deposit accounts that have a floating interest rate and no set term or duration. A sustained decline in prevailing interest rates may negatively affect our business by reducing the size of the yield available to us and thus the amount of the custodial revenue we can realize from Client-held funds. Changes in prevailing interest rates are driven by macroeconomic trends and government policies over which we have no control.
Cash and cash equivalents. We consider all highly liquid investments purchased with an original maturity of three months or less to be unrestricted cash equivalents. Our unrestricted cash and cash equivalents are held in institutions in the U.S. and include deposits in a money market account that is unrestricted as to withdrawal or use. As of July 31, 2021, we had unrestricted cash and cash equivalents of $753.8 million. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our cash and cash equivalents as a result of changes in interest rates.
Credit agreement. As of July 31, 2021, we had $987.5 million outstanding under our term loan facility and no amounts drawn under our revolving credit facility. Our overall interest rate sensitivity under these credit facilities is primarily influenced by any amounts borrowed and the prevailing interest rates on these instruments. The interest rate on our term loan credit facility and revolving credit facility is variable and was 1.84 percent at July 31, 2021. Accordingly, we may incur additional expense if interest rates increase in future periods. For example, a one percent increase in the interest rate on the amount outstanding under our credit facilities at July 31, 2021 would result in approximately $9.6 million of additional interest expense over the next 12 months. 
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management, with the participation of the Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of the Company’s disclosure controls and procedures as of July 31, 2021, the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, the CEO and CFO have concluded that as of July 31, 2021, the Company’s disclosure controls and procedures were not effective because of the material weaknesses in internal control over financial reporting at the Company’s wholly owned subsidiary, WageWorks, described below.
Notwithstanding the ineffective disclosure controls and procedures as a result of the identified material weaknesses in its WageWorks subsidiary, management has concluded that the condensed consolidated financial statements
-33-

included elsewhere in this Quarterly Report on Form 10-Q present fairly, in all material respects, the Company’s financial position, results of operations and cash flows in accordance with generally accepted accounting principles in the United States of America.
In accordance with interpretive guidance issued by SEC staff, companies are allowed to exclude acquired businesses from the assessment of internal control over financial reporting during the first year after completion of an acquisition and from the assessment of disclosure controls and procedures to the extent subsumed in such internal control over financial reporting. In accordance with this guidance, as the Company acquired Luum on March 8, 2021, management's evaluation and conclusion as to the effectiveness of the Company's disclosure controls and procedures as of July 31, 2021 excluded the portion of disclosure controls and procedures that are subsumed by internal control over financial reporting of Luum. Luum’s assets and revenues represented approximately 1%, excluding the effects of purchase accounting, of the Company's consolidated total assets and consolidated total revenues as of and for the fiscal quarter ended July 31, 2021.
Material Weaknesses in Internal Control over Financial Reporting
Management identified certain deficiencies in WageWorks' internal control over financial reporting that aggregated to material weaknesses in the following components of the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO Framework”):
Risk Assessment – The WageWorks subsidiary did not sufficiently identify and analyze risks arising from changes in the business environment, including risks arising in connection with the integration of acquisitions and financial system implementations.
Information and Communication – The WageWorks subsidiary did not establish cross-functional procedures and policies relating to effective information and communication necessary to support the functioning of internal control over financial reporting.
Monitoring – The WageWorks subsidiary did not implement effective monitoring controls that were responsive to changes in the business or the timely remediation of identified control deficiencies.
The COSO Framework component material weaknesses described above contributed to deficiencies at the control activity level that aggregated to the material weaknesses described below:
A. Accounting Close and Financial Reporting
The WageWorks subsidiary had inadequate process level and monitoring controls in the area of accounting close and financial reporting specifically, but not exclusively, around the review of account reconciliations, completeness and accuracy of data material to financial reporting, accounting estimates and related cut-off, the establishment, review, and implementation of accounting policies, and the review of the accuracy and completeness of certain manual and complex data feeds into journal entries and reconciliations of high-volume standard transactions.
B. Contract to Cash Process
The WageWorks subsidiary did not have effective controls around the contract-to-cash life cycle of service fees, including ineffective process level controls around billing set-up during customer implementation, managing change to existing customer billing terms and conditions, timely termination of customers, implementing complex and/or non-standard billing arrangements that require manual intervention or manual controls for billing to customers, processing timely adjustments, lack of robust, established and documented policies to assess collectability and reserve for revenue, bad debts and accounts receivable, availability of customer contracts, and reviews of non-standard contracts.
C. Information Technology General Controls
The WageWorks subsidiary did not have effective controls related to information technology general controls (ITGCs) in the areas of logical access and change-management over certain information technology systems that supported its financial reporting processes. WageWorks’ business process controls (automated and manual) that are dependent on the affected ITGCs were also deemed ineffective because they could have been adversely impacted.
These material weaknesses resulted in material misstatements of WageWorks' historical financial statements, which preceded the acquisition, and could result in a misstatement of our account balances or disclosures that would result in a material misstatement to the annual or interim condensed consolidated financial statements that would not be prevented or detected.

-34-

Ongoing Integration and Remediation Efforts
Management has assessed the impact of the acquisition of WageWorks on the Company’s internal control over financial reporting and continues to assess changes driven by the integration of WageWorks with the existing operations at the consolidated Company. As part of this assessment, management has continued to evaluate the Company’s internal control environment to ensure that it has appropriate controls in place to mitigate the risks of a material misstatement to its consolidated financial statements associated with the WageWorks subsidiary and the Company as a whole.
In response to the COSO Framework component material weaknesses in the WageWorks subsidiary’s internal control over financial reporting, management has taken the following actions:
performed its semi-annual risk assessment and scoping of key systems and business processes, including a risk assessment at the financial statement assertion level to ensure that the level of precision of relevant controls is adequate to address the identified risks;
dedicated certain senior finance, accounting, operational, and IT leadership team members to work on remediation efforts and appointed third-party internal controls advisors to assist with such efforts;
implemented a periodic assessment to monitor business changes impacting accounting processes and controls;
incorporated certain WageWorks processes into the Company’s existing entity-level controls;
established periodic reporting of the remediation plan progress to the Audit and Risk Committee of the Company's board of directors;
continued to execute its plan to formalize documentation underlying processes and controls to promote knowledge and information transfer across functions and upon personnel changes; and
continued to monitor the operating effectiveness of the existing entity-level controls.
In response to the material weakness “A. Accounting Close and Financial Reporting,” management has taken the following actions:
incorporated certain WageWorks processes into the Company’s process-level controls, including, but not limited to, those that address the monitoring of the accounting close cycle and enhanced the evaluation of accounting policies;
redesigned certain processes and controls in conjunction with the enterprise resource planning “ERP” system migration described below;
continued to execute its plan to assess the relevancy of information and data used in key controls, including a plan to design or augment controls to incorporate the review of the accuracy and completeness of such items; and
continued to monitor the operating effectiveness of the process-level and redesigned controls.
In response to the material weakness “B. Contract to Cash Process,” management has taken the following actions:
continued to execute its plan to consolidate service platforms related to the contract-to-cash cycle, which will reduce a significant number of manual business process controls; and
enhanced the design of existing controls including information and data used in controls, where applicable, and implemented additional controls to further strengthen the control environment.
In response to the material weakness “C. Information Technology General Controls,” management has taken the following actions:
continued to execute its plan to consolidate service platforms, which will reduce the number of ITGCs;
enhanced the design of existing controls, where applicable, and implemented additional controls to further strengthen the control environment; and
continued to monitor the operating effectiveness of controls related to logical access and change management for relevant WageWorks applications and systems.
As we continue to evaluate operating effectiveness and monitor improvements to our internal control over financial reporting, we may take additional measures to address control deficiencies or modify the remediation plans described above.
As part of our integration efforts, we have migrated all of our material operations to a single ERP system for the consolidated Company that will enhance our business and financial processes and standardize our information systems. We have re-assessed risks in response to the ERP system migration and the associated changes to underlying processes. We have redesigned certain controls in response to the current risks and continue to monitor the operating effectiveness of the redesigned controls.
-35-

Changes in Internal Control Over Financial Reporting
Other than continuing to make progress on the ongoing integration and remediation efforts described above, there were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended July 31, 2021 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
-36-


Part II—Other Information
Item 1. Legal Proceedings
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Except as described in Note 6—Commitments and contingencies, as of the date of this Quarterly Report on Form 10-Q, we were not a party to any litigation whereby the outcome of such litigation, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our results of operations, cash flows or financial position. For a description of these legal proceedings, see Note 6—Commitments and contingencies of the Notes to condensed consolidated financial statements.
Item 1A. Risk factors
The risks described in “Risk factors” in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021 could materially and adversely affect our business, financial condition and results of operations. Except as described below, there have been no material changes in such risks. These risk factors do not identify all risks that we face, and our operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial to our operations.
The ongoing COVID-19 pandemic has materially impacted our business and may continue to materially impact our business.
Our business has been, and may continue to be, materially and adversely affected by the COVID-19 pandemic. The Federal Reserve’s interest rate cut in response to the economic impact of COVID-19 and other interest rate market conditions have caused interest rates to decline significantly. While interest rates have improved somewhat since these actions were taken by the Federal Reserve, the funds that we place with our depository partners in this environment continue to be placed at lower interest rates than we originally expected. We have also seen an increase in regulatory changes related to our products due to government responses to the COVID-19 pandemic and may continue to see additional regulatory changes, which changes require substantial time and costs for us to ensure compliance. For example, regulatory changes related to our COBRA product have created uncertainty and additional workload on our team members. Further regulatory changes could reduce our operational efficiency and result in additional costs.
Our financial results related to certain of our products have also been adversely affected. For example, we have seen a significant decline in the use of commuter benefits, and the recent spread of the Delta variant of COVID-19 and the associated decisions by employers to delay return-to-office plans for their employees will further delay the recovery of use of these commuter benefits. In addition, to the extent the "work from home" trend continues after the pandemic, that would further negatively impact the revenue we receive from commuter benefits.
During the initial stages of the pandemic, we saw a negative impact on our members' spend on healthcare, which negatively impacted both our interchange revenue and service revenue. If the current increase in COVID-19 cases associated with the Delta variant results in new lockdowns or restrictions on elective medical procedures, our interchange revenue and service revenue could again be negatively impacted. In the event our financial results are severely impacted, it may make it more difficult for us to comply with the financial covenants in our credit agreement, which could result in a breach of the financial covenants and the acceleration of our outstanding debt by our lenders.
As a result of the ongoing pandemic, substantially all of our team members have been working from home. Sales opportunities have been impacted by the lack of travel and in-person meetings, with some opportunities delayed and most now being held virtually. The rise in the Delta variant may mean that sales opportunities and lack of travel continue to be impacted longer than we anticipated and likely means that we will be supporting the open enrollment activities of our Clients virtually again during the upcoming open enrollment season. We may be unable to meet our service level commitments to our Clients as a result of disruptions to our work force and disruptions to third-party contractors that we rely on to provide our services. The risk of cybersecurity breaches and incidents, and the potential impact of these on our operations, is also higher while our team members log in to our network remotely.
The extent to which the COVID-19 pandemic will continue to negatively impact our business remains highly uncertain and, as a result, may continue to have a material and adverse impact on our business and financial results.
-37-

Failure to adequately manage and maintain our custodial assets, or the failure of any of our depository or insurance partners, could materially and adversely affect our business, financial condition and results of operations.
As a non-bank custodian, we rely on our federally insured custodial depository partners and our insurance company partners to hold the vast majority of the HSA Assets that we hold in custody. If any material adverse event were to affect one of our depository partners or our insurance company partners, including a significant decline in its financial condition, a decline in the quality of its service, loss of deposits, its inability to comply with applicable banking and financial services regulatory requirements, systems failure or its inability to return principal or pay interest thereon, our business, financial condition and results of operations could be materially and adversely affected.
The HSA Assets held through our insurance company partners are not federally insured. As a result, in the event of a failure of one of our insurance company partners, the HSA Assets held through that partner would be at risk and no assurance can be given that these contractual provisions will be sufficient. Although the members bear the risk of loss with respect to investment of their HSA Assets, we would suffer reputational harm if one of our insurance company partners failed or otherwise breached its obligations to guarantee principal or pay interest thereon, which could in turn lead to financial harm to the Company.
Certain of our arrangements with our depository and insurance company partners require that we keep a minimum amount of HSA Assets with such partner, including sufficient liquid assets. If we fail to comply with those minimum HSA Asset requirements, including as a result of withdrawals by our members, we may be subject to penalties payable to our partners or a reduction in the interest payable. These requirements accordingly restrict our ability to quickly terminate our arrangements with these partners and remove our HSA Assets. Such penalties or reductions, if imposed, could have a material and adverse impact on our business, financial condition and results of operations.
In addition, certain of our insurance company partners have commitments to us with respect to the interest rates paid; however, some of these commitments are conditional upon certain market events and/or satisfaction of our obligations to the partner. A reduction of the interest rate payable, or a requirement that we post collateral in lieu of any such reduction, could have a material and adverse impact on our business, financial condition and results of operations.
In addition to any potential penalties payable, if we were required to change depository or insurance company partners, we cannot accurately predict the success of such change or that the terms of our agreement with the new partner would be as favorable to us as our current agreements.
Our acquisition of the Further business may not be consummated, and the integration of the Further business may not be successful.
We have entered into two agreements to acquire Further: (1) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto, and (2) an amended agreement to acquire the remainder of the Further business. Completion of this acquisition is subject to a number of risks and uncertainties, and we can provide no assurance that the various closing conditions to each part of this acquisition will be satisfied. Many of the conditions required to close the acquisition are not within our control, and we cannot predict when, or if, the acquisition will be completed. In particular, the closing of the VEBA portion of the acquisition is subject to our ability to arrange group annuity contracts with an insurance company partner for the assets of each of the VEBA plans being transferred in the acquisition, and no assurance can be given that all or a significant portion of the VEBA plans will agree to enter into such group annuity contracts. These new group annuity contracts are subject to the approval of applicable state insurance departments and will be subject to counterparty risk with our insurance company partner. The inability to complete the acquisition of Further could have a material adverse effect on our results of operations, financial condition and prospects.
The success of the Further acquisition, if completed, will depend in part on our ability to realize the anticipated business opportunities from combining the operations of Further with our business in an efficient and effective manner. The Further business is being carved out from the operations of its parent company. As such, the successful integration of the Further business with the Company is dependent on our ability to successfully carve out the Further business from its parent. While we intend to enter into a transition services agreement in order to effectively carve-out the Further business from its parent, no assurance can be given that the carve-out will be successful. In addition, the integration process could take longer than anticipated and could result in the loss of key employees, the disruption of the Company's ongoing business and the Further business, tax costs or inefficiencies, or inconsistencies in standards, controls, information technology systems, procedures and policies, any of which
-38-

could adversely affect our ability to maintain relationships with team members, Clients, Network Partners, or other third parties, or our ability to achieve the anticipated benefits of the acquisition, and could harm our financial performance. If we are unable to successfully or timely integrate the operations of Further with our business, we may incur unanticipated liabilities and be unable to realize the revenue growth, synergies and other anticipated benefits resulting from the acquisition of Further, and our business, results of operations and financial condition could be materially and adversely affected.
We rely on our management team and team members, and our business could be harmed if we are unable to retain qualified personnel.
Our success depends, in part, on the skills, working relationships and continued services of our executive leadership team and other key personnel. While we have entered into offer letters or employment agreements with certain of our executive officers, all of our team members are “at-will” employees, and their employment can be terminated by us or them at any time, for any reason, and without notice, subject, in certain cases, to severance payment rights. In order to retain valuable team members, in addition to salary and cash incentives, we provide equity-based awards that vest over time or based on performance. The value to team members of these awards will be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract offers from other organizations. The departure of key personnel could adversely affect the conduct of our business. In such event, we would be required to hire other personnel to manage and operate our business, and there can be no assurance that we would be able to employ a suitable replacement for the departing individual, or that a replacement could be hired on terms that are favorable to us. Volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart.
Our success also depends on our ability to attract, retain, and motivate additional skilled management personnel and other team members. For example, competition for qualified personnel in our field and geographic markets is intense due to the limited number of individuals who possess the skills and experience required by our industry, particularly in the technology-related fields. In addition, we have experienced team member turnover as a result of both the WageWorks Acquisition and the ongoing "great resignation" occurring throughout the American economy, and we expect to continue to experience team member turnover in the future. New hires require significant training and, in most cases, take significant time before they achieve full productivity. New team members may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. For example, it has become more difficult for us to hire entry-level team members in our member service and client service teams. If our retention efforts are not successful or our team member turnover rate continues to increase in the future, our business, results of operations and financial condition could be materially and adversely affected.
-39-

Item 6. Exhibits
Incorporate by reference
Exhibit
no.
DescriptionFormFile No.ExhibitFiling Date
10.1†8-K001-365682.1September 8, 2021
10.2†8-K001-365682.2September 8, 2021
31.1+
31.2+
32.1*#
32.2*#
101.INSXBRL Instance document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy schema linkbase document
101.CALInline XBRL Taxonomy calculation linkbase document
101.DEFInline XBRL Taxonomy definition linkbase document
101.LABInline XBRL Taxonomy labels linkbase document
101.PREInline XBRL Taxonomy presentation linkbase document
104
The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2021, formatted in Inline XBRL.
+Filed herewith.
*Furnished herewith.
#These certifications are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference in any filing the registrant makes under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, irrespective of any general incorporation language in any filings.
Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. HealthEquity hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the SEC.
 

-40-

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HEALTHEQUITY, INC.
Date: September 9, 2021By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:Executive Vice President and Chief Financial Officer

-41-
EX-31.1 2 exhibit311-ceo302xfy22q2.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as Adopted Pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Jon Kessler, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: September 9, 2021
 
By:/s/ Jon Kessler
Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 exhibit312-cfo302xfy22q2.htm EX-31.2 Document

Exhibit 31.2
Certification of Principal Financial Officer
pursuant to
Exchange Act Rules 13a-14(a) and 15d-14(a),
as adopted pursuant to
Section 302 of Sarbanes-Oxley Act of 2002
I, Tyson Murdock, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of HealthEquity, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 9, 2021
By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


EX-32.1 4 exhibit321-ceo906xfy22q2.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jon Kessler, the Chief Executive Officer (Principal Executive Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended July 31, 2021 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: September 9, 2021
 
By: /s/ Jon Kessler
Name:Jon Kessler
Title:
Chief Executive Officer
(Principal Executive Officer)


EX-32.2 5 exhibit322-cfo906xfy22q2.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Tyson Murdock, Executive Vice President and Chief Financial Officer (Principal Financial Officer) of HealthEquity, Inc. (the “Company”), hereby certify that, to my knowledge:
1.Our Quarterly Report on Form 10-Q for the quarter ended July 31, 2021 (the “Report”), of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: September 9, 2021
 
By:/s/ Tyson Murdock
Name:Tyson Murdock
Title:
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 


EX-101.SCH 6 hqy-20210731.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed consolidated balance sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed consolidated balance sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed consolidated statements of cash flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Summary of business and significant accounting policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of business and significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Summary of business and significant accounting policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Net income (loss) per share link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Net income (loss) per share (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Net income (loss) per share (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Business combination link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Business combination (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Business combination (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Business combination (Acquired Identified Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Supplemental financial statement information link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Supplemental financial statement information (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Supplemental financial statement information (Lease Cost) (Details) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2119105 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 2320304 - Disclosure - Intangible assets and goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Intangible assets and goodwill (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2123106 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 2424413 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Indebtedness link:presentationLink link:calculationLink link:definitionLink 2328305 - Disclosure - Indebtedness (Tables) link:presentationLink link:calculationLink link:definitionLink 2429415 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) link:presentationLink link:calculationLink link:definitionLink 2430416 - Disclosure - Indebtedness (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2131109 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 2332306 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2433417 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) link:presentationLink link:calculationLink link:definitionLink 2434418 - Disclosure - Stock-based compensation (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2435419 - Disclosure - Stock-based compensation (Stock option activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Fair value link:presentationLink link:calculationLink link:definitionLink 2338307 - Disclosure - Fair value (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Fair value (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 hqy-20210731_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 hqy-20210731_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 hqy-20210731_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Supplemental cash flow data: Supplemental Cash Flow Information [Abstract] Asset Acquisition [Axis] Asset Acquisition [Axis] Amortization of acquired intangible assets Amortization Of Acquired Intangible Amortization of Acquired Intangible Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Trade names & trademarks Trademarks and Trade Names [Member] Merger integration Business Combination, Integration Related Costs Leasehold improvements Leasehold Improvements [Member] Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Other income (expense), net Other Nonoperating Income (Expense), Miscellaneous Other Nonoperating Income (Expense), Miscellaneous Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Accrued compensation Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Acquisition gains (costs), net Business Combination, Acquisition Related Costs Statistical Measurement [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Forfeited (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Debt Covenant, Acquisition Holiday Provision Debt Covenant Period Four [Member] Debt Covenant Period Four Entity Filer Category Entity Filer Category Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Other offering expenses payable Stock Issuance Costs Payable Stock Issuance Costs Payable Beginning balance, maximum (in usd per share) Ending balance, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding Fifth Third Bank HSA portfolio Acquisition Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member] Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member] Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Shares available for grant under incentive plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Other Income (Expense), Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Additions to goodwill due to measurement period adjustments Goodwill, Purchase Accounting Adjustments Document Fiscal Year Focus Document Fiscal Year Focus Subsequent Event Type [Domain] Subsequent Event Type [Domain] Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization expense Amortization of Intangible Assets Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Revenue recognition Contract with Customer, Liability, Revenue Recognized Sale of Stock [Axis] Sale of Stock [Axis] Liability Class [Axis] Liability Class [Axis] Operating lease not yet commenced undiscounted amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount Business Combination and Asset Acquisition [Abstract] Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Business Acquisition [Axis] Business Acquisition [Axis] Exercised, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised Award Type [Domain] Award Type [Domain] Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Vested and expected to vest, weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Beginning balance, minimum (in usd per share) Ending balance, minimum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding Performance units awards (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Intangible assets and goodwill Goodwill and Intangible Assets Disclosure [Text Block] Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively Preferred Stock, Value, Issued Fair value Finite-lived Intangible Assets Acquired New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Acquired trade names Trade Names [Member] Accumulated earnings Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Long-term liabilities Liabilities, Noncurrent [Abstract] Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Percentage of capital stock Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Secured Debt Secured Debt [Member] Accounts receivable, net Increase (Decrease) in Accounts Receivable Purchases of property and equipment included in accounts payable or accrued liabilities Capital Expenditures Incurred but Not yet Paid Operating lease right-of-use assets obtained in exchange for new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Interest income Investment Income, Nonoperating Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Award vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Entity Interactive Data Current Entity Interactive Data Current Basic (in usd per share) Earnings Per Share, Basic Operating lease expense Operating Lease, Expense Sublease income Sublease Income Balance as of January 31, 2021 Balance as of July 31, 2021 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Total consideration paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Exercised, maximum (in usd per share) Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Current Reporting Status Entity Current Reporting Status Number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Operating cash flows from operating leases Operating Lease, Payments Other non-cash items Other Noncash Income (Expense) Effective tax rate, primarily due to excess tax benefit on stock-based compensation expense (benefit) Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted Recently Adopted Accounting Pronouncements [Policy Text Block] Recently Adopted Accounting Pronouncements [Policy Text Block] Aggregate fair value of WageWorks stock acquired Business Combination, Consideration Transferred Contingent consideration recognized at acquisition Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Term loan facility Long-term Debt, Gross Operating lease liabilities, non-current Increase (Decrease) In Operating Lease Liability, Noncurrent Increase (Decrease) In Operating Lease Liability, Noncurrent Plan Name [Axis] Plan Name [Axis] Long-term debt, net of issuance costs Long-term Debt Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Customary Base Rate Base Rate [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ equity Liabilities and Equity Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Service revenue Service [Member] Additional paid-in capital Additional Paid in Capital Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Unrecognized tax benefits that would impact the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Net income (loss) per share Earnings Per Share [Text Block] Operating expenses Operating Expenses [Abstract] Supplemental financial statement information Additional Financial Information Disclosure [Text Block] Minimum Minimum [Member] Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Gross profit Gross Profit Long-term line of credit Long-term Line of Credit Less: unamortized loan issuance costs Debt Issuance Costs, Net Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Gross unrecognized tax benefits Unrecognized Tax Benefits Debt Covenant Period [Axis] Debt Covenant Period [Axis] Debt Covenant Period [Axis] Trading Symbol Trading Symbol Ownership interest (as a percent) Business Acquisition, Percentage of Voting Interests Acquired Current liabilities Liabilities, Current [Abstract] General and administrative General and Administrative Expense Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Indebtedness Debt Disclosure [Text Block] Exercisable, weighted-average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Line of Credit Line of Credit [Member] Stock-based compensation Share-based Payment Arrangement [Text Block] Outstanding stock options, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Underwriting discounts and commissions Payments of Stock Issuance Costs Cost of revenue Cost of Revenue [Abstract] Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Common stock, $0.0001 par value, 900,000 shares authorized, 83,608 and 77,168 shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively Common Stock, Value, Issued Total other expense Nonoperating Income (Expense) Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Goodwill acquired Goodwill, Acquired During Period Basis of presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies (see Note 6) Commitments and Contingencies Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Business combination Business Combination Disclosure [Text Block] Restricted Stock Awards Restricted Stock [Member] Document Period End Date Document Period End Date Weighted-average dilutive effect of stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Entity Registrant Name Entity Registrant Name Numerator (basic and diluted): Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Net proceeds from follow on offering Sale of Stock, Consideration Received on Transaction Maximum purchase price Payments to Acquire Productive Assets Accrued liabilities Accrued Liabilities, Current Revenue Revenue from Contract with Customer, Excluding Assessed Tax Common stock: Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Other expense Other Nonoperating Income (Expense) [Abstract] Income (loss) from operations Operating Income (Loss) Custodial revenue Financial Service, Other [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liabilities Operating Lease, Liability, Current Summary of business and significant accounting policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Additional paid-in capital: Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation expense Depreciation Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Deferred revenue interchange arrangement recognition term Contract With Customer, Recognition Term, Interchange Arrangement Contract With Customer, Recognition Term, Interchange Arrangement Debt Covenant Period [Domain] Debt Covenant Period [Domain] [Domain] for Debt Covenant Period [Axis] Accounts payable, accrued liabilities, and other current liabilities Increase (Decrease) in Accrued Liabilities Sales and marketing Sales and Marketing [Member] Sales and Marketing [Member] Summary of Restricted Stock Unit Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Other income (expense), net Total other income (expense), net Other Nonoperating Income (Expense) Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Effective interest rate percentage Line of Credit Facility, Interest Rate at Period End Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Legal Entity [Axis] Legal Entity [Axis] Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, issued (in shares) Common Stock, Shares, Issued Further Health Savings Account Portfolio Acquisition Further Health Savings Account Portfolio Acquisition [Member] Further Health Savings Account Portfolio Acquisition Preferred stock, issued (in shares) Preferred Stock, Shares Issued Exercisable, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Minimum interest coverage ratio Debt Instrument, Covenant Description, Interest Coverage Ratio Debt Instrument, Covenant Description, Interest Coverage Ratio WageWorks Insurers WageWorks Insurers [Member] WageWorks Insurers [Member] Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Software and software development costs Software and Software Development Costs [Member] Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Other long-term liabilities Increase (Decrease) in Other Deferred Liability Operating lease not yet commenced undiscounted, term Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted, Term Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted, Term Interest expense Interest Expense Accrued compensation Increase (Decrease) in Employee Related Liabilities Purchase price for HSA portfolio Payments For Asset Acquisition Payments For Asset Acquisition Debt Covenant, Beginning July 31, 2021 Debt Covenant Period Two [Member] Debt Covenant Period Two City Area Code City Area Code Accumulated earnings Retained Earnings (Accumulated Deficit) Restricted Stock Units Restricted Stock Units (RSUs) [Member] Number of HSA members transferred in portfolio acquisition Number Of HSA Members Transferred Number Of HSA Members Transferred Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Preliminary Allocation of Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Business Acquisition [Line Items] Business Acquisition [Line Items] Incentive Plan Incentive Plan [Member] Incentive Plan [Member] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Schedule of Change in the Fair Value of the Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Exercise of common stock options receivable Exercise of Stock Options Receivable Exercise of Stock Options Receivable Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax benefit Income tax benefit Income Tax Expense (Benefit) Accounts receivable, net of allowance for doubtful accounts of $5,824 and $4,239 as of July 31, 2021 and January 31, 2021, respectively Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Total current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Entity File Number Entity File Number Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Fair value Fair Value Measurement, Policy [Policy Text Block] Current portion of long-term debt Long-term Debt, Current Maturities Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Sales and marketing Selling and Marketing Expense Statement [Line Items] Statement [Line Items] Weighted- average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Issuance of common stock upon exercise of stock options, and for restricted stock Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Contingent consideration recognized at acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Counterparty Name [Domain] Counterparty Name [Domain] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Entity Address, State or Province Entity Address, State or Province Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity [Domain] Entity [Domain] Estimated life (in years) Finite-Lived Intangible Asset, Useful Life Other expense Other Expense [Member] Interchange revenue Credit and Debit Card [Member] Schedule of Earnings (Loss) Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Local Phone Number Local Phone Number Summary of Share Based Compensation Recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Value of HSA assets transferred in portfolio acquisition Asset Acquisition, Assets Acquired And Liabilities, Assets Asset Acquisition, Assets Acquired And Liabilities, Assets Proceeds from follow-on equity offering, net of payments for offering costs Proceeds from Issuance of Common Stock Total assets Assets Deferred taxes Deferred Income Taxes and Tax Credits Plan Name [Domain] Plan Name [Domain] Common stock, authorized (in shares) Common Stock, Shares Authorized Vested and expected to vest, weighted average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Interest expense paid in cash Interest Paid, Excluding Capitalized Interest, Operating Activities Contingent Consideration Contingent Consideration [Member] Contingent Consideration Technology and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Stated interest rate percentage Debt Instrument, Interest Rate, Stated Percentage Contingent payments payable Business Combination, Contingent Consideration, Liability Total long-term liabilities Liabilities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Revolving Credit Facility Revolving Credit Facility [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Lease Cost Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Basic (in shares) Weighted-average common shares outstanding (in shares) Weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in usd per share) Earnings Per Share, Diluted Offering price per share (in usd per share) Sale of Stock, Price Per Share Income tax payments (refunds), net Income Taxes Paid, Net Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Denominator (diluted): Weighted Average Number of Shares Outstanding, Diluted [Abstract] Deferred tax liability Deferred Income Tax Liabilities, Net Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Fair value Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization Maximum leverage ratio Debt Instrument, Covenant Description, Leverage Ratio Debt Instrument, Covenant Description, Leverage Ratio Technology and development Technology and Development [Member] Technology and Development [Member] Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Cost of revenue Cost of Goods and Services Sold Revenues [Abstract] Revenues [Abstract] Computer software intangible asset Computer Software, Intangible Asset [Member] Acquisition of intangible member assets Payments to Acquire Intangible Assets Number of options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Net operating lease expense Lease, Cost Property and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Facility term Debt Instrument, Term Customer relationships Acquired customer relationships Customer Relationships [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Range of exercise prices Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract] Other long-term liabilities Other Liabilities, Noncurrent Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Principal payments on long-term debt Repayments of Long-term Debt Earnings Per Share [Abstract] Earnings Per Share [Abstract] Acquired HSA portfolios Acquired HSA Intangible Assets [Member] Acquired HSA Intangible Assets [Member] Property and equipment, gross Property, Plant and Equipment, Gross Document Quarterly Report Document Quarterly Report Other assets Increase (Decrease) in Other Operating Assets Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Grant date fair value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value Settle of claims Loss Contingency Accrual Purchase price for VEBA assets Asset Acquisition, Consideration Transferred Opening balance (in usd per share) Ending balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Long-term debt, net of issuance costs Long-term Debt, Excluding Current Maturities Asset Acquisition [Domain] Asset Acquisition [Domain] Other issuance of common stock Stock Issued During Period, Value, Other Total stock-based compensation expense Share-based Payment Arrangement, Expense Exercisable, weighted-average contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Net income (loss) per share: Net income (loss) per share: Earnings Per Share, Basic and Diluted [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Effective tax rate Effective Income Tax Rate Reconciliation, Percent Follow-on equity offering costs accrued during the period Stock Issuance Costs Incurred But Not Yet Paid Stock Issuance Costs Incurred But Not Yet Paid Amortization of debt issuance costs Amortization of Debt Issuance Costs Counterparty Name [Axis] Counterparty Name [Axis] Vested and expected to vest, aggregate intrinsic value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value WageWorks, Inc WageWorks Inc. [Member] WageWorks Inc. [Member] Beginning cash and cash equivalents Ending cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Common stock, shares (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Current assets Assets, Current [Abstract] Amortizable intangible assets, gross Finite-Lived Intangible Assets, Gross Entity Central Index Key Entity Central Index Key Schedule of Acquired Identified Intangible Assets Schedule of Finite-lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Security Exchange Name Security Exchange Name Acquisition threshold for maximum total net leverage ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio Term Loan Facility Term Loan Facility [Member] Term Loan Facility [Member] Luum Acquisition Luum Acquisition [Member] Luum Acquisition [Member] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Income taxes Income Tax Disclosure [Text Block] Denominator (basic): Weighted Average Number of Shares Outstanding, Basic [Abstract] Follow on equity offering Follow On Equity Offering [Member] Follow On Equity Offering [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Variable rate borrowing spread Debt Instrument, Basis Spread on Variable Rate Operating lease right-of-use assets Increase (Decrease) In Operating Lease, Right-Of-Use Asset Increase (Decrease) In Operating Lease, Right-Of-Use Asset Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value General and administrative General and Administrative Expense [Member] Principles of consolidation Consolidation, Policy [Policy Text Block] Total current liabilities Liabilities, Current Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Credit facility, amount Line of Credit Facility, Maximum Borrowing Capacity Weighted-average number of shares used in computing net income (loss) per share: Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Entity Address, Postal Zip Code Entity Address, Postal Zip Code Proceeds from sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Other current assets Other Assets, Current Number of derivative lawsuits Loss Contingency Number Of Lawsuits Loss Contingency Number Of Lawsuits Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation Noncash or Part Noncash Acquisition, Intangible Assets Acquired Statistical Measurement [Axis] Statistical Measurement [Axis] Purchases of software and capitalized software development costs Payments for Software Subsequent Event Subsequent Event [Member] Cover page. Cover [Abstract] Amortizable intangible assets, net Finite-Lived Intangible Assets, Net Goodwill Goodwill Goodwill Cost of revenue Cost of Sales [Member] Settlement of client-held funds obligation, net Payments To Settle Client Held Funds Payments To Settle Client Held Funds Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Developed technology Acquired developed technology Developed Technology Rights [Member] Computer equipment Computer Equipment [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] EX-101.PRE 10 hqy-20210731_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 hqy-20210731_htm.xml IDEA: XBRL DOCUMENT 0001428336 2021-02-01 2021-07-31 0001428336 2021-08-31 0001428336 2021-07-31 0001428336 2021-01-31 0001428336 us-gaap:ServiceMember 2021-05-01 2021-07-31 0001428336 us-gaap:ServiceMember 2020-05-01 2020-07-31 0001428336 us-gaap:ServiceMember 2021-02-01 2021-07-31 0001428336 us-gaap:ServiceMember 2020-02-01 2020-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2021-05-01 2021-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2020-05-01 2020-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2021-02-01 2021-07-31 0001428336 us-gaap:FinancialServiceOtherMember 2020-02-01 2020-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2021-05-01 2021-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2020-05-01 2020-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2021-02-01 2021-07-31 0001428336 us-gaap:CreditAndDebitCardMember 2020-02-01 2020-07-31 0001428336 2021-05-01 2021-07-31 0001428336 2020-05-01 2020-07-31 0001428336 2020-02-01 2020-07-31 0001428336 2021-04-30 0001428336 2020-04-30 0001428336 2020-01-31 0001428336 us-gaap:CommonStockMember 2021-04-30 0001428336 us-gaap:CommonStockMember 2020-04-30 0001428336 us-gaap:CommonStockMember 2021-01-31 0001428336 us-gaap:CommonStockMember 2020-01-31 0001428336 us-gaap:CommonStockMember 2020-02-01 2020-07-31 0001428336 us-gaap:CommonStockMember 2020-05-01 2020-07-31 0001428336 us-gaap:CommonStockMember 2021-07-31 0001428336 us-gaap:CommonStockMember 2020-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-04-30 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-05-01 2021-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-05-01 2020-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-02-01 2021-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2020-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001428336 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001428336 us-gaap:RetainedEarningsMember 2021-04-30 0001428336 us-gaap:RetainedEarningsMember 2020-04-30 0001428336 us-gaap:RetainedEarningsMember 2021-01-31 0001428336 us-gaap:RetainedEarningsMember 2020-01-31 0001428336 us-gaap:RetainedEarningsMember 2021-05-01 2021-07-31 0001428336 us-gaap:RetainedEarningsMember 2020-05-01 2020-07-31 0001428336 us-gaap:RetainedEarningsMember 2021-02-01 2021-07-31 0001428336 us-gaap:RetainedEarningsMember 2020-02-01 2020-07-31 0001428336 us-gaap:RetainedEarningsMember 2021-07-31 0001428336 us-gaap:RetainedEarningsMember 2020-07-31 0001428336 2020-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-02-01 2021-07-31 0001428336 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-02-01 2020-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2021-02-01 2021-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2020-02-01 2020-07-31 0001428336 hqy:FollowOnEquityOfferingMember 2021-02-01 2021-04-30 0001428336 hqy:FollowOnEquityOfferingMember 2021-04-30 0001428336 hqy:LuumAcquisitionMember 2021-03-08 2021-03-08 0001428336 hqy:LuumAcquisitionMember 2021-03-08 0001428336 srt:MaximumMember hqy:LuumAcquisitionMember 2021-03-08 0001428336 hqy:LuumAcquisitionMember 2021-07-31 0001428336 hqy:LuumAcquisitionMember us-gaap:CustomerRelationshipsMember 2021-03-08 2021-03-08 0001428336 hqy:LuumAcquisitionMember us-gaap:DevelopedTechnologyRightsMember 2021-03-08 2021-03-08 0001428336 hqy:LuumAcquisitionMember us-gaap:TrademarksAndTradeNamesMember 2021-03-08 2021-03-08 0001428336 us-gaap:LeaseholdImprovementsMember 2021-07-31 0001428336 us-gaap:LeaseholdImprovementsMember 2021-01-31 0001428336 us-gaap:FurnitureAndFixturesMember 2021-07-31 0001428336 us-gaap:FurnitureAndFixturesMember 2021-01-31 0001428336 us-gaap:ComputerEquipmentMember 2021-07-31 0001428336 us-gaap:ComputerEquipmentMember 2021-01-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-07-31 0001428336 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-01-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2021-07-31 0001428336 hqy:AcquiredHSAIntangibleAssetsMember 2021-01-31 0001428336 us-gaap:CustomerRelationshipsMember 2021-07-31 0001428336 us-gaap:CustomerRelationshipsMember 2021-01-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2021-07-31 0001428336 us-gaap:DevelopedTechnologyRightsMember 2021-01-31 0001428336 us-gaap:TradeNamesMember 2021-07-31 0001428336 us-gaap:TradeNamesMember 2021-01-31 0001428336 hqy:FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember 2021-04-01 2021-04-30 0001428336 hqy:FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember 2021-04-30 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember 2021-04-01 2021-04-30 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember 2021-04-30 0001428336 hqy:FurtherHealthSavingsAccountPortfolioAcquisitionMember us-gaap:SubsequentEventMember 2021-09-09 2021-09-09 0001428336 2021-04-01 2021-04-30 0001428336 hqy:WageWorksInc.Member 2021-07-31 0001428336 hqy:WageWorksInsurersMember 2021-07-31 0001428336 2018-09-06 2018-09-06 0001428336 2018-06-22 2018-06-22 0001428336 hqy:TermLoanFacilityMember 2021-07-31 0001428336 hqy:TermLoanFacilityMember 2021-01-31 0001428336 us-gaap:RevolvingCreditFacilityMember 2021-07-31 0001428336 us-gaap:RevolvingCreditFacilityMember 2021-01-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2021-02-01 2021-07-31 0001428336 hqy:TermLoanFacilityMember hqy:CreditAgreementMember us-gaap:SecuredDebtMember 2021-07-31 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-02-01 2021-07-31 0001428336 us-gaap:RevolvingCreditFacilityMember hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-07-31 0001428336 srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-01 2021-07-31 0001428336 srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-01 2021-07-31 0001428336 srt:MinimumMember us-gaap:BaseRateMember 2021-02-01 2021-07-31 0001428336 srt:MaximumMember us-gaap:BaseRateMember 2021-02-01 2021-07-31 0001428336 hqy:CreditAgreementMember us-gaap:LineOfCreditMember 2021-07-31 0001428336 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2021-02-01 2021-07-31 0001428336 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2021-02-01 2021-07-31 0001428336 hqy:DebtCovenantPeriodTwoMember 2021-07-31 0001428336 hqy:DebtCovenantPeriodFourMember 2021-07-31 0001428336 us-gaap:CostOfSalesMember 2021-05-01 2021-07-31 0001428336 us-gaap:CostOfSalesMember 2020-05-01 2020-07-31 0001428336 us-gaap:CostOfSalesMember 2021-02-01 2021-07-31 0001428336 us-gaap:CostOfSalesMember 2020-02-01 2020-07-31 0001428336 hqy:SalesandMarketingMember 2021-05-01 2021-07-31 0001428336 hqy:SalesandMarketingMember 2020-05-01 2020-07-31 0001428336 hqy:SalesandMarketingMember 2021-02-01 2021-07-31 0001428336 hqy:SalesandMarketingMember 2020-02-01 2020-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2021-05-01 2021-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2020-05-01 2020-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2021-02-01 2021-07-31 0001428336 hqy:TechnologyandDevelopmentMember 2020-02-01 2020-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2021-05-01 2021-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2020-05-01 2020-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2021-02-01 2021-07-31 0001428336 us-gaap:GeneralAndAdministrativeExpenseMember 2020-02-01 2020-07-31 0001428336 us-gaap:OtherExpenseMember 2021-05-01 2021-07-31 0001428336 us-gaap:OtherExpenseMember 2020-05-01 2020-07-31 0001428336 us-gaap:OtherExpenseMember 2021-02-01 2021-07-31 0001428336 us-gaap:OtherExpenseMember 2020-02-01 2020-07-31 0001428336 hqy:IncentivePlanMember 2021-07-31 0001428336 2020-02-01 2021-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0001428336 us-gaap:RestrictedStockMember 2021-01-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2021-02-01 2021-07-31 0001428336 us-gaap:RestrictedStockMember 2021-02-01 2021-07-31 0001428336 us-gaap:RestrictedStockUnitsRSUMember 2021-07-31 0001428336 us-gaap:RestrictedStockMember 2021-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2021-02-01 2021-07-31 0001428336 hqy:PerformanceRestrictedStockUnitsMember 2021-07-31 0001428336 srt:MinimumMember hqy:PerformanceRestrictedStockUnitsMember 2021-02-01 2021-07-31 0001428336 srt:MaximumMember hqy:PerformanceRestrictedStockUnitsMember 2021-02-01 2021-07-31 0001428336 hqy:ContingentConsiderationMember 2021-01-31 0001428336 hqy:ContingentConsiderationMember 2021-02-01 2021-07-31 0001428336 hqy:ContingentConsiderationMember 2021-07-31 shares iso4217:USD iso4217:USD shares pure hqy:hsaMember hqy:lawsuit 0001428336 --01-31 2022 Q2 false 10-Q true 2021-07-31 false 001-36568 HEALTHEQUITY, INC. DE 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper, UT 84020 801 727-1000 Common stock, par value $0.0001 per share HQY NASDAQ Yes Yes Large Accelerated Filer false false false 83508975 753754000 328803000 5824000 4239000 74223000 72767000 32637000 58607000 860614000 460177000 27382000 29106000 83768000 89508000 770329000 767003000 1363568000 1327193000 42973000 37420000 3148634000 2710407000 4696000 1614000 40154000 50670000 49098000 75880000 78125000 62500000 13051000 14037000 185124000 204701000 895449000 924217000 69998000 74224000 20091000 8808000 115306000 119729000 1100844000 1126978000 1285968000 1331679000 0.0001 0.0001 100000000 100000000 0 0 0 0 0 0 0.0001 0.0001 900000000 900000000 83608000 83608000 77168000 77168000 8000 8000 1648743000 1158372000 213915000 220348000 1862666000 1378728000 3148634000 2710407000 109182000 103805000 211716000 215076000 48776000 46909000 95754000 93808000 31145000 25325000 65835000 57166000 189103000 176039000 373305000 366050000 67334000 65246000 137966000 136259000 4824000 4998000 9833000 10043000 4974000 4011000 10419000 9890000 77132000 74255000 158218000 156192000 111971000 101784000 215087000 209858000 15476000 12167000 29562000 23622000 37898000 30654000 73367000 61732000 22812000 20493000 43499000 39491000 20289000 19077000 40103000 37779000 16371000 10365000 25178000 23135000 112846000 92756000 211709000 185759000 -875000 9028000 3378000 24099000 7254000 8895000 13943000 21158000 344000 -824000 -3286000 -1588000 -6910000 -9719000 -17229000 -22746000 -7785000 -691000 -13851000 1353000 -3967000 -543000 -7418000 -325000 -3818000 -3818000 -148000 -148000 -6433000 -6433000 1678000 1678000 -0.05 0.00 -0.08 0.02 -0.05 0.00 -0.08 0.02 83481000 72343000 82628000 71669000 83481000 72343000 82628000 72971000 1848270000 1040650000 1378728000 1030295000 8000 7000 8000 7000 0 1000 1000 8000 8000 8000 8000 1630529000 827303000 1158372000 818774000 2599000 1618000 5315000 2751000 -2000 286777000 456640000 286777000 15617000 11438000 28416000 18834000 1648743000 1127136000 1648743000 1127136000 217733000 213340000 220348000 211514000 -3818000 -148000 -6433000 1678000 213915000 213192000 213915000 213192000 1862666000 1340336000 1862666000 1340336000 -6433000 1678000 64819000 56106000 28416000 18834000 2482000 2533000 1011000 0 752000 -1145000 -4051000 -568000 230000 -628000 -20636000 3187000 -6060000 -5563000 -10639000 -13854000 -30213000 30000 -4556000 -5723000 1616000 5477000 68166000 68662000 49533000 0 32097000 21787000 6352000 8987000 2653000 24922000 2367000 0 -88268000 -55696000 456642000 287318000 15625000 215625000 2636000 10292000 6672000 2817000 445053000 64218000 424951000 77184000 328803000 191726000 753754000 268910000 9838000 17659000 -5545000 798000 4077000 1262000 357000 1104000 8147000 0 119000 66000 0 58000 0 1177000 0 540000 Summary of business and significant accounting policies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of consolidation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements as of July 31, 2021 and for the three and six months ended July 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-on equity offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal year 2022, the Company closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. The Company received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million. The Company used $50.2 million of the net proceeds from the offering to acquire 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum, and intends to use the remaining net proceeds from the offering for general corporate purposes, which may include prepayments under its term loan facility or potential acquisitions, including the acquisitions of Further and the Fifth Third Bank HSA portfolio.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements as of July 31, 2021 and for the three and six months ended July 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. Certain reclassifications have been made to prior year amounts to conform to the current year presentation. 5750000 80.30 456600000 4600000 500000 50200000 1 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting pronouncements not yet adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> Net income (loss) per share<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per share: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numerator (basic and diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,481 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,971 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended July 31, 2021 and 2020, 1.9 million and 2.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended July 31, 2021 and 2020, approximately 2.0 million and 0.6 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income (loss) per share: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Numerator (basic and diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (basic):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator (diluted):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,481 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average dilutive effect of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,481 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,628 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,971 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.00 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -3818000 -148000 -6433000 1678000 83481000 72343000 82628000 71669000 83481000 72343000 82628000 71669000 0 0 0 0 1302000 83481000 72343000 82628000 72971000 -0.05 -0.00 -0.08 0.02 -0.05 -0.00 -0.08 0.02 1900000 2100000 2000000 600000 Business combination<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Luum</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). Luum provides employers with a suite of commute tools as well as real-time commute data to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits. The aggregate purchase price consisted of $50.2 million in cash, and up to $20.0 million in additional payments which are contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. The Company recorded an $8.1 million liability representing its best estimate of the fair value of the contingent consideration as of the acquisition date. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs and will be remeasured to fair value quarterly, with any changes in the fair value recorded as other income (expense), net, in the condensed consolidated statement of operations and comprehensive income (loss). As of July 31, 2021, the fair value of the contingent consideration liability was $9.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to adjustment during the measurement period (up to one year from the acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's current allocation of the consideration paid:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,306 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Luum Acquisition resulted in $36.4 million of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational, and financial benefits expected from the Luum Acquisition, including an expanded commuter offering beyond traditional pre-tax commuter benefits and additional cross-selling opportunities. The goodwill created in the Luum Acquisition is not expected to be deductible for tax purposes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names &amp; trademarks (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma effects of the Luum Acquisition would not materially impact the Company's reported results for any period presented, and as a result no pro forma financial information is presented.</span></div> 1 50200000 20000000 8100000 9200000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's current allocation of the consideration paid:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,306 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 626000 626000 1469000 1469000 23900000 36374000 100000 597000 3566000 58306000 36400000 <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">($ in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade names &amp; trademarks (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total acquired intangible assets</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,900 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2021</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,023,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(253,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770,329 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,003 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12400000 P7Y 10900000 P5Y 600000 P3Y 23900000 P6Y Supplemental financial statement information<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following as of July 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2021</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,014 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,545 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,093 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,382 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,106 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended July 31, 2021 and 2020 was $3.5 million and $4.1 million, respectively, and $7.4 million and $8.0 million for the six months ended July 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract balances</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of July 31, 2021 and January 31, 2021, the balance of deferred revenue was $4.0 million and $4.1 million, respectively. The balances are related to cash received in advance for an interchange revenue arrangement, other up-front fees and other commuter deferred revenue, and are generally recognized within twelve months, with the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exception of the interchange arrangement, which is recognized over a term of approximately ten years. During the three and six months ended July 31, 2021, approximately $0.5 million and $1.1 million of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,475 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,909 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition gains (costs), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,286)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,588)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company's operating leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,480 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following as of July 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2021</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,604 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,014 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,927 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,592 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,545 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,093 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,987)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,382 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,106 </span></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 20604000 22271000 9014000 9230000 33927000 28592000 63545000 60093000 36163000 30987000 27382000 29106000 3500000 4100000 7400000 8000000 4000000 4100000 P10Y 500000 1100000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease costs were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,809 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,249 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating lease expense</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,048 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,475 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,909 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,349 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company's operating leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease obligations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,480 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3498000 3925000 7809000 8249000 450000 450000 900000 900000 3048000 3475000 6909000 7349000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net, consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition gains (costs), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,286)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,588)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 533000 76000 941000 676000 1665000 -28000 7604000 66000 1476000 -928000 3377000 -2198000 344000 -824000 -3286000 -1588000 7261000 6468000 320000 17480000 Intangible assets and goodwill<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2021 and January 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2021</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software and software development costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired HSA portfolios</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613,781 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601,381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired developed technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,023,434 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">962,752 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(253,105)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(195,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770,329 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767,003 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended July 31, 2021 and 2020 was $29.5 million and $24.5 million, respectively, and $57.4 million and $48.1 million for the six months ended July 31, 2021 and 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended July 31, 2021, goodwill increased by $36.4 million due to the Luum Acquisition. For further information, see Note 3—Business combination. There were no other changes to the carrying value of goodwill during the six months ended July 31, 2021.</span></div> 161134000 127005000 127794000 125141000 613781000 601381000 107825000 96925000 12900000 12300000 1023434000 962752000 253105000 195749000 770329000 767003000 29500000 24500000 57400000 48100000 36400000 Commitments and contingencies<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent acquisition consideration. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Luum Acquisition, the Company agreed to pay up to $20.0 million in additional payments which are contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. For further information, see Note 3—Business combination.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fifth Third Bank HSA portfolio acquisition. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition custodianship of Fifth Third’s HSA portfolio to HealthEquity. The definitive agreement contemplates a $60.8 million dollar purchase price for a transfer of approximately 149,000 HSA members and their approximately $477.0 million of HSA assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA assets actually transferred. The transaction is subject to satisfaction of certain customary closing conditions and is expected to close by the end of the Company's fiscal third quarter.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Further acquisition. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 550,000 HSAs and $1.7 billion of HSA assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto for, which is anticipated to close on January 31, 2022 for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021, and (2) an amended agreement to acquire the remainder of the Further business for $455 million, with a target closing date on November 1, 2021. The transactions are subject to satisfaction of certain customary closing conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company exercised its right to terminate an operating lease that had not yet commenced with aggregate undiscounted lease payments of $63.1 million and a term of approximately 11 years following the landlord's failure to fulfill its obligations under the lease agreement. The Company's right to terminate the lease agreement is disputed by the landlord. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other commitments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s other commitments consist primarily of a term loan facility, operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. Except for the items noted above, there were no material changes during the three and six months ended July 31, 2021, outside of the ordinary course of business, in our commitments from those disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, the Company's right to terminate an operating lease agreement with aggregate undiscounted lease payments of $63.1 million is disputed by the landlord.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of covenants, representations, and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal matters</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against the Company's subsidiary WageWorks, Inc. ("WageWorks"), its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleged claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering. The class action settled for $30.0 million. During the quarter ended July 31, 2021, WageWorks </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contributed $5.0 million and its insurers paid the remaining $25.0 million. The court granted final approval of the settlement and entered a final judgment on August 20, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages, fees and costs. Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint. On June 24, 2020, the court granted the defendants’ motion to dismiss the amended complaint. The plaintiffs subsequently filed a notice of appeal. The District Court action is currently stayed.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense fees and costs of its former directors and officers in the legal proceedings described above.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Except with respect to the Securities Class Action, which has been settled, the Company does not believe, based on currently available information, that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.</span></div> 20000000 60800000 149000 477000000 500000000 550000 1700000000 45000000 455000000 63100000 P11Y 63100000 30000000 5000000 25000000 2 2 Income taxes<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows Accounting Standards Codification ("ASC") 740-270, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes - Interim Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income (loss) to determine the interim benefit or provision for income taxes. For the three and six months ended July 31, 2021, the Company recorded an income tax benefit of $4.0 million and $7.4 million, respectively. This resulted in an effective income tax benefit rate of 50.8% and 53.6% for the three and six months ended July 31, 2021, respectively, compared with an effective income tax benefit rate of 78.6% and 24.0% for the three and six months ended July 31, 2020, respectively. For the three and six months ended July 31, 2021, discrete tax items had an effective tax rate benefit of 25.6% and 28.9%, respectively, compared with an effective tax rate benefit of 62.9% and 57.4% for the three and six months ended July 31, 2020, respectively, primarily due to excess tax benefits on stock-based compensation expense recognized in the provision for income taxes. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 31, 2021 and January 31, 2021, the Company’s total gross unrecognized tax benefit was $10.7 million and $10.2 million, respectively. If recognized, $9.9 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and in the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2001.</span></div> -4000000 -7400000 -0.508 -0.536 -0.786 -0.240 -0.256 -0.289 -0.629 -0.574 10700000 10200000 9900000 Indebtedness<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2021</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term loan facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">987,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: unamortized loan issuance costs (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net of issuance costs</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973,574 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,717 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">In addition to the $13.9 million and $16.4 million of unamortized issuance costs related to the term loan facility as of July 31, 2021 and January 31, 2021, respectively, $4.3 million and $5.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the condensed consolidated balance sheets as of July 31, 2021 and January 31, 2021, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a credit facility (the "Credit Agreement”) that provides for:</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion; and</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350.0 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of July 31, 2021. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of July 31, 2021, the stated interest rate was 1.84% and the effective interest rate was 2.37%. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 4.50 to 1.00 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100.0 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of July 31, 2021, and for the period then ended.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and Fort Effect Corp and are secured by security interests in substantially all assets of HealthEquity and the guarantors, subject to certain customary exceptions.</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">July 31, 2021</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">January 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Term loan facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">987,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,003,125 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: unamortized loan issuance costs (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net of issuance costs</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973,574 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">986,717 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(1)In addition to the $13.9 million and $16.4 million of unamortized issuance costs related to the term loan facility as of July 31, 2021 and January 31, 2021, respectively, $4.3 million and $5.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the condensed consolidated balance sheets as of July 31, 2021 and January 31, 2021, respectively. 987500000 1003125000 13926000 16408000 973574000 986717000 13900000 16400000 4300000 5000000 P5Y 1250000000 P5Y 350000000 0 0.0125 0.0225 0.0025 0.0125 0.0184 0.0237 0.0020 0.0040 4.50 5.00 100000000 3.00 Stock-based compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,617 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,438 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,758 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,834 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Equity-based awards exchanged for cash in connection with the Luum Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock award plans</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Plan. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2021, 7.5 million shares were available for grant under the Incentive Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding stock options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,083 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest as of July 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable as of July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.95 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,645 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted stock units and restricted stock awards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and RSA activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs and PRSUs</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs and PRSAs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.66 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.72 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance restricted stock units.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> During the first quarter of fiscal year 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million. </span></div>Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended July 31,</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended July 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,068 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,471 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,848 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Technology and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,706 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense (1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,617 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,438 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,758 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,834 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.24pt">Equity-based awards exchanged for cash in connection with the Luum Acquisition.</span></div> 3068000 2065000 5471000 3528000 2660000 1818000 4848000 2776000 3693000 2493000 6706000 5410000 6196000 5062000 11391000 7120000 0 0 342000 0 15617000 11438000 28758000 18834000 2600000 0.03 7500000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding stock options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for exercise prices and term)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range of<br/>exercise<br/>prices</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>exercise<br/>price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>average<br/>contractual<br/>term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,164 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 44.53</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.25 - 82.39</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,083 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest as of July 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercisable as of July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,352 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.95 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.20</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,645 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1674000 1.25 82.39 31.46 P5Y 87164000 225000 1.25 44.53 23.69 1449000 1.25 82.39 32.66 P4Y4M24D 60083000 1449000 32.66 P4Y4M24D 60083000 1352000 29.95 P4Y2M12D 59645000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU and RSA activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs and PRSUs</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs and PRSAs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except weighted-average grant date fair value)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average grant date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of January 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding as of July 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,611 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.66 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.72 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1832000 60.41 193000 61.77 1265000 72.47 0 0 383000 57.64 116000 61.77 103000 60.43 73000 61.77 2611000 66.66 4000 61.72 249750 22400000 0 2 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of July 31, 2021 due to the short-term nature of these instruments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liability resulting from the Luum Acquisition was determined using a Monte Carlo valuation model based on Level 3 inputs. The estimate of fair value of the contingent consideration obligation requires subjective assumptions to be made regarding revenue growth rates, discount rates, peer revenue volatilities, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of achieving certain revenue targets. The fair value measurement is based on inputs unobservable in the market and thus represents a level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation. For further information, see Note 3—Business combination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the period presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of January 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of July 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,158 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—unobservable inputs based on the Company’s own assumptions.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the period presented:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.444%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of January 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration recognized at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance as of July 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,158 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 8147000 1011000 9158000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
6 Months Ended
Jul. 31, 2021
Aug. 31, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jul. 31, 2021  
Document Transition Report false  
Entity File Number 001-36568  
Entity Registrant Name HEALTHEQUITY, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 52-2383166  
Entity Address, Address Line One 15 West Scenic Pointe Drive  
Entity Address, Address Line Two Suite 100  
Entity Address, City or Town Draper,  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84020  
City Area Code 801  
Local Phone Number 727-1000  
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol HQY  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   83,508,975
Entity Central Index Key 0001428336  
Current Fiscal Year End Date --01-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated balance sheets - USD ($)
$ in Thousands
Jul. 31, 2021
Jan. 31, 2021
Current assets    
Cash and cash equivalents $ 753,754 $ 328,803
Accounts receivable, net of allowance for doubtful accounts of $5,824 and $4,239 as of July 31, 2021 and January 31, 2021, respectively 74,223 72,767
Other current assets 32,637 58,607
Total current assets 860,614 460,177
Property and equipment, net 27,382 29,106
Operating lease right-of-use assets 83,768 89,508
Intangible assets, net 770,329 767,003
Goodwill 1,363,568 1,327,193
Other assets 42,973 37,420
Total assets 3,148,634 2,710,407
Current liabilities    
Accounts payable 4,696 1,614
Accrued compensation 40,154 50,670
Accrued liabilities 49,098 75,880
Current portion of long-term debt 78,125 62,500
Operating lease liabilities 13,051 14,037
Total current liabilities 185,124 204,701
Long-term liabilities    
Long-term debt, net of issuance costs 895,449 924,217
Operating lease liabilities, non-current 69,998 74,224
Other long-term liabilities 20,091 8,808
Deferred tax liability 115,306 119,729
Total long-term liabilities 1,100,844 1,126,978
Total liabilities 1,285,968 1,331,679
Commitments and contingencies (see Note 6)
Stockholders’ equity    
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively 0 0
Common stock, $0.0001 par value, 900,000 shares authorized, 83,608 and 77,168 shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively 8 8
Additional paid-in capital 1,648,743 1,158,372
Accumulated earnings 213,915 220,348
Total stockholders’ equity 1,862,666 1,378,728
Total liabilities and stockholders’ equity $ 3,148,634 $ 2,710,407
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated balance sheets (Parenthetical) - USD ($)
$ in Thousands
Jul. 31, 2021
Jan. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 5,824 $ 4,239
Preferred stock, par value (in usd per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (in shares) 100,000,000 100,000,000
Preferred stock, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in usd per share) $ 0.0001 $ 0.0001
Common stock, authorized (in shares) 900,000,000 900,000,000
Common stock, issued (in shares) 83,608,000 77,168,000
Common stock, outstanding (in shares) 83,608,000 77,168,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Revenues [Abstract]        
Revenue $ 189,103 $ 176,039 $ 373,305 $ 366,050
Cost of revenue        
Cost of revenue 77,132 74,255 158,218 156,192
Gross profit 111,971 101,784 215,087 209,858
Operating expenses        
Sales and marketing 15,476 12,167 29,562 23,622
Technology and development 37,898 30,654 73,367 61,732
General and administrative 22,812 20,493 43,499 39,491
Amortization of acquired intangible assets 20,289 19,077 40,103 37,779
Merger integration 16,371 10,365 25,178 23,135
Total operating expenses 112,846 92,756 211,709 185,759
Income (loss) from operations (875) 9,028 3,378 24,099
Other expense        
Interest expense (7,254) (8,895) (13,943) (21,158)
Other income (expense), net 344 (824) (3,286) (1,588)
Total other expense (6,910) (9,719) (17,229) (22,746)
Income (loss) before income taxes (7,785) (691) (13,851) 1,353
Income tax benefit (3,967) (543) (7,418) (325)
Net income (loss) (3,818) (148) (6,433) 1,678
Comprehensive income (loss) $ (3,818) $ (148) $ (6,433) $ 1,678
Net income (loss) per share:        
Basic (in usd per share) $ (0.05) $ (0.00) $ (0.08) $ 0.02
Diluted (in usd per share) $ (0.05) $ (0.00) $ (0.08) $ 0.02
Weighted-average number of shares used in computing net income (loss) per share:        
Basic (in shares) 83,481 72,343 82,628 71,669
Diluted (in shares) 83,481 72,343 82,628 72,971
Service revenue        
Revenues [Abstract]        
Revenue $ 109,182 $ 103,805 $ 211,716 $ 215,076
Cost of revenue        
Cost of revenue 67,334 65,246 137,966 136,259
Custodial revenue        
Revenues [Abstract]        
Revenue 48,776 46,909 95,754 93,808
Cost of revenue        
Cost of revenue 4,824 4,998 9,833 10,043
Interchange revenue        
Revenues [Abstract]        
Revenue 31,145 25,325 65,835 57,166
Cost of revenue        
Cost of revenue $ 4,974 $ 4,011 $ 10,419 $ 9,890
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated statements of stockholders' equity (unaudited) - USD ($)
$ in Thousands
Total
Common stock:
Additional paid-in capital:
Accumulated earnings
Beginning balance at Jan. 31, 2020 $ 1,030,295 $ 7 $ 818,774 $ 211,514
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock   0 2,751  
Other issuance of common stock   1 286,777  
Stock-based compensation     18,834  
Net income (loss) 1,678     1,678
Ending balance at Jul. 31, 2020 1,340,336 8 1,127,136 213,192
Beginning balance at Apr. 30, 2020 1,040,650 7 827,303 213,340
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     1,618  
Other issuance of common stock   1 286,777  
Stock-based compensation     11,438  
Net income (loss) (148)     (148)
Ending balance at Jul. 31, 2020 1,340,336 8 1,127,136 213,192
Beginning balance at Jan. 31, 2021 1,378,728 8 1,158,372 220,348
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     5,315  
Other issuance of common stock     456,640  
Stock-based compensation     28,416  
Net income (loss) (6,433)     (6,433)
Ending balance at Jul. 31, 2021 1,862,666 8 1,648,743 213,915
Beginning balance at Apr. 30, 2021 1,848,270 8 1,630,529 217,733
Stockholders' Equity        
Issuance of common stock upon exercise of stock options, and for restricted stock     2,599  
Other issuance of common stock     (2)  
Stock-based compensation     15,617  
Net income (loss) (3,818)     (3,818)
Ending balance at Jul. 31, 2021 $ 1,862,666 $ 8 $ 1,648,743 $ 213,915
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed consolidated statements of cash flows (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Cash flows from operating activities:    
Net income (loss) $ (6,433) $ 1,678
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation and amortization 64,819 56,106
Stock-based compensation 28,416 18,834
Amortization of debt issuance costs 2,482 2,533
Change in fair value of contingent consideration 1,011 0
Other non-cash items (752) 1,145
Deferred taxes (4,051) (568)
Changes in operating assets and liabilities:    
Accounts receivable, net (230) 628
Other assets 20,636 (3,187)
Operating lease right-of-use assets 6,060 5,563
Accrued compensation (10,639) (13,854)
Accounts payable, accrued liabilities, and other current liabilities (30,213) 30
Operating lease liabilities, non-current (4,556) (5,723)
Other long-term liabilities 1,616 5,477
Net cash provided by operating activities 68,166 68,662
Cash flows from investing activities:    
Acquisitions, net of cash acquired (49,533) 0
Purchases of software and capitalized software development costs (32,097) (21,787)
Purchases of property and equipment (6,352) (8,987)
Acquisition of intangible member assets (2,653) (24,922)
Proceeds from sale of equity securities 2,367 0
Net cash used in investing activities (88,268) (55,696)
Cash flows from financing activities:    
Proceeds from follow-on equity offering, net of payments for offering costs 456,642 287,318
Principal payments on long-term debt (15,625) (215,625)
Settlement of client-held funds obligation, net (2,636) (10,292)
Proceeds from exercise of common stock options 6,672 2,817
Net cash provided by financing activities 445,053 64,218
Increase in cash and cash equivalents 424,951 77,184
Beginning cash and cash equivalents 328,803 191,726
Ending cash and cash equivalents 753,754 268,910
Supplemental cash flow data:    
Interest expense paid in cash 9,838 17,659
Income tax payments (refunds), net (5,545) 798
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable or accrued liabilities 357 1,104
Contingent consideration recognized at acquisition 8,147 0
Exercise of common stock options receivable 119 66
Additions to goodwill due to measurement period adjustments 0 1,177
Follow-on equity offering costs accrued during the period 0 540
Computer software intangible asset    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation 4,077 1,262
Acquired HSA portfolios    
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation $ 0 $ 58
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of business and significant accounting policies
6 Months Ended
Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of business and significant accounting policies Summary of business and significant accounting policies
Business
HealthEquity, Inc. ("HealthEquity" or the "Company") was incorporated in the state of Delaware on September 18, 2002. HealthEquity is a leader in administering health savings accounts (“HSAs”) and complementary consumer-directed benefits (“CDBs”), which empower consumers to access tax-advantaged healthcare savings while also providing corporate tax advantages for employers.
Principles of consolidation
The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation
The accompanying condensed consolidated financial statements as of July 31, 2021 and for the three and six months ended July 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Follow-on equity offering
In the first quarter of fiscal year 2022, the Company closed a follow-on public offering of 5,750,000 shares of common stock at a public offering price of $80.30 per share, less the underwriters' discount. The Company received net proceeds of $456.6 million after deducting underwriting discounts and commissions of $4.6 million and other offering expenses of approximately $0.5 million. The Company used $50.2 million of the net proceeds from the offering to acquire 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum, and intends to use the remaining net proceeds from the offering for general corporate purposes, which may include prepayments under its term loan facility or potential acquisitions, including the acquisitions of Further and the Fifth Third Bank HSA portfolio.
Significant accounting policies
There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Net income (loss) per share
6 Months Ended
Jul. 31, 2021
Earnings Per Share [Abstract]  
Net income (loss) per share Net income (loss) per share
The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2021202020212020
Numerator (basic and diluted):
Net income (loss)$(3,818)$(148)$(6,433)$1,678 
Denominator (basic):
Weighted-average common shares outstanding83,481 72,343 82,628 71,669 
Denominator (diluted):
Weighted-average common shares outstanding83,481 72,343 82,628 71,669 
Weighted-average dilutive effect of stock options and restricted stock units— — — 1,302 
Diluted weighted-average common shares outstanding83,481 72,343 82,628 72,971 
Net income (loss) per share:
Basic $(0.05)$0.00 $(0.08)$0.02 
Diluted$(0.05)$0.00 $(0.08)$0.02 
For the three months ended July 31, 2021 and 2020, 1.9 million and 2.1 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
For the six months ended July 31, 2021 and 2020, approximately 2.0 million and 0.6 million shares, respectively, attributable to stock options and restricted stock units were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination
6 Months Ended
Jul. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Business combination Business combination
Acquisition of Luum
On March 8, 2021, the Company acquired 100% of the outstanding capital stock of Fort Effect Corp, d/b/a Luum (the "Luum Acquisition"). Luum provides employers with a suite of commute tools as well as real-time commute data to help them design and implement flexible return-to-office and hybrid-workplace strategies and benefits. The aggregate purchase price consisted of $50.2 million in cash, and up to $20.0 million in additional payments which are contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. The Company recorded an $8.1 million liability representing its best estimate of the fair value of the contingent consideration as of the acquisition date. The fair value of this contingent consideration was determined using a Monte Carlo valuation model based on Level 3 inputs and will be remeasured to fair value quarterly, with any changes in the fair value recorded as other income (expense), net, in the condensed consolidated statement of operations and comprehensive income (loss). As of July 31, 2021, the fair value of the contingent consideration liability was $9.2 million.
The Luum Acquisition was accounted for under the acquisition method of accounting for business combinations. Consideration paid was allocated to the tangible and intangible assets acquired and liabilities assumed based on their fair values as of the acquisition date. The initial allocation of the consideration paid was based on a preliminary valuation and is subject to adjustment during the measurement period (up to one year from the acquisition date). Balances subject to adjustment primarily include the valuations of acquired assets (tangible and intangible) and liabilities assumed, as well as tax-related matters. The Company expects the allocation of the consideration transferred to be finalized within the measurement period.
The following table summarizes the Company's current allocation of the consideration paid:
(in thousands)Estimated fair value
Cash and cash equivalents$626 
Other current assets1,469 
Intangible assets23,900 
Goodwill36,374 
Other assets100 
Current liabilities(597)
Deferred tax liability(3,566)
Total consideration paid$58,306 
The Luum Acquisition resulted in $36.4 million of goodwill. The preliminary goodwill to be recognized is attributable to several strategic, operational, and financial benefits expected from the Luum Acquisition, including an expanded commuter offering beyond traditional pre-tax commuter benefits and additional cross-selling opportunities. The goodwill created in the Luum Acquisition is not expected to be deductible for tax purposes.
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.

The pro forma effects of the Luum Acquisition would not materially impact the Company's reported results for any period presented, and as a result no pro forma financial information is presented.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information
6 Months Ended
Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental financial statement information Supplemental financial statement information
Selected condensed consolidated balance sheet and condensed consolidated statement of operations and comprehensive income (loss) components consisted of the following:
Property and equipment
Property and equipment consisted of the following as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Leasehold improvements$20,604 $22,271 
Furniture and fixtures9,014 9,230 
Computer equipment33,927 28,592 
Property and equipment, gross63,545 60,093 
Accumulated depreciation(36,163)(30,987)
Property and equipment, net$27,382 $29,106 
Depreciation expense for the three months ended July 31, 2021 and 2020 was $3.5 million and $4.1 million, respectively, and $7.4 million and $8.0 million for the six months ended July 31, 2021 and 2020, respectively.
Contract balances
The Company does not recognize revenue until its right to consideration is unconditional and therefore has no related contract assets. The Company records a receivable when revenue is recognized prior to payment and the Company has unconditional right to payment. Alternatively, when payment precedes the related services, the Company records a contract liability, or deferred revenue, until its performance obligations are satisfied. As of July 31, 2021 and January 31, 2021, the balance of deferred revenue was $4.0 million and $4.1 million, respectively. The balances are related to cash received in advance for an interchange revenue arrangement, other up-front fees and other commuter deferred revenue, and are generally recognized within twelve months, with the
exception of the interchange arrangement, which is recognized over a term of approximately ten years. During the three and six months ended July 31, 2021, approximately $0.5 million and $1.1 million of revenue was recognized that was included in the balance of deferred revenue as of January 31, 2021.
Leases
The components of operating lease costs were as follows:
Three months ended July 31,Six months ended July 31,
(in thousands)
2021202020212020
Operating lease expense$3,498 $3,925 $7,809 $8,249 
Sublease income(450)(450)(900)(900)
Net operating lease expense$3,048 $3,475 $6,909 $7,349 
Other income (expense), net
Other income (expense), net, consisted of the following:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Interest income$533 $76 $941 $676 
Acquisition gains (costs), net(1,665)28 (7,604)(66)
Other income (expense), net1,476 (928)3,377 (2,198)
Total other income (expense), net$344 $(824)$(3,286)$(1,588)
Supplemental cash flow information related to the Company's operating leases was as follows:
Six months ended July 31,
(in thousands)20212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,261 $6,468 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$320 $17,480 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill
6 Months Ended
Jul. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill Intangible assets and goodwill
Intangible assets
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$161,134 $127,005 
Acquired HSA portfolios127,794 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,023,434 962,752 
Accumulated amortization(253,105)(195,749)
Amortizable intangible assets, net$770,329 $767,003 
Amortization expense for the three months ended July 31, 2021 and 2020 was $29.5 million and $24.5 million, respectively, and $57.4 million and $48.1 million for the six months ended July 31, 2021 and 2020, respectively.
Goodwill
During the six months ended July 31, 2021, goodwill increased by $36.4 million due to the Luum Acquisition. For further information, see Note 3—Business combination. There were no other changes to the carrying value of goodwill during the six months ended July 31, 2021.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and contingencies
6 Months Ended
Jul. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies Commitments and contingencies
Commitments
Contingent acquisition consideration. In connection with the Luum Acquisition, the Company agreed to pay up to $20.0 million in additional payments which are contingent on Luum achieving certain revenue targets during the two-year period following the closing of the Luum Acquisition and, if achieved, would be payable in fiscal years 2023 and 2024. For further information, see Note 3—Business combination.
Fifth Third Bank HSA portfolio acquisition. In April 2021, the Company entered into a definitive agreement with Fifth Third Bank, National Association ("Fifth Third"), to transition custodianship of Fifth Third’s HSA portfolio to HealthEquity. The definitive agreement contemplates a $60.8 million dollar purchase price for a transfer of approximately 149,000 HSA members and their approximately $477.0 million of HSA assets. The agreement includes a mechanism to adjust the purchase price based on the amount of HSA assets actually transferred. The transaction is subject to satisfaction of certain customary closing conditions and is expected to close by the end of the Company's fiscal third quarter.
Further acquisition. In April 2021, the Company entered into a definitive agreement to acquire Further for $500 million. Further is a leading provider of HSA and other CDB administration services, with approximately 550,000 HSAs and $1.7 billion of HSA assets. In September 2021, the terms of the acquisition were amended pursuant to two agreements: (1) an agreement to acquire all cash balances and investment assets included in any voluntary employee beneficiary association (“VEBA”) account that is funding a health reimbursement arrangement (either Section 501(c)(9) or Section 115 trusts) and all contracts related exclusively thereto for, which is anticipated to close on January 31, 2022 for a maximum purchase price of $45 million, calculated based on the actual amount of VEBA assets transferred relative to the total amount of VEBA assets as of April 30, 2021, and (2) an amended agreement to acquire the remainder of the Further business for $455 million, with a target closing date on November 1, 2021. The transactions are subject to satisfaction of certain customary closing conditions.
Lease termination. In April 2021, the Company exercised its right to terminate an operating lease that had not yet commenced with aggregate undiscounted lease payments of $63.1 million and a term of approximately 11 years following the landlord's failure to fulfill its obligations under the lease agreement. The Company's right to terminate the lease agreement is disputed by the landlord. Because the lease had not yet commenced, the Company had not recognized a right-of-use asset, operating lease liability, or any rent expense associated with the lease.
Other commitments. The Company’s other commitments consist primarily of a term loan facility, operating lease obligations for office space, data storage facilities, and other leases, a processing services agreement with a vendor, and contractual commitments related to network infrastructure, equipment, and certain maintenance agreements under long-term, non-cancelable commitments. Except for the items noted above, there were no material changes during the three and six months ended July 31, 2021, outside of the ordinary course of business, in our commitments from those disclosed in our Annual Report on Form 10-K for the fiscal year ended January 31, 2021.
Contingencies
As described above, the Company's right to terminate an operating lease agreement with aggregate undiscounted lease payments of $63.1 million is disputed by the landlord.
In the normal course of business, the Company enters into contracts and agreements that contain a variety of covenants, representations, and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.
Legal matters
On March 9, 2018, a putative class action was filed in the U.S. District Court for the Northern District of California (the “Securities Class Action”). On May 16, 2019, a consolidated amended complaint was filed by the lead plaintiffs asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, against the Company's subsidiary WageWorks, Inc. ("WageWorks"), its former Chief Executive Officer and its former Chief Financial Officer on behalf of purchasers of WageWorks common stock between May 6, 2016 and March 1, 2018. The complaint also alleged claims under the Securities Act of 1933, as amended, arising from WageWorks’ June 19, 2017 common stock offering against those same defendants, as well as the members of its board of directors at the time of that offering. The class action settled for $30.0 million. During the quarter ended July 31, 2021, WageWorks
contributed $5.0 million and its insurers paid the remaining $25.0 million. The court granted final approval of the settlement and entered a final judgment on August 20, 2021.
On June 22, 2018 and September 6, 2018, two derivative lawsuits were filed against certain of WageWorks’ former officers and directors and WageWorks (as nominal defendant) in the Superior Court of the State of California, County of San Mateo. The actions were consolidated. On July 23, 2018, a similar derivative lawsuit was filed against certain former WageWorks’ officers and directors and WageWorks (as nominal defendant) in the U.S. District Court for the Northern District of California (together, the “Derivative Suits”). The allegations in the Derivative Suits relate to substantially the same facts as those underlying the Securities Class Action described above. The plaintiffs seek unspecified damages, fees and costs. Plaintiffs in the Superior Court action filed an amended consolidated complaint on October 28, 2019, naming as defendants certain former officers and directors of WageWorks and alleging a direct claim of "inseparable fraud/breach of fiduciary duty" on behalf of a class. WageWorks was not named as a party in that complaint. On June 24, 2020, the court granted the defendants’ motion to dismiss the amended complaint. The plaintiffs subsequently filed a notice of appeal. The District Court action is currently stayed.
WageWorks previously entered into indemnification agreements with its former directors and officers and, pursuant to these indemnification agreements, is covering the defense fees and costs of its former directors and officers in the legal proceedings described above.
The Company and its subsidiaries are involved in various other litigation, governmental proceedings and claims, not described above, that arise in the normal course of business. It is not possible to determine the ultimate outcome or the duration of such litigation, governmental proceedings or claims, or the impact that such litigation, proceedings and claims will have on the Company’s financial position, results of operations, and cash flows.
As required under GAAP, the Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Except with respect to the Securities Class Action, which has been settled, the Company does not believe, based on currently available information, that any liabilities relating to these matters are probable or that the amount of any resulting loss is estimable. However, litigation is subject to inherent uncertainties and the Company’s view of these matters may change in the future. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on the Company’s financial position, results of operations and cash flows for the period in which the unfavorable outcome occurs, and potentially in future periods.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Income taxes
6 Months Ended
Jul. 31, 2021
Income Tax Disclosure [Abstract]  
Income taxes Income taxes
The Company follows Accounting Standards Codification ("ASC") 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income (loss) to determine the interim benefit or provision for income taxes. For the three and six months ended July 31, 2021, the Company recorded an income tax benefit of $4.0 million and $7.4 million, respectively. This resulted in an effective income tax benefit rate of 50.8% and 53.6% for the three and six months ended July 31, 2021, respectively, compared with an effective income tax benefit rate of 78.6% and 24.0% for the three and six months ended July 31, 2020, respectively. For the three and six months ended July 31, 2021, discrete tax items had an effective tax rate benefit of 25.6% and 28.9%, respectively, compared with an effective tax rate benefit of 62.9% and 57.4% for the three and six months ended July 31, 2020, respectively, primarily due to excess tax benefits on stock-based compensation expense recognized in the provision for income taxes.
As of July 31, 2021 and January 31, 2021, the Company’s total gross unrecognized tax benefit was $10.7 million and $10.2 million, respectively. If recognized, $9.9 million of the total gross unrecognized tax benefits would affect the Company's effective tax rate as of July 31, 2021.
The Company files income tax returns with U.S. federal and state taxing jurisdictions and is currently under examination by the IRS and in the state of Texas. These examinations may lead to ordinary course adjustments or proposed adjustments to our taxes, net operating losses, and/or tax credit carryforwards. As a result of the Company's net operating loss carryforwards and tax credit carryforwards, the Company remains subject to examination by one or more jurisdictions for tax years after 2001.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness
6 Months Ended
Jul. 31, 2021
Debt Disclosure [Abstract]  
Indebtedness Indebtedness
Long-term debt consisted of the following:
(in thousands)July 31, 2021January 31, 2021
Term loan facility$987,500 $1,003,125 
Less: unamortized loan issuance costs (1)13,926 16,408 
Long-term debt, net of issuance costs$973,574 $986,717 
(1)In addition to the $13.9 million and $16.4 million of unamortized issuance costs related to the term loan facility as of July 31, 2021 and January 31, 2021, respectively, $4.3 million and $5.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the condensed consolidated balance sheets as of July 31, 2021 and January 31, 2021, respectively.
The Company is party to a credit facility (the "Credit Agreement”) that provides for:
(i)       a five-year senior secured term loan A facility (the “Term Loan Facility”), in an aggregate principal amount of $1.25 billion; and
(ii)      a five-year senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Credit Facilities”), in an aggregate principal amount of up to $350.0 million, which may be used for working capital and general corporate purposes, including acquisitions and other investments. No amounts were drawn under the Revolving Credit Facility as of July 31, 2021.
Borrowings under the Credit Facilities bear interest at an annual rate equal to, at the option of HealthEquity, either (i) LIBOR (adjusted for reserves) plus a margin ranging from 1.25% to 2.25% or (ii) an alternate base rate plus a margin ranging from 0.25% to 1.25%, with the applicable margin determined by reference to a leverage-based pricing grid set forth in the Credit Agreement. As of July 31, 2021, the stated interest rate was 1.84% and the effective interest rate was 2.37%. The Company is also required to pay certain fees to the lenders, including, among others, a quarterly commitment fee on the average unused amount of the Revolving Credit Facility at a rate ranging from 0.20% to 0.40%, with the applicable rate also determined by reference to a leverage-based pricing grid set forth in the Credit Agreement.
The Credit Agreement contains customary affirmative and negative covenants, including covenants that limit, among other things, the ability of the Company to incur additional indebtedness, create liens, merge or dissolve, make investments, dispose of assets, engage in sale and leaseback transactions, make distributions and dividends and prepayments of junior indebtedness, engage in transactions with affiliates, enter into restrictive agreements, amend documentation governing junior indebtedness, modify its fiscal year and modify its organizational documents, in each case, subject to customary exceptions, thresholds, qualifications and “baskets.” In addition, the Credit Agreement contains financial performance covenants, which require the Company to maintain (i) a maximum total net leverage ratio, measured as of the last day of each fiscal quarter, of no greater than 4.50 to 1.00 (subject to a customary “acquisition holiday” provision that allows the maximum total net leverage ratio to increase to 5.00 to 1.00 for the four fiscal quarter period ending on or following the date of a permitted acquisition by the Company in excess of $100.0 million), and (ii) a minimum interest coverage ratio, measured as of the last day of each fiscal quarter, of no less than 3.00 to 1.00. The Company was in compliance with all covenants under the Credit Agreement as of July 31, 2021, and for the period then ended.
The obligations of HealthEquity under the Credit Agreement are required to be unconditionally guaranteed by WageWorks and Fort Effect Corp and are secured by security interests in substantially all assets of HealthEquity and the guarantors, subject to certain customary exceptions.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation
6 Months Ended
Jul. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-based compensation Stock-based compensation
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Cost of revenue$3,068 $2,065 $5,471 $3,528 
Sales and marketing2,660 1,818 4,848 2,776 
Technology and development3,693 2,493 6,706 5,410 
General and administrative6,196 5,062 11,391 7,120 
Other expense (1)— — 342 — 
Total stock-based compensation expense$15,617 $11,438 $28,758 $18,834 
(1)Equity-based awards exchanged for cash in connection with the Luum Acquisition.
Stock award plans
Incentive Plan. The Company grants stock options, restricted stock units ("RSUs"), and restricted stock awards ("RSAs") under the HealthEquity, Inc. 2014 Equity Incentive Plan (as amended and restated, the "Incentive Plan"), which provided for the issuance of stock awards to the directors and team members of the Company to purchase up to an aggregate of 2.6 million shares of common stock.
In addition, under the Incentive Plan, the number of shares of common stock reserved for issuance under the Incentive Plan automatically increases on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of July 31, 2021, 7.5 million shares were available for grant under the Incentive Plan.
Stock options
A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20211,674 
$1.25 - 82.39
$31.46 5.00$87,164 
Exercised(225)
$1.25 - 44.53
$23.69 
Outstanding as of July 31, 20211,449 
$1.25 - 82.39
$32.66 4.40$60,083 
Vested and expected to vest as of July 31, 20211,449 $32.66 4.40$60,083 
Exercisable as of July 31, 20211,352 $29.95 4.20$59,645 
Restricted stock units and restricted stock awards
A summary of RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20211,832 $60.41 193 $61.77 
Granted1,265 72.47 — — 
Vested(383)57.64 (116)61.77 
Forfeited(103)60.43 (73)61.77 
Outstanding as of July 31, 20212,611 $66.66 $61.72 
Performance restricted stock units. During the first quarter of fiscal year 2022, the Company awarded 249,750 performance restricted stock units ("PRSUs") subject to a market condition based on the Company’s total shareholder return ("TSR") relative to the Russell 2000 index as measured on January 31, 2024. The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $22.4 million.
Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied. The market condition allows for a range of vesting from 0% to 200% based on the level of performance achieved. The PRSUs cliff vest upon approval by the Compensation Committee of the board of directors.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value
6 Months Ended
Jul. 31, 2021
Fair Value Disclosures [Abstract]  
Fair value Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
Level 1 instruments are valued based on publicly available daily net asset values. Level 1 instruments consist primarily of cash and cash equivalents. The carrying value of cash and cash equivalents approximate fair values as of July 31, 2021 due to the short-term nature of these instruments.
Our long-term debt is considered a Level 2 instrument and is recorded at book value in our condensed consolidated financial statements. Our long-term debt reprices frequently due to variable interest rate terms and entails no significant changes in credit risk. As a result, we believe the fair value of our long-term debt approximates carrying value.
The contingent consideration liability resulting from the Luum Acquisition was determined using a Monte Carlo valuation model based on Level 3 inputs. The estimate of fair value of the contingent consideration obligation requires subjective assumptions to be made regarding revenue growth rates, discount rates, peer revenue volatilities, and probabilities assigned to various potential business result scenarios and was determined using probability assessments with respect to the likelihood of achieving certain revenue targets. The fair value measurement is based on inputs unobservable in the market and thus represents a level 3 measurement. Changes in current expectations of progress could change the probability of achieving the targets within the measurement periods and result in an increase or decrease in the fair value of the contingent consideration obligation. For further information, see Note 3—Business combination.
The following table reconciles the change in the fair value of the contingent consideration during the period presented:
(in thousands)Carrying Amount
Balance as of January 31, 2021$— 
Contingent consideration recognized at acquisition8,147 
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)1,011 
Balance as of July 31, 2021$9,158 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of business and significant accounting policies (Policies)
6 Months Ended
Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Principles of consolidation The condensed consolidated financial statements include the accounts of HealthEquity and its direct and indirect subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Basis of presentation The accompanying condensed consolidated financial statements as of July 31, 2021 and for the three and six months ended July 31, 2021 and 2020 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2021. The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted
Recently adopted accounting pronouncements
None.
Recently issued accounting pronouncements not yet adopted
None.
Fair value
Fair value measurements are made at a specific point in time based on relevant market information. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:
Level 1—quoted prices in active markets for identical assets or liabilities;
Level 2—inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
Level 3—unobservable inputs based on the Company’s own assumptions.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Net income (loss) per share (Tables)
6 Months Ended
Jul. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings (Loss) Per Share, Basic and Diluted The following table sets forth the computation of basic and diluted net income (loss) per share:
Three months ended July 31,Six months ended July 31,
(in thousands, except per share data)2021202020212020
Numerator (basic and diluted):
Net income (loss)$(3,818)$(148)$(6,433)$1,678 
Denominator (basic):
Weighted-average common shares outstanding83,481 72,343 82,628 71,669 
Denominator (diluted):
Weighted-average common shares outstanding83,481 72,343 82,628 71,669 
Weighted-average dilutive effect of stock options and restricted stock units— — — 1,302 
Diluted weighted-average common shares outstanding83,481 72,343 82,628 72,971 
Net income (loss) per share:
Basic $(0.05)$0.00 $(0.08)$0.02 
Diluted$(0.05)$0.00 $(0.08)$0.02 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Tables)
6 Months Ended
Jul. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Preliminary Allocation of Consideration The following table summarizes the Company's current allocation of the consideration paid:
(in thousands)Estimated fair value
Cash and cash equivalents$626 
Other current assets1,469 
Intangible assets23,900 
Goodwill36,374 
Other assets100 
Current liabilities(597)
Deferred tax liability(3,566)
Total consideration paid$58,306 
Schedule of Acquired Identified Intangible Assets
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$161,134 $127,005 
Acquired HSA portfolios127,794 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,023,434 962,752 
Accumulated amortization(253,105)(195,749)
Amortizable intangible assets, net$770,329 $767,003 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Tables)
6 Months Ended
Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Property and Equipment Property and equipment consisted of the following as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Leasehold improvements$20,604 $22,271 
Furniture and fixtures9,014 9,230 
Computer equipment33,927 28,592 
Property and equipment, gross63,545 60,093 
Accumulated depreciation(36,163)(30,987)
Property and equipment, net$27,382 $29,106 
Lease Cost The components of operating lease costs were as follows:
Three months ended July 31,Six months ended July 31,
(in thousands)
2021202020212020
Operating lease expense$3,498 $3,925 $7,809 $8,249 
Sublease income(450)(450)(900)(900)
Net operating lease expense$3,048 $3,475 $6,909 $7,349 
Supplemental cash flow information related to the Company's operating leases was as follows:
Six months ended July 31,
(in thousands)20212020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$7,261 $6,468 
Operating lease right-of-use assets obtained in exchange for new operating lease obligations$320 $17,480 
Other Income (Expense), Net Other income (expense), net, consisted of the following:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Interest income$533 $76 $941 $676 
Acquisition gains (costs), net(1,665)28 (7,604)(66)
Other income (expense), net1,476 (928)3,377 (2,198)
Total other income (expense), net$344 $(824)$(3,286)$(1,588)
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill (Tables)
6 Months Ended
Jul. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-lived Intangible Assets
The preliminary allocation of consideration exchanged to acquired identified intangible assets is as follows:
($ in thousands)Fair valueEstimated life
(in years)
Customer relationships (1)$12,400 7.0
Developed technology (1)10,900 5.0
Trade names & trademarks (1)600 3.0
Total acquired intangible assets$23,900 6.0
(1) The Company preliminarily valued the acquired assets utilizing the discounted cash flow method, a form of the income approach.
The gross carrying amount and associated accumulated amortization of intangible assets were as follows as of July 31, 2021 and January 31, 2021:
(in thousands)July 31, 2021January 31, 2021
Amortizable intangible assets:
Software and software development costs$161,134 $127,005 
Acquired HSA portfolios127,794 125,141 
Acquired customer relationships613,781 601,381 
Acquired developed technology107,825 96,925 
Acquired trade names12,900 12,300 
Amortizable intangible assets, gross1,023,434 962,752 
Accumulated amortization(253,105)(195,749)
Amortizable intangible assets, net$770,329 $767,003 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness (Tables)
6 Months Ended
Jul. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Long-term debt consisted of the following:
(in thousands)July 31, 2021January 31, 2021
Term loan facility$987,500 $1,003,125 
Less: unamortized loan issuance costs (1)13,926 16,408 
Long-term debt, net of issuance costs$973,574 $986,717 
(1)In addition to the $13.9 million and $16.4 million of unamortized issuance costs related to the term loan facility as of July 31, 2021 and January 31, 2021, respectively, $4.3 million and $5.0 million of unamortized issuance costs related to our revolving credit facility are included within other assets on the condensed consolidated balance sheets as of July 31, 2021 and January 31, 2021, respectively.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Tables)
6 Months Ended
Jul. 31, 2021
Share-based Payment Arrangement [Abstract]  
Summary of Share Based Compensation Recognized
The following table shows a summary of stock-based compensation in the Company's condensed consolidated statements of operations and comprehensive income (loss) during the periods presented:
Three months ended July 31,Six months ended July 31,
(in thousands)2021202020212020
Cost of revenue$3,068 $2,065 $5,471 $3,528 
Sales and marketing2,660 1,818 4,848 2,776 
Technology and development3,693 2,493 6,706 5,410 
General and administrative6,196 5,062 11,391 7,120 
Other expense (1)— — 342 — 
Total stock-based compensation expense$15,617 $11,438 $28,758 $18,834 
(1)Equity-based awards exchanged for cash in connection with the Luum Acquisition.
Summary of Stock Option Activity A summary of stock option activity is as follows:
Outstanding stock options
(in thousands, except for exercise prices and term)Number of
options
Range of
exercise
prices
Weighted-
average
exercise
price
Weighted-
average
contractual
term
(in years)
Aggregate
intrinsic
value
Outstanding as of January 31, 20211,674 
$1.25 - 82.39
$31.46 5.00$87,164 
Exercised(225)
$1.25 - 44.53
$23.69 
Outstanding as of July 31, 20211,449 
$1.25 - 82.39
$32.66 4.40$60,083 
Vested and expected to vest as of July 31, 20211,449 $32.66 4.40$60,083 
Exercisable as of July 31, 20211,352 $29.95 4.20$59,645 
Summary of Restricted Stock Unit Activity A summary of RSU and RSA activity is as follows:
RSUs and PRSUsRSAs and PRSAs
(in thousands, except weighted-average grant date fair value)SharesWeighted-average grant date fair valueSharesWeighted-average grant date fair value
Outstanding as of January 31, 20211,832 $60.41 193 $61.77 
Granted1,265 72.47 — — 
Vested(383)57.64 (116)61.77 
Forfeited(103)60.43 (73)61.77 
Outstanding as of July 31, 20212,611 $66.66 $61.72 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value (Tables)
6 Months Ended
Jul. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Change in the Fair Value of the Contingent Consideration
The following table reconciles the change in the fair value of the contingent consideration during the period presented:
(in thousands)Carrying Amount
Balance as of January 31, 2021$— 
Contingent consideration recognized at acquisition8,147 
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)1,011 
Balance as of July 31, 2021$9,158 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of business and significant accounting policies (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended
Mar. 08, 2021
Apr. 30, 2021
Luum Acquisition    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Aggregate fair value of WageWorks stock acquired $ 50.2  
Ownership interest (as a percent) 100.00%  
Follow on equity offering    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Common stock, shares (in shares)   5,750,000
Offering price per share (in usd per share)   $ 80.30
Net proceeds from follow on offering   $ 456.6
Underwriting discounts and commissions   4.6
Other offering expenses payable   $ 0.5
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Net income (loss) per share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Numerator (basic and diluted):        
Net income (loss) $ (3,818) $ (148) $ (6,433) $ 1,678
Denominator (basic):        
Weighted-average common shares outstanding (in shares) 83,481 72,343 82,628 71,669
Denominator (diluted):        
Weighted-average common shares outstanding (in shares) 83,481 72,343 82,628 71,669
Weighted-average dilutive effect of stock options and restricted stock units (in shares) 0 0 0 1,302
Diluted weighted-average common shares outstanding (in shares) 83,481 72,343 82,628 72,971
Net income (loss) per share:        
Basic (in usd per share) $ (0.05) $ (0.00) $ (0.08) $ 0.02
Diluted (in usd per share) $ (0.05) $ (0.00) $ (0.08) $ 0.02
Antidilutive securities excluded from computation of earnings per share (in shares) 1,900 2,100 2,000 600
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Narrative) (Details) - USD ($)
$ in Thousands
Mar. 08, 2021
Jul. 31, 2021
Jan. 31, 2021
Business Acquisition [Line Items]      
Goodwill   $ 1,363,568 $ 1,327,193
Luum Acquisition      
Business Acquisition [Line Items]      
Ownership interest (as a percent) 100.00%    
Aggregate fair value of WageWorks stock acquired $ 50,200    
Contingent payments payable 8,100 $ 9,200  
Goodwill 36,374    
Luum Acquisition | Maximum      
Business Acquisition [Line Items]      
Contingent payments payable $ 20,000    
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Preliminary Allocation of Consideration) (Details) - USD ($)
$ in Thousands
Jul. 31, 2021
Mar. 08, 2021
Jan. 31, 2021
Business Acquisition [Line Items]      
Goodwill $ 1,363,568   $ 1,327,193
Luum Acquisition      
Business Acquisition [Line Items]      
Cash and cash equivalents   $ 626  
Other current assets   1,469  
Intangible assets   23,900  
Goodwill   36,374  
Other assets   100  
Current liabilities   (597)  
Deferred tax liability   (3,566)  
Total consideration paid   $ 58,306  
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Business combination (Acquired Identified Intangible Assets) (Details) - Luum Acquisition
$ in Thousands
Mar. 08, 2021
USD ($)
Business Acquisition [Line Items]  
Fair value $ 23,900
Estimated life (in years) 6 years
Customer relationships  
Business Acquisition [Line Items]  
Fair value $ 12,400
Estimated life (in years) 7 years
Developed technology  
Business Acquisition [Line Items]  
Fair value $ 10,900
Estimated life (in years) 5 years
Trade names & trademarks  
Business Acquisition [Line Items]  
Fair value $ 600
Estimated life (in years) 3 years
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Property and equipment) (Details) - USD ($)
$ in Thousands
Jul. 31, 2021
Jan. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 63,545 $ 60,093
Accumulated depreciation (36,163) (30,987)
Property and equipment, net 27,382 29,106
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 20,604 22,271
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,014 9,230
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 33,927 $ 28,592
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Jan. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]          
Depreciation expense $ 3.5 $ 4.1 $ 7.4 $ 8.0  
Remaining performance obligation 4.0   $ 4.0   $ 4.1
Deferred revenue interchange arrangement recognition term     10 years    
Revenue recognition $ 0.5   $ 1.1    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Lease Cost) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Operating lease expense $ 3,498 $ 3,925 $ 7,809 $ 8,249
Sublease income (450) (450) (900) (900)
Net operating lease expense $ 3,048 $ 3,475 $ 6,909 $ 7,349
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Other income (expense), net) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Interest income $ 533 $ 76 $ 941 $ 676
Acquisition gains (costs), net (1,665) 28 (7,604) (66)
Other income (expense), net 1,476 (928) 3,377 (2,198)
Total other income (expense), net $ 344 $ (824) $ (3,286) $ (1,588)
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental financial statement information (Supplemental Cash Flow Information) (Details) - USD ($)
$ in Thousands
6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 7,261 $ 6,468
Operating lease right-of-use assets obtained in exchange for new operating lease obligations $ 320 $ 17,480
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill (Schedule of intangible assets) (Details) - USD ($)
$ in Thousands
Jul. 31, 2021
Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross $ 1,023,434 $ 962,752
Accumulated amortization (253,105) (195,749)
Amortizable intangible assets, net 770,329 767,003
Software and software development costs    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 161,134 127,005
Acquired HSA portfolios    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 127,794 125,141
Acquired customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 613,781 601,381
Acquired developed technology    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross 107,825 96,925
Acquired trade names    
Finite-Lived Intangible Assets [Line Items]    
Amortizable intangible assets, gross $ 12,900 $ 12,300
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible assets and goodwill (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization expense $ 29.5 $ 24.5 $ 57.4 $ 48.1
Goodwill acquired     $ 36.4  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and contingencies - Narrative (Details)
hsaMember in Thousands, $ in Millions
1 Months Ended
Sep. 09, 2021
USD ($)
Sep. 06, 2018
lawsuit
Jun. 22, 2018
lawsuit
Apr. 30, 2021
USD ($)
hsaMember
Jul. 31, 2021
USD ($)
Mar. 08, 2021
USD ($)
Loss Contingencies [Line Items]            
Operating lease not yet commenced undiscounted amount       $ 63.1    
Operating lease not yet commenced undiscounted, term       11 years    
Settle of claims         $ 30.0  
Number of derivative lawsuits | lawsuit   2 2      
WageWorks Insurers            
Loss Contingencies [Line Items]            
Settle of claims         25.0  
WageWorks, Inc            
Loss Contingencies [Line Items]            
Settle of claims         5.0  
Fifth Third Bank HSA portfolio Acquisition            
Loss Contingencies [Line Items]            
Purchase price for HSA portfolio       $ 60.8    
Number of HSA members transferred in portfolio acquisition | hsaMember       149    
Value of HSA assets transferred in portfolio acquisition       $ 477.0    
Further Health Savings Account Portfolio Acquisition            
Loss Contingencies [Line Items]            
Purchase price for HSA portfolio       $ 500.0    
Number of HSA members transferred in portfolio acquisition | hsaMember       550    
Value of HSA assets transferred in portfolio acquisition       $ 1,700.0    
Further Health Savings Account Portfolio Acquisition | Subsequent Event            
Loss Contingencies [Line Items]            
Maximum purchase price $ 45.0          
Purchase price for VEBA assets $ 455.0          
Luum Acquisition            
Loss Contingencies [Line Items]            
Contingent payments payable         $ 9.2 $ 8.1
Luum Acquisition | Maximum            
Loss Contingencies [Line Items]            
Contingent payments payable           $ 20.0
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Jan. 31, 2021
Income Tax Disclosure [Abstract]          
Income tax benefit $ 3,967 $ 543 $ 7,418 $ 325  
Effective tax rate (50.80%) (78.60%) (53.60%) (24.00%)  
Effective tax rate, primarily due to excess tax benefit on stock-based compensation expense (benefit) (25.60%) (62.90%) (28.90%) (57.40%)  
Gross unrecognized tax benefits $ 10,700   $ 10,700   $ 10,200
Unrecognized tax benefits that would impact the effective tax rate $ 9,900   $ 9,900    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness (Schedule of Long-term Debt) (Details) - USD ($)
$ in Thousands
Jul. 31, 2021
Jan. 31, 2021
Term Loan Facility    
Debt Instrument [Line Items]    
Term loan facility $ 987,500 $ 1,003,125
Less: unamortized loan issuance costs 13,926 16,408
Long-term debt, net of issuance costs 973,574 986,717
Revolving Credit Facility    
Debt Instrument [Line Items]    
Less: unamortized loan issuance costs $ 4,300 $ 5,000
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Indebtedness (Narrative) (Details)
6 Months Ended
Jul. 31, 2021
USD ($)
Debt Instrument [Line Items]  
Effective interest rate percentage 2.37%
Acquisition threshold for maximum total net leverage ratio $ 100,000,000
Minimum interest coverage ratio 3.00
Debt Covenant, Beginning July 31, 2021  
Debt Instrument [Line Items]  
Maximum leverage ratio 4.50
Debt Covenant, Acquisition Holiday Provision  
Debt Instrument [Line Items]  
Maximum leverage ratio 5.00
London Interbank Offered Rate (LIBOR) | Minimum  
Debt Instrument [Line Items]  
Variable rate borrowing spread 1.25%
London Interbank Offered Rate (LIBOR) | Maximum  
Debt Instrument [Line Items]  
Variable rate borrowing spread 2.25%
Customary Base Rate | Minimum  
Debt Instrument [Line Items]  
Variable rate borrowing spread 0.25%
Customary Base Rate | Maximum  
Debt Instrument [Line Items]  
Variable rate borrowing spread 1.25%
Revolving Credit Facility | Minimum  
Debt Instrument [Line Items]  
Commitment fee percentage 0.20%
Revolving Credit Facility | Maximum  
Debt Instrument [Line Items]  
Commitment fee percentage 0.40%
Credit Agreement | Secured Debt | Term Loan Facility  
Debt Instrument [Line Items]  
Facility term 5 years
Credit facility, amount $ 1,250,000,000
Credit Agreement | Line of Credit  
Debt Instrument [Line Items]  
Stated interest rate percentage 1.84%
Credit Agreement | Line of Credit | Revolving Credit Facility  
Debt Instrument [Line Items]  
Facility term 5 years
Credit facility, amount $ 350,000,000
Long-term line of credit $ 0
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Summary of share based compensation recognized) (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 15,617 $ 11,438 $ 28,758 $ 18,834
Cost of revenue        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,068 2,065 5,471 3,528
Sales and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 2,660 1,818 4,848 2,776
Technology and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 3,693 2,493 6,706 5,410
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense 6,196 5,062 11,391 7,120
Other expense        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Total stock-based compensation expense $ 0 $ 0 $ 342 $ 0
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Narrative) (Details)
$ in Millions
6 Months Ended
Jul. 31, 2021
USD ($)
shares
Performance restricted stock units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Performance units awards (in shares) 249,750
Grant date fair value | $ $ 22.4
Performance restricted stock units | Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting rights percentage 0.00%
Performance restricted stock units | Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Award vesting rights percentage 200.00%
Incentive Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of shares authorized (in shares) 2,600,000
Percentage of capital stock 3.00%
Shares available for grant under incentive plan (in shares) 7,500,000
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Stock option activity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended 12 Months Ended
Jul. 31, 2021
Jan. 31, 2021
Number of options (shares)    
Outstanding, beginning balance (in shares) 1,674  
Exercised (in shares) (225)  
Outstanding, ending balance (in shares) 1,449 1,674
Vested and expected to vest (in shares) 1,449  
Exercisable (in shares) 1,352  
Range of exercise prices    
Beginning balance, minimum (in usd per share) $ 1.25  
Beginning balance, maximum (in usd per share) 82.39  
Exercised, minimum (in usd per share) 1.25  
Exercised, maximum (in usd per share) 44.53  
Ending balance, minimum (in usd per share) 1.25 $ 1.25
Ending balance, maximum (in usd per share) 82.39 82.39
Weighted- average exercise price    
Opening balance (in usd per share) 31.46  
Exercised (in usd per share) 23.69  
Ending balance (in usd per share) 32.66 $ 31.46
Vested and expected to vest, weighted average exercise price (in usd per share) 32.66  
Exercisable, weighted-average exercise price (in usd per share) $ 29.95  
Outstanding stock options, weighted average contractual term (in years) 4 years 4 months 24 days 5 years
Vested and expected to vest, weighted average contractual term (in years) 4 years 4 months 24 days  
Exercisable, weighted-average contractual term (in years) 4 years 2 months 12 days  
Aggregate intrinsic value $ 60,083 $ 87,164
Vested and expected to vest, aggregate intrinsic value (in usd per share) 60,083  
Exercisable, aggregate intrinsic value $ 59,645  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-based compensation (Restricted stock unity activity) (Details)
shares in Thousands
6 Months Ended
Jul. 31, 2021
$ / shares
shares
Restricted Stock Units  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning balance (in shares) | shares 1,832
Granted (in shares) | shares 1,265
Vested (in shares) | shares (383)
Forfeited (in shares) | shares (103)
Outstanding, ending balance (in shares) | shares 2,611
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning balance (in usd per share) | $ / shares $ 60.41
Granted (in usd per share) | $ / shares 72.47
Vested (in usd per share) | $ / shares 57.64
Forfeited (in usd per share) | $ / shares 60.43
Outstanding, ending balance (in usd per share) | $ / shares $ 66.66
Restricted Stock Awards  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Outstanding, beginning balance (in shares) | shares 193
Granted (in shares) | shares 0
Vested (in shares) | shares (116)
Forfeited (in shares) | shares (73)
Outstanding, ending balance (in shares) | shares 4
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning balance (in usd per share) | $ / shares $ 61.77
Granted (in usd per share) | $ / shares 0
Vested (in usd per share) | $ / shares 61.77
Forfeited (in usd per share) | $ / shares 61.77
Outstanding, ending balance (in usd per share) | $ / shares $ 61.72
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value (Details) - Contingent Consideration
$ in Thousands
6 Months Ended
Jul. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Balance as of January 31, 2021 $ 0
Contingent consideration recognized at acquisition 8,147
Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss) 1,011
Balance as of July 31, 2021 $ 9,158
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

^Z:-Q_=J)$#>_YN0#T#8(J7ZWZT_S1Q$V_D@WC\KH$+V5[C%#,J MQ]+%[-7Y1+CXK2"^!%OS_7QG Q*.'PN%[' D@/G! !D !X;"]W;W)K&ULM5A;;]LV%/XKA!%@":#:LB3+=I $2-L5:[&MP=)M#\,>:(NVB%&B M1E)QLE^_[U 7RV[M=0/V8O%VSOG.G?3-3IL_;"Z$8\^%*NWM*'>NNIY,[#H7 M!;=C78D2.QMM"NXP-=N)K8S@F27DME-[=CJ:C;N$GNI%$N%PW'%_YW6'+BMNQ1NM?I69RV]'BQ'+Q(;7ROVD=]^)5I\9\5MK9?TO MV[5GPQ%;U];IHB4&@D*6S9<_MW;X&H*H)8@\[D:01_F6.WYW8_2.&3H-;C3P MJGIJ@),E.>71&>Q*T+F[Q[JJE("5'5=L(TM>KB5&UG'G5YDL&\_#A#<3!XE$ M-UFWW%\WW*,3W%/V@RY=;MFW92:R0_H)D/9PHP[NZ^@LPP^U&K-X&K HC*9G M^,6]^K'G%Y_@]]%L>2G_\NH%[(TNK58RXTW E!E[,,*2;?R"WK!WO84>.PM9 M]MO]RCJ#^/K]#**D1Y1X1,G_Y)"SW"G%KVW%U^)V5)%JYDF,_I5(]N@32F1L MK>'3TC:CUFR8K+@"O6!-22$;GCBX9P^[HL@8S]^V) 7@Y93[3P+B,1?L4FEK MK_R>+KWAB9^TQ PL7"[81BM4&5ENK^$YXNE>/#_Q9RTK+^O$\FE.C%M:0^"] M]('GB3_PLD89ZQ>OV:4L0:MKBVT /20Y/LZ^%R@FN589DU!6/[7!=('=( T3 M&D1!-)^R=[4II:N-\&(W\IG&EBV#<)K@-XI#!&Y1U4Z8@49Q'"RC.8L6P6P9 MG5 [8%L#F[(T#F;)C*5A$"YC=K]>UT6MO),R 3\@&KSK+^,TF*;Q%09AL%S, MKTZR+>%ZX)\'\2*BP3*8ABE[.V0FGBL*"AC:>(.[W C!BJ9<""H77[ Y!B'; MP2,7\7B&S.DF M$K,V&YBT.$,))&F*I"0(0(K6I1$0.2?.8-=X:]WAX-8*].H#&"3=9,@O&@GY MQ%=*L!URK$<#83W$C%5&DE4TJ_B+CZA6=,^0A!^"ZY5H2<;L7B$J2]YYPHOK M^%$PB RV(::="E22)"P8'(C:8^]55)*OI)(.7 $3?5@8 _I6EV!@6D2H+U]4 ME?1*R6U7:&! B['=2)$!ZE?F>8.L*W,@.9;=!&@R"*_S =JXJ0\=@M59@^*! MV[SU&!9087CVY"53S')$2 D+KW->;O=AQ8VA>9.+FL*%U=6KC8'MV$:(IL8V MZZBFA:\81SVM1=4V3%H8P M#^#M# M(VX7X7$AF>[]1,*'3AU =#EW?@W-2=59XYI_"HRVE1P%U+AI!4W1&'2W?5N$ MCHJ.8-=B8R>,Y]7T*'L-PM.U\_&D.8[:E0]X7V#WHX]'\KNB?<'B(%DN_'<9 MS?"=!XMPB>\BB)(E>ZQ7#4'7NI-9>-7]+L/^]T?TB6,=AS+"I)&1S$E&&BR] M#+05R/CHX[<3T%)=-;WGS%YP]M;POUGR/<6_L*X#=<%F<4RZI/A9)E-2#^/[ M-9JH]?64;?&DLNS2^[S5ZW(:I.D,$A;L1 M J+WD=\K!6!&%Y^CIH",4N_!($D7GR6-[XJO].95;47;F=&''+S; $*M;.HB M(2[QCCW.B&'3@D>@Y06;SH-D$;(O/3@F@]=@(9-_@,W6PI")38@#&ULK59M;]LV$/XK!RT8$D"PWOV2V0;L9EM;K$/0 MK-V'81]HZ6P1I4B7I.)XOWY'2E&7>:'Y3^9&I$"W>- MD&81U-;N+Z/(E#4VS(S4'B7M;)5NF*6IWD5FKY%5WJ@141K'XZAA7 ;+N5^[ MULNY:JW@$J\UF+9IF#ZN4:C#(DB"^X7W?%=;MQ MYWNVPQNT'_;7FF;1@%+Q M!J7A2H+&[2)8)9?KW.E[A8\<#^9$!A?)1JE/;O*F6@2Q(X0"2^L0& VW^ J% M<$!$XW./&0PNG>&I?(_^BX^=8MDP@Z^4^)-7MEX$TP JW+)6V/?J\!K[> J' M5RIA_#\<.MTB"Z!LC55-;TP,&BZ[D=WUYW!B,(V?,4A[@]3S[AQYEE?,LN5< MJP-HITUH3O"A>FLBQZ6[E!NK:9>3G5V^D9;)'=\(!&8,6@-,5K!3JCIP(>:1 M)1].,RI[O'6'ESZ#-X9W2MK:P,^RPNJQ?430$O&P+./%[V#-ZO?6@^SI/H5UWT5]R40IE6(_RUVABKZ=G\_8+;?'";>[?Y M_W;._P4/GF[_42/LM#(&2J;UD7=IQN#3OX"V3+27]L'@)YUR"K55K:-MB;.]1,6EW"CMO; '!7R9>XG%=Y2U=E3#;%0*D-TSR 9)V&2Y4Y*)V$< M%[ J/[=<4[2O;U:P)S<4"U?&[T]F.8U%F.3)@UZ7EJBI* E_-*;F>P/C) LG MTP3&<1)FTQ/]G@9)%LM:*J%V1TCB23A-"YB-PUEZ0H)>7(4@68..03B+8S=D M-+QX!&%_N4D8IUF84X"S<1I.BI20G[G/\[3(PB0N+N \F17A))]=?,N'I"YQ M!I-)'&;IS$EC=X398.9Q\8XZAD%Z$IHN&.FG$:'IR@*ZLO"5]T%"# =Z/6?I M;%10I1/"%VW:.DOSAY60#MWLT==R<0P[A6(RRA^;Y--1,JS<$S'\[GMH/'8Q M@J%B7+7:ITIW2@"?G5*! M\CAE3?=)SZIW.M2!6R:("J7MP+KZWDA'7RN-T4D[HC39^:;K^%&UZ3K3L#KT M]577SA[4NX^"=TSON#0@<$NF\6A2!*"[1MM-K-K[YK91EG+2BS5]FZ!V"K2_ M5716_<0Y&+YVEO\"4$L#!!0 ( %R *5/IS"[7Q@T &0D 9 >&PO M=V]R:W-H965TW>3#;>-]^5U/7D[6M^]MF^?6U:7^I:?;;"M54E[?VU*LWNS60Q20]^TNN-IP>G M;U\W9(@\=]6W:BR)$%0X_=^\V;R8N)R%4AV]+_9'8?5+3G@N1EIG3\K]B%M1?+B7;U];LA*75D$8?V%3>#>5T34&Y]19O M-?;YMS>FJK2'E[T3LLY%9FJOZ[6J,ZW>!_Y_;[73G O8 MX'2NK*1O,_$=/ZECHNRTWPB_4>*'MJW$5;]MRD\AOI'UO9!KJU0NO!&-O!=M M0Y^.EO/9'# M2Q*DD71YSEME2:N"3KN-SC9"PL=9KQV6\W$RVVBUQ4.1*>M! M*LC\K:I;);RT:X7M>6OI-:GB=^;9O9)6-,IJDXO"E""9])8B29]-<= :\MQ4 MZ"(>J?!E9]HR%RM%NLI5JLR4: M8ST,T688,8[156-UR8DPC@3\IRQ"H6N$0!(GZ5H3V848D==#4/?/FXJ/,D;G MRCF3:?XFCB>#A9.3*446J5 G\! KY1K?-[HA[PY6L[G/7[D]2R#@@Y*EW[R' M1?Y^AL7JL)X$"54UI?1 LA1'E_/9BPY0.>)+T6YMM@$3"_@C4XBZQ4I6L$ @ MH)!L&FON-**ARGNQ.'\YG<_GK%*EJI6R(6O@0FWWUAZ=/W\^0#!DT2[I') 7 MM.Y5U756MCFK62DH5&M7D:4R_PT>X@CM:4KE(R>HTSM9F9: /SR"BE0K2RB2 MS$%!\3)\+L;R[E@F< _=Y*"]P!Q3$#_DRX^HA^D$023V$^NIAW MP>D/UA2"$AT)V8AH;HG:.L>2(;SLYMTU8H,:JHG8V5M.V2T"XZ8A/\98N+B8 M)]P$?QTM9L_%ZC T8.^M:CS#:V S+*U<;_A*J(U)P9&1'8FA+0(V10JIE[ ML-5*U8@#& /Y9 +**.7\U>_O+^^XH^+5] GRQB[?B,]>;]H:_:]%!O.9@W,9B!Q/A']TE& M3TBEL_DT0HN<8Q(^A!2IM5JDF<6><7 Q-#-L22V]%' M#IO)V(]F&W >V[('!.6XNG\E16:*9R2. 3Y]$))22U LFH0I,0*)LJ0A%:HZ[&)N2A'JE)J)3XSJ MK.]^1\[H.A.SORQTPZC8 !:PJ!$DBEJ(7VD &R WJ;2G[3 HE$:F*(@R7",S M-:6$D0((MQAODQ!-U:8O2BR&GE#A H-S$J2RM-^_28%6.">*2UV_C:0S-"?Q M(Z)>*T]#,36G5J+JM5AMH9@"/32T.DJ*Z4A$X55-I610@R+:2E.OGY%/I@AL M_2RC525WR2.7O[_+4 ?9&10;C9+H" D$@!6(8QJX.A3 V@A*"ZO)A T5B7%_ MOX$.K*'3=Z(*DV6@.\R%'7_C7]-Z&F@2Q0&W #O1BJ$J1(\3VTVI".+IR&6% M-6C=-E0>\C "AF))ZZ[JFCS\DZ)VENB/;@/$8O[L'YV1@QDAJ3>N,*#(\:") MC@*=8V;U:N27IS/W ('M ^3_XZLGT_^[4-UJFF[*@PY]T-RYT-OU)9L)L0<4 MTRZ])= !U$@ZY3GK,G@"^/.0:E5CEE&;Z2$4 M_8U'/G <=^B_HJ#\2O>V4Z1G-L/$WCVA>9W:!;J-H*%GHU6!(W$\!^83%R@; M!H7]9=]JXGXBX[3,$!PVLBQ(T=076Z:0[D1F4AJFO,F^8+G?$:#)[\'MEWQ8 MP,HB8"4@O?>Z+)VA+E^M*1A#O^[YKG?9V9[+K.;2R4S>J1;3'=6B5F(1@/I\ MK"\JMN*"TSN=RH"#9!I-(3[0$0[;*>2/=*Q3NDB ,N3&E9&6!^8<;7>&B@_5 M0OR0/;$L2=\=%NT?)@F:(4^PXV;\;'"-ADSI*V(!94JY M!LT"!R^]:X\EM2^5&Q#AX>3Q&2W+5\] MVDAB*=D]3TI#WIK2BCH4N5M)Z>&5B3=*D3G8B"$]1;\@QLNSGF.=1FC0:#ST MPX"\]KT0+7[@B3_!!5]'Y@8#)E:$)B+2^KO>LEL*;\_G["ZBB=AR1Q7V-\06 MF"=/D*:GCB'A+7$QVYEKRON498_4E?V6+>@SJ U.J2^0Y1J5H?_ MLEQ6\"+8HU J7=4[ZI(_]YL.(RFR0HQF/:A4@_+5$RB6?D+H^/+I12IVM:R8 MV-R R/81\0@ 1OP>KV#4.MSQA%6!IFGA!$A3C;3%CIO MPZU2WOK[R;B@R$"!L\%9.\::)]W)<&I_(-K'+HK;QFCS@#7.F4?F 41CKO*; M(8TGV%>&O0M\H.^MM'/Q1G:O&W@88* )LQ-H#&"*L2%UXS41*%'),NS:RXC^ MYA;0LD$ @'E/6=Y;CXYWJTWKRKU;TKV>=MBH\983A7PZ>,CR$ON('G2571C^& *VFN!8[7J.A_N^ZU*?3@W ME#0]P&5IGD;:KN.O,&O2OB9K]@YEY;G+F#+8#HQBTG-+H9+FCXX_&)"X_28Y M&"F1$,B=^-_2']L3NJG,1L.R^*% M[ ,YATT/XP!/(O$",;N)-YA/E(5T\=SK$EFYL=6Y4 ,M* ME?2SX[2_1.Z906ZE+N,OD(.?%8.Y$)(,)A7";3+E:$KJ-*%1IG2N8J#$GK3W M18@#A93O%,@K]*L0NP&[9N*#V4%)U.<>4'L_/^F:[G,@KJUC;>G&\T.@VM)? M:H0H#%2E&3I.1:-Q&>3(/Y34D%[(K0E%)B413C<9O);NE-2==CYP>4C% JN M--T]D\QAC^M2YFNQOP?]KO6)/TG#FH *9H$#-K !,8,:XU5J5:A$AQD^2'*S M0W^'<#KXRP_0[YK_OH5X&_$-?P32/>W^A.8J_.5(OSS\_0T&-!1X!XXNL'4^ M>WXQ"9=0Z8LW#?\="5+0FXH_;C <*TL+\+XP4#]^H0.Z/RQZ^U]02P,$% M @ 7( I4Q7BH!^U! \ L !D !X;"]W;W)K&ULI59=;]LV%/TKA)9L+6#+MNS$3N<8<-(52X$"09QN#\,>:.G*9B*)*DG5 M]G[]#DE9D=,D2+876Z+N/??<3][I1JI[O28R;)MGA3X/UL:4'WH]':\IYSJ4 M)17XDDJ5KI4A%/G%*>]:)^_[27<[5 M[H(RN3D/!L'^X$:LUL8>]&;3DJ]H0>9K>:WPUFM0$I%3H84LF*+T/)@//ER, MK+P3^$/01K>>F?5D*>6]?;E*SH.^)409Q<8BAI3#I/Z,0U0J1X^T-.98?N>&SJ9(;IJPTT.R#<]5I M@YPH;%(61N&K@)Z9716QS(D9OB4][1D@VO->7&M?>.WH&>U3]D469JW9;T5" MR:%^#TP:.M&>SD7T(N#G*@O9<-!A43\:O( W;-P;.KSAR^[=\BW[*'2<25TI M8G_-E]HH%,3?+Y@8-29&SL3H/T;P]=KL=DWL4N8E+W8LE1D:1K-Y',NJ,*)8 ML87A1<)5HB&4B%3$W!7VNV"^N S>L_&HWXW&_0Y['C=)?KU7 M;2(=5QQ<06HCS/K5+,83:]M:B^#UFUGT'X?C[;E)T.F*C*B@?M%/2D BJ5R#T#8FK=LYT SE MA2LCON_:FRIQE'&!^G:FK7TF5ZZK0OSCB\M2>JDUYMHZ4_!B,\G-HB(]WN#M1AI0KM:^9KN A9 M2@DI,',58+@O4SN5[RHE="+X6YPN+U MF-NG["'V/V(>JCN'G\-^/)WM;JJQ=B[O7)+EXR!*7!J@FDNL!H=)2&L/[#T$ MFRDN%22]/PB?VAMZK2TL)[5RNZ9F[OKV"UESVJRS<[_%/8C[7?@+5RO+.:,4 MJNB,DX IOU_Z%R-+M],MI<&&Z![72"@I*X#OJ91F_V(--$O^[%]02P,$% M @ 7( I4P02-!"T!P :!, !D !X;"]W;W)K&ULM5AK<]LV%OTK&*VS8\\P$O6RG<3VC)W'-)VTFTFSFP\[^P$B00HQ"# M:,7]]3WWDI1H^=%MI_UB4R!P'^>>^P#/-LY?A[5247ROC WGHW6,]%,X7\F(G[ZNZAT)')5R,;$3V[S@^K\69*\S)G M?\6FW3L[&8FL"=%5W6%84&G;_I??.QP&!T[31P[,N@,SMKM5Q%:^D5%>G'FW M$9YV0QH]L*M\&L9I2T'Y)7J\U3@7+][;7*VBRJT*X6P2(9'6)UEW^JH]/7OD M]+'XR=FX#N(MQ.1WST]@R=:<66_.U>Q)@3\V9BSFTT3,TMGT"7GSK7MSEC=_ M1-X;."?>Z) 9%QJOQ'\O5R%Z4.%_3PA?;(4O6/CB3V+W_Y\6'YPMGT?E*T&+ M(G-@?2:(&T>C@00N]TB)GZ4MD%N[18^DTSC MI!6%S+31\58G)\DR3?$T3=)TGDQG2_$!9KP4C965\U'_"M5\2H?02)LI MF!1B$(?3(S&=)R]FQV)ZG"S2TSW+$V%12&#TWCGH/)DGRY,%:S].3J8G+.L] M\C+/-2=H=.SJP70^?@&J&\-9:W.L'(\7VQ4('UJYI\@K(PFW3EB\[[X,).(N M;*1E'[H$LD*MN&J8VT0<+,;SNV8MQ^D?M\HU'C]OG+E!-$7F%;P?& >.:IN9 M!NF$2A#7"+:#(QYF!P5)A-.:Q((]-F 34<49G;/\E32LE>M!^).NCL5G:'CM MJEK:6W@B:NEA&FR7]^P])&-&K]O5R](KA8(=__F/T]EL^NH(ILHH:N]N=*X" M2.R)OD>04T#3\ULET1Z4U8[^9=:][;0F0@WM" MEK"C!![0#"QU+8U 9!K+Q#R8CL'V51NV5PS'H7[:IL?#-33LTW97!\>>?:0J M 8JEXGA2<#F4]QU*Q$#L76%:A3_F;E-3X [FRW1'UD1LUCI;HXW'^R5[*6D>2 FQ*997'<^9\[3QK:? 45$@ZHM()F7UK=. T#GRLY:RV-RI$ M8D08BY]=9U80&P6:YUYN+)(FQT;R]U'\'J+Q6%PY[[DBAH&,>V#!/TEV@%:P M1("-A)@%_8U@;]0W>HPNH744B49I>(OA_>7_WKDSB4 M^=>&:S1A!_'*P]LC49L&& !<7R) 7MJ2?"J\JP11[QG%8\8/SG?4@TD&%EHR MB$:,UK0G!*6]():8[,@DZ]KH3*Z,ZL_EBE(*O0?5X9;&*"!!)8+3V:@;1+=4 MSTEK3@3*2$?I=0[V1_(,@K4=@KO-\K&XO!^8EKLAD<5BW2U7139;$N*+" *TK3>&04P5S*[%A@0 M;9!\:PB=/(B(7J^:787+-34UC&#\"Q0NY;O= X5M#P@J(V& M8[PO^5R72"'8&"!>1BX MO<+N35O\J.^A[#1QHH22:1@:4$MSA5E^1NA2O'5_4]TS5'6IQ#=O7 MSN1XIA*K"U!\AU[7W,#?:\1CW+?(P3B8/$C>'4T+#;)E&D;6RO/EM!VWMLQL M>UQ7*_9)1M=5KAGM.((+E:Z:"F^H[]$(VZ<8I:1V1#09>!AHFQ&7&(EZE4OF M,$/3X=J5E836K4-6$F&)_:CSB_$R;>LVQN_# 8IR@&,'SJ"IBC6/>-M1@D4F&] 91(VMO&\C N]X0RMKE("[#C4CV(H6@3+-)&LSUIA!R;LW@NP8^\#TTKK7H]TABT=+\*J\ MU>]61I==RNQ-(T^J ]F'#9(&/$O7A:ZH76( MM]R7@8"O>9%D]L,P3O CF=%'A $"F='V;=2L@^#IKRQ[QO?=OS/#43,>UI.N MFS]45\8/W=HG@Z\?W _H&P_Z&'7K]D/(=G7[&>FR_7JRV]Y^@_J)9Z8 7A0X MFHY/EB/AV^\Z[8_H:OZ6LG(1QO'C6DD$@S;@?>%<['^0@NW'M8O? %!+ P04 M " !<@"E36)U! 00' "<$ &0 'AL+W=O MREK84&]E@R]K;6KA,#6;L=T:*0J_J:[&\622C6NAFM'MM5^[,[?7NG65:N2= M(=O6M3!/[V2E]S>C:'18N%>;TO'"^/9Z*S;R0;K?MG<&L_&@I5"U;*S2#1FY MOADMHZMW*2GXF8T88=D)7/'&@1^=O*]K"I6!#<^ M]SI'@TG>>#P^:/_>QXY85L+*][KZJ I7WHSF(RKD6K25N]?['V4?SY3UY;JR M_B_M.]DT&5'>6J?K?C,\J%73_8K'/@]'&^:3,QOB?D/L_>X,>2^_%4[<7AN] M)\/2T,8#'ZK?#>=4PX?RX R^*NQSMP].YY_>.VAGF7'> M:WK7:8K/:,KH%]VXTM)W32&+Y_O'\&IP+3ZX]BY^5>'/;152$@443^+H%7W) M$&KB]27G0BV%D7VH=^()R'*T-$8T&^G'_UJNK#. R;]?,98.QE)O+/T_Y/55 M35R55W8K6Q*'P2*_)GMNO M&G)0\1YKHGGZN\57'&?3R3565ZH0#A/K\,-ILZP.'&'\?IAI.HU&EERZ.PF5 MF$NZJ+2UEU2TQGL&(]BD=&')A]5 ZQ7<-U)2W0%),I (,'CR,'A0CV>^7'BO M=6MA'"88+_QG?T("K9 M!8.4?9*.?8Z#+)M0%,RC.:7!/)UC93;+Z(/,RT97>O/D-Q0P4>FMQU029(L$ M8BG^9L%LDK&9:$(_R 89J[R\*%#7BJ''! 6Q:,%BDRRF* J2142S($((OR)G MAN0C'Q;2&5W2W_XRCZ/XF^$W2>-A_$$[Z#][S@^5*?]+_ M:-N:ECET6,5?0O( [A31MA( SD]-CHQQ!NXP#SV2>QC2!E4*I/EH #:/M !G MB:2IO(,C?VD;!:F+T?W#;W9T&?CLOA#JG6>I):2PJ4!:VQ?.4@7 OBH.R0>#'%I!%[7Z+DT>[,O55X"['JGBCYG+*FL;06$A[(\ M>.BT_UXH@W1JTZ'125%3+>N5-+[RCHJ5-VQ;@S/!N;9;GL)-L=D8N8%C+!V' M&9I(5?'A6*9#KP/ J'F!C8<($X@L_#$%1\EY'D\79-.R'][QD\JHYZLNV"'0 M /7#,MJ&_I>KDS+Y!6Q$2F0R2 EI*5W<:!)9L. 9N'T:PSLI9$D=D)5OE_P8?F*.WM2 MA_KM2Y&6+WI+_ZF[=7'U*,L'U+4F>T6_'F7E65D_)_. 249NG?=)/DJ3*\L9 M4[D\U(.I+^F?0W[NF9!X\-'?QV3Q]FBT'&KAV'R'FR_GTB4*2,AF*;V)PGA* M;VD>A\F"NT,4IF#G<#+!9 YBSL /O5\%7<3Q]'+8DZ;A-&$^3<)L<_^W$_O3:8Q MQ[ (%U/LC7GO=!%DZ93N3_/O:ZS[#"B@:2\,(CZ+$Z9R+W3G1\S9A^GR'%;V MAP,7.S19P*$#,U]<:"V4H9VH6GE)#QWZ/_XI\?]1^D\!;)[$_B3"%+,%0R6+ MPMF,?F"52%T4Q+B:S.(PG;WH]3T(+I)YG"]Q!)GQ%_ -K:.1W7;\'M%;_037XQM=?V_SUU?SHL=<6D9Z1K#;K\Z,/#/70;6777L[XKW[<@YJI""& "!9I\ MY"S6Z%>MZLV,CUZ,M30;_R[FRW[;N.[Q.*P.3^]E]^+\(MZ]VW\1 M!AW8HE6ML742SJ8C,MU;N)LXO?7OSY5V:.]^6$J!'+, OJ^U=H<)&QC^(7'[ M7U!+ P04 " !<@"E3C2Q(@:T& Q$ &0 'AL+W=OB:1OK=-1FWO9C,)_V+=WI=1WXQNSQOY9K>4_RM?>OQ-!NT*-V0#=I9 MX6EU,;F:GUX?\_ZTX:.F;1BM!4>R=.Z&'WY2%Y-#=H@,59$U2/QLZ"49PXK@ MQJ>B3DXE0M)*=B>_<]D-!HFW_EYY*'D<#)X0,"BR*P2'YG0\G+[V64E^?> M;87GW=#&BQ1JDH9SVG)1WD>/KQIR\?*5U%YLI.GH?!:AC]_.JB)[G647#\@^ M%V^U@03V6]M MVPY6.1>U"W2_)-?1+;GN-=BA M"%2M.++@.E]1F,(E#>&QUKN:V-F7KD&2=E]_=;*8OS@;:H#<=TW+3H<#\:$& M0$7<(J!="]^1C:*IEAL2%29"9%1 W@Y O" MH*]N3P4IP6JOK.V61E?P36ZD-LF>PF(G;"XJ_B:1!U16,*;1EL@+,L%RJ'4E M0YV"2POZU&FHX.T)&7CK_8XKGHO]F("0;>O=9^B.- )(8-*!'&; ;I@!0D%9 MZB$2H78^?AO)-\+*V/ED)294CKQ'TW3 A+/KO%71,C*SI:# &$QN/3I&R'IX*UE4=" ML VAE@@WR'1!!O83TN\Y/RP;DG/8C1H&84&[>FV9\)G3*X!YG=&+%E0:TI=PN$28GKD]L)K<]2V?; MB028G=CNZZYK0+> 0M!I]U;RR&&[B<:ZP-ME.E6@':0W;L2;C5,HV@#RTERE MD[);2%N&%<*Z'61\S&F'=EGG)==%\QDA=,N_*-/!J >Y4LLR>SVM,2K88P]7 M+.RL<72(=2HY7]YY5N*>&DA72NT.$>2R7B6-Y@G0A=0HZ M.]&%,*74([T'XN4(^)WW;(L^(^:UYS15Z?"26Z6<0?;9N!4B?RQA MI=3T[HTB:@F95CG5)?_Y1()C#89@2'-<45D7!5^$1IS.H&K5^31Q1L>V*4Y> M)'X!'H;IL/%L@L&0+JCY(;HV70J7+N**F98U[O3D>0.^KQS0 M51[8P/!?@LM_ %!+ P04 " !<@"E3:7&HG[ & "J$0 &0 'AL+W=O M&]65>(/DYNK1J_H@=)O MS7W VZ374IJ:7#3>J4#+Z]'\],WM!>^7#?\QM(Z#9\61++S_P"\_E->C*3M$ MEHK$&C3^/=(=6H-\F"P^>M]G<2.V)9Z$AWWO[7E*FZ'EV,5$E+ MW=KTWJ^_IRZ>5ZRO\#;*7[7N]DY'JFAC\G4G# ]JX_)__:G#X4L$9IW 3/S. MAL3+?^BD;ZZ"7ZO NZ&-'R14D89SQG%2'E+ JH%NM**O?E)_"_#V*V#>)V=E3AOUH[5F>G)VHVG9T>T7?6@W(F^LZ>T?=+ M6&EG_M3,FQ-UYUU$L*7.- (X]X$BN90_ +EWQFE7&&W5 SX2.)NB^GV^B"F M=?\[XM'+WJ.7XM'+9SRZ#P8&&@OD8:\8>G0(_^/*?JV(590H+2H'RO"R[".) MNTA@VK8EJ02YC@OBQO>D;:K>?FQ-V@@N!M]+$U!P^=5U+[%=1%,:'<"7L9I; MNT-=IN=?E8 ^%S44KY15?J1U(+(*;(&E2#^&K=61R/Q-8,T'T+YN)I?.[0D+JZ=OP.Y%@? Z\W77YV>3R^WY!98T(HE%ZD* M1%VU?E)UKBGBFGI.$@]3I0.IUNFV-&R>/^^@1<@-UK? C'ZYWQ^/_HVYYAA:AHT$[VPI$++ M2GDAT*JU.N<>PKSO@8HVF&2Z'6\_%95V*T*%UK6),B=>C![>WD$UI'4HV5>A MEZD'."-&'SB.L?HAN^H;X[I:KK7#,.(LG,C25AS)TMM*@'EP6)=_H#]+ODXD MI28*.-Y9Z:>.IP9;@].!%_8$'!7HM=QZ.9U:+;4)>XS;!HU/F#"QS_K6H09_ M?8EZNJ.0,'VQD&?TMDLYGPCE& OK8PLMG4-PK@M#,J6=:^'E018.V<#9#R7V M4&8#IW! G!VYX:8':3CU31MBRR6>/'I 41W.[EBA5#"+?2"!//Z][A0KW]H2 M7B@^E'3$_:-U>>J+KRDWO,_57(=9W,.'9>]R$7\3U3RC]5X8A$PK/AJHT^EW M/_;Y60)Q;-F0#MMBU! *3^I1HAYN_@Z;GPM\H:T@G\]I0L4U6D0)"CQR.,'7 M:EO0AV([P7"'G!<2I+ZA,XN'! F$7L[Y7FPDO\>ZZ7G?3<^/ML'W5%B-VN1F M+^D^U$F/J]@2/#Q5->!?K7E ^8PQVA.2(1G0M8R3_!TT[)H:,U)8@=($0'GO ML/J.A?ZZ#_WUYT)GW;KTTA;W^J=W>"X&S,N;N3AC;(_NY@QNJ-=[",\O\8L[ M]F<]^[=W-/[_?H<^$LE%Q!+C]S+<%S^0&G8;<=J8,)P6:(&&:8H' ,; M"Q[6,+/>M:J"I'2Y,Q(/$W38&*$7Q&VTD04Y_BR)IX,U>F$LC^*N)743&%4. M@=I'AIS=P^SR;=PZN>U)O>H]/;")EDX!B1V6N>2$AV8 ,FP*<$LB;X! MCMR-0)'YCA)H.Z[$\(T=IN"9J@P.":&H9# R4'E,)2HJ9SZVZ#T]T.N*8&([ MZYH65J58/>;"04G.HU]$"H]R@D"4K=N]C]4ON[5.'X8-WPIS(_4+;B[;+HHS M*S7*YQ;*/ &K"\]X.Q>V$#_\\S-7U!+ P04 " !<@"E3MAV_/3,# "4 M!P &0 'AL+W=OJLX)+O-9@NJ9A^NL*A=HM@B0X''SDV]JZ@V@Y;]D6 MUVC_::\U[:(!I>0-2L.5!(W5(KA,9JNQD_<"GSCNS-$:G"<;I6[=YJ]R$<2. M$ HLK$-@]+O#5RB$ R(:_^TQ@\&D4SQ>']#?>-_)EPTS^$J)S[RT]2+( RBQ M8IVP']7N+>[]N7!XA1+&?V'7RUY, R@Z8U6S5R8 ?]G]WOXW"DD,FTBQZ5+RMIJNN6D9Y: MZ8'F*GT2\.].G$.6A)#&:?($7C:XG7F\[ 3>:Z8EEUL#U^3MVGO[Y7)CK*8J M^?<)_/& /_;XXQ/X:VJ>LA,(JH+!UNB=#_!@,H05,[P )DNXXJ*S_P]5'YDG M+;FFG9F6%;@(J"L-ZCL,EC%]@:X\* MKJ0*/O,I=I_X:/6A:U SJS2,'C$]F\'C*GX&HRS,D]RODG'_GX3C+'.K))Q, M<[A"J:BECF )ZK/O8RQ?L#NRN/6!(F]ZA@9HKAE+QEU<\RPN.3V MEYWD5!//_\C3)/WST3\)LS@]%";L?I5Y&KZ<)C_(U%%5]>U B8K/XPN7)_K' M^WV^WS\P^IG,,# _Q\AM02P,$ M% @ 7( I4[8T$WR;! M0H !D !X;"]W;W)K&ULA5;;;N,V$/V5@1&T,2#$NMM.'0-.=K>;!18--FG[4/2!EBB+6(K4 MDE0A[Z>3BC Q6B[K!&FPD:RF_V\U]?C/R+2#*:6:L!8*?9WI'.;>&$,:/SN:H=VD5 MA^N]]4\N=HQE332]D_QOEIOR9C0;04X+TG#S36X_TRX>!S"37+M?V+:R23R" MK-%&5ITR(JB8:+_DI*(U9+):,T%&CR&E^K#]!:#V^<(_O-CQK\$O#KR */ C],#AC+^KCC9R]Z&?Q MW@WB)2*'E=;8 JOL1\,T4^4.3F7\K&';M->Z)AF]&6%7:JJ>Z6CY5%(H)+K9,K$!8ZO9 MM1U[I1H,7F/\-1&[7['RC5)4&"!'L*Q,-H0&-6'Y-5PR@7>RT9@T/8:/VC#L M#9I#09B"9\(;M$UTZ9*:V07%E.(YNM!P 6F8PA]H7!W\VLQK"+PXG<.],$1L MF 71-_=]^%W*?,LXARCUHFG.FO=W 9>4F:CN%)&L)/Q(I@DYD7^2F)\)]8![QT4^#IJ^9"6"L(F2^%QV(-D!)'M3 M'*9QU5%-(SDNX)@>GPZD.#"%LP(YXMXV+"&"<^YUR6JL6##&O >A%V-)IU<^ M%N\9_SEJ"XIFI9!<;G9.*O =+Q*4>5(DIR!(A27_A53U;V#L"=+]>VLQ1<'( M"KI2'T)[$\_%GFXI2EO-IT.K#/+(^*Z-*G=]TAOLK#0&&?;J6@]ON' G,%%<4LY1X0L'^L^X9C I]AM%?72I*LO'+N-TK:]YDHM;,F266-N?9" M=S)C+JVZDLJPU[[*;\/<4D4'A;-+E,.W=M>_M<[!%R(:RYK]X9OV M/U;YOSBL.B36]1L4U_ H"[,E%@KZTOM-WE:\LLV<2>VJ$J2!%T2QH\;4\_WD MT$2?'U=0HQN,A4GM[J?S&+^)%\3!02X[3;@TB+SI+$"*!%XT&\CGIX@7^%-O M%B8P3[UY. !A!@Q$\EH&X2?"S]D4>%UQ \]'WL48X#P-O6D2HN5WZGD9)I$7 M^,D8Z3E/O&D\'__,A\ _M@N83GTO"N=VE=H41B>?M1@W@[T'TE:L.$!DX+5/6OIOA\J79(:C=&UFXP64N#E7'+$N=* MJJP WA=2FOW&.N@GU>5_4$L#!!0 ( %R *5,$-EWUG@0 &8+ 9 M>&PO=V]R:W-H965T\G MHXIRXR,247[%&!;JJ*JI<;5LKMS N\P\87OMX8NS&:3VNZ9@MF M?J\?%:Y&G96"5TQH+@4HMIIYU\'536+/NP-_<+;51S+83)92?K6+^V+F^38@ M5K+<6 L4IV=VR\K2&L(PONUM>IU+JW@L'ZQ_=+EC+DNJV:TL_^2%V(71Q MMXY@[&FT9@67JM/&X+BP15D8A5\YZIGYHJGKDB'*AI:PXH** MG*.D#35N%[AH*V\A'#S19MF_ =-PE\EL)L--R)@A5O M]4<8(C[)NPU^*DI+R$*"(1^&/38BSH<(FL?>@UI3P?]Q>1*XE4++ MDA=MVE04\*B8MB"Y#;F"CQU4BP-4&OZZ7FJCL-'^[HDH[B**743Q.Q$]*F2> M,B_._=VWAM?6R3GH>^U85E_IFN9LYM4V"?7,O+?&V<$XY)@WUX85-D6S8;"2 M)=*6BS50;?<0]I<.=J?\B8H&V=QM7L& "]25C<;/>GBB3S'LH+_$H2/[9"2,)) !\;);AI%'-N5WQG90T9\8,8QS#RL6Q5W1BFCC** M(I*%$PA3,LY".)\V@;626D,2D7$\AL0G?A;!=9XW55-2BT;!$#JL=LN"*"%! M$@U1\$F63H;OFA5XJ6+\$Q*EH14R$O@)]/3&N.N-<6]O.- P77VV'WIUS_?# M$]8Z1_2D<.ACI6U&F"]6OG3."+_CN MG2\G+>(: 0?_2'HX\<]V^!_"^0(B$F>IF[-PC/.$I'Z&&)])"1S/K"4SL?1I9E3O8$5HO'FJE2L M[1PC'8]L9U+Q\I,^]8F0(IS'B/X'U&YM"#7E2 NI@%:RL45$ ,K&&G!J6"3T MAY1QM, "MRF7G"YYR0UGZ/H5\RXI#$S)ZONH+11A$CAHXB3]KES*_@T_R-6' M1MN&T<8]2/&#OW&.F-(?])SI?Z/Y+D7> LR;0Y! M7< XBFS-$ARRV)4-Y>L<[RK-7<.NL30:!H[F;>PP"$B2C-%#"H.)O8R1.TDR MA)Y\(4#")$BQ,!TB>:+)! 8A"3)1Y$I:FR8.54M2KJI ME&Z8I:W>1*;5R$JOU(@HC>-IU# N@]7"G]WHU4)U5G")-QI,US1,[RY0J.TR M2(+#P5>^J:T[B%:+EFWP%NVW]D;3+AI02MZ@-%Q)T%@M@W5R?C%Q\E[@+XY; M,UJ#B^1>J0>W^50N@]@YA (+ZQ 8?1[Q$H5P0.3&]SUF,)ATBN/U ?W:QTZQ MW#.#ETK\S4M;+X.S $JL6"?L5[7]B/MXF3QH MN.R_[&F?AY'"6?R&0KI72+W?O2'OY16S;+70:@O:21.:6_A0O38YQZ4KRJW5 M=,M)SZX^2#XCM&5.5E$EHPYE:C8 U_TP.D; MP%/XHJ2M#7R0)9;/]2-RP/O MST.,+N!1&M9]&JZX*80RG4;X9WUOK";^_/N.VTMM579D1U5P MS26W^+L@7K[BPFLY?Q?;-?"Y:5F!RX ZU*!^Q&!U5R/03G!B#[4=,"%4P7Q+ MD N%HOXJ4?<'^%34Y 1Y8Q4US/>.:UK3O;2\XF[Y@BZ<&&.@4H2Z->=P?$0R M8&O5&'-FYJW!HZ3$SB") TG M<0RSTQBN\)'>CM8YA44ME5";G9=*XG!.,CG)W&E6(DC6H('?6-/^ =:=T#OS MT"-.23!S@LHR,0KM13Q'D&8>=DK23M/E[U(U+9.[41ZYV/51D5<%,#17E"AJD+)4A,'!/JZN%$^6RH)P :UNM6%&?>O,; MK8PA5:UW#I(U#LSSELRI@ONLP;^,QDYUAS.*0*/Z_O3+UXB7Q+/P+,UA/@WGZ<@).V(@D=IWD6)G%^0O2C_0O3&^X-""P(M7X=)8' MH/LQV6^L:OUHNE>6*N.7-?VS0.T$Z+Y2RAXVSL#P7V7U'U!+ P04 " !< M@"E3DZ_#4Y$" !3!0 &0 'AL+W=OJMA*%30.!A(!M+Z:]<)-+8^'8F>U0ND^_L].& M,M&^2>SS_7]W9_L\72O];$I$"Z^5D&86E-;6DR@R68D5,V>J1DDKA=(5LS35 MJ\C4&EGN196(TC@>1A7C,IA/O>U>SZ>JL8)+O-=@FJIB>K- H=:S( EVA@>^ M*JTS1/-IS5;XB/9[?:]I%G64G%V-PE2R5 M>G:3ZWP6Q"XA%)A91V#T>\%+%,*!*(T_6V;0A73"_?&._M773K4LF<%+)7[R MW):S8!Q C@5KA'U0ZV^XK6?@>)D2QG]AW?JFHP"RQEA5;<640<5E^V>OVWW8 M$XSC X)T*TA]WFT@G^45LVP^U6H-VGD3S0U\J5Y-R7'I#N71:EKEI+/S:YGC MTF(NT1@X>6)+@>9T&EE".X/E[?40I=7FEN[P6 MZ5'@32/.H)>$D,9I5[O .^*JH0K;C*A3*,1?ETLC=5T)WX?@?<[ M>-_#^P?@C]0J>2,05 &W2JX^6]05N) ?[>11EFO"B:E9AK. NLR@?L%@_@9U MIP69HJ8P=&HNH"T1"B6HN[A<3>"$2S*IQC"9FU.@?=QT^P@W3#;4>F^&)\<4 MBDDH6,8%MQOX!.?C43B(8QHE81SWPB0=P"W=CPDTDE5*6_Z70GL5-Z9A,D-* MR5BZ0,DI)+WP/!U",@S[\1C>9QZ"I'>&DOY/1S%'O7 PZOOHPW"4C."CN7;V1"DD;:]\YVU>S$NVD9Y&ULE5?;RD>M EYP8>ZZK1EZ/2F,WY9*+SDM=,NW+#&_RRDJIF!I=J/=$; MQ5EAE>IJ$GA>,JF9:$:S"[MWJV87LC65:/BM MW6-5-/5[R2N\N1/]IO+,2Z M-+0QF5ULV)HON?FXN56XF@PHA:AYHX5L0/'5Y6CNGU\E)&\%/@F^TP=SH$CN MI7R@Q6_%Y<@CAWC%+FLM/V%72<;I2/(6VUDW2NC![5HNI$] M]GDX4,B\(PI!KQ!8OSM#ULM?F&&S"R5WH$@:T6AB0[7:Z)QHJ"A+H_"K0#TS M6QJ9/[RFN K(98VUULRFZ^R.W5=]*#BM987.)9@V&B@:ZE#L-;-]I9%L?J[-HP" $^<.:IY\T?L6R M-9UG7+$1+7',XJJ?48BE99S] ( M*@E9:$!9C4B\.(>[4G$.=4<83H0!+/>3+?=2/![Y$$_WL'L M6FI#GBJ^Y4W+X16$CI=D. 8XQCC&3I3Z=C\.,E@R9+L-!E/VP WY'#A)XH'O M9'X&D9-%&>ZD:0)W/"\;6G".]<;EO/+D:6DVO+1;/Y=VR#;O]X@: @$ M$D7W7:?/X4-KL#N:@BASJ*"_Y:E#^>,;8Y/''[G*!=9CHT3>$\]P58_AC[:^ MQ[*C\07EFB:?[=W"B]<'L_EZK?@:>_(;\\QVYSO6M!3 _LQ$"B=I!*]\-XCA M-62!&TZ)^+X;(?%=X60B?N*;3A<(GAN:T,!*VN'T*^5FLWG=[!#ZO&\8! MQ3!UIS'J!J0;3YTDBN$$/Y.!G\E+^;E ][&N%$Q'U8^-,">)>A+Z!41=+#_: M)"Z6\Z,\19F.:+=VAJ+#@GXQX"GW\K+JR$[Z$$&0GA+ WW O_5#GB/^'33)(DE;>];\"SI M)@=ON9JKM7VQTJW<-J9[U@V[PZ-XWKT%OXIW+^KW3*T%GD(57Z&JYZ9X&JKN ME=HMC-S8E^&]-/C.M-,2'_9&PO=V]R:W-H965T:C!543#]ND"AMM,@"G8+=WR= M6[<0SB8E6^,]VI_EK:99V**DO$!IN)*@,9L&\VB\&+IX'_#(<6LZ8W!.5DH] MN>_D9<4,+I7XQ5.; M3X-1 "EFK!+V3FV_8^/GU.$E2AC_"]LZ]NPB@*0R5A5-,BDHN*R_[*4YAT[" MJ/]!0MPDQ%YW3>157C++9A.MMJ!=-*&Y@;?JLTD')*A5%>]4+>*# M@->5.(%!U(.X'T<'\ :MRX''&QQR^>A=7G*3"&4JC09^SU?&:GH8?PYP#%N. MH><8?L!Q3_625@)!9;#,F5PC< DV1^BPTYY;6=)Q<8J0U@T-3U$S]TC?._J# MK*YFQZ9D"4X#*DJ#>H/![($H,B6HX(@$K+M6*J!$R833!7L%R9["[.T5- J3 M-X5)5R&DE?:@%%.BYBH%SRLMIF,X\GBJ,DRFYAB63.M7%STO5$5("R:83!"8 M<3373%;4!]I[AL_PY=,HCN*OW?/99W,M(/QM*G<*PDC_I>36J W%!@049SUXXVCH#F5#+T MDLAGU.M'T?_N*K%G[:(7G8[@O7<6=JJW0+WV/&PO=V]R:W-H965T M:(#EX*J>PJR)TK MWX:AC7,LN!WI$A7-I-H4W%'79*$M#?*D-BID&#$V#PLN5+!>UF-W9KW4E9-" MX9T!6Q4%-S_>H=3[53 .#@-?198[/Q"NER7/\![=0WEGJ!=V*(DH4%FA%1A, M5\%F_'8[CKQ!O>)?@7M[T@;ORD[K)]_YD*P"YAFAQ-AY"$Z?9]RBE!Z)>'QO M08-N3V]XVCZ@OZ^=)V=VW.)6RT>1N'P5+ )(,.65=%_U_A]L'9IYO%A+6__# MOEW+ H@KZW31&A.#0JCFRU_:0)P8C*=G#*+6(/J_!I/68%([VC"KW;KECJ^7 M1N_!^-6$YAMU;&IK\D8HG\9[9VA6D)U;WS?I YW"KK(T:2UPE8 5F1*IB+ER M%.I85\H)E4&II8@%6KBX1<>%M)?P!A[N;^'BU26\@A!LS@U-"P4/2CA[18/4 M_B2DI*399>B(L]\YC%M^[QI^T1E^G[@9 5M<0<2B<8_Y=MA\4Y+YA/69AQ2I M+EQ1%ZZHQIN>P?M8505LXN^5L,++< !RTD%.:LC)&SK#OOZ;]#'HJ.S&'1UJXN"_*Q%<'4X[A>T>=/L2\.V M09R=ZN%ZQNC7+XF;CLK-L"3:($-I1(Q>" V)FDYED^-(+ZL&?''":L%&DWY* M8W:LIVR0U&>Z>DNC8\3$0FIT 6DGCGY5M'6,_7%HIK/Y:'Z&STE]'P_R>5 ) MFKT1M2H286N%-#4^IE0*:\\4YFT+[(D=*9TE=*R@X^$2^L7EE)9#* !?Z$5B M24,E_\%W$GN91'_$AHUFOQ$)3RY!_P*AFR,3RH+$E*S8Z)KT9YI+O>DX7=;W MXDX[NF7K9DX/(31^ &ULO5==;ZLX$/TK M5M2'5KHM& A)JB124[+:7>FNJMOMWF<7G,0JX*QMFMY_OV-#" 6'L!_:EP0/ M9\YX#N./F1^X>),[2A7ZR-)<+D8[I?;WCB/C'6<%RIE.7T22!991L2/%4WY83'"HZ/A&]ON ME#8XR_F>;.DS52_[)P$CIV9)6$9SR7B.!-TL1@_X?HT#[6 0?S!ZD(UGI%-Y MY?Q-#WY)%B-7SXBF-%::@L#?.WVD::J98!Y_5J2C.J9V;#X?V7\RR4,RKT32 M1YY^9XG:+4;3$4KHAA2I^L8//],JH;'FBWDJS2\Z5%AWA.)"*IY5SC"#C.7E M/_FHA&@X (_=P:L4:N7U$OY:I'?(QU^0YWK8 M,I_'X>ZN+9U_%WW]CZ-_$L.OZ\8W?/ZYNBDR*HCB EW#.F4Q@H^,$I86BB8W M]ST!@CI 8 ($0PO35D$E16@H]);XOKSUIW@Z=]Z;W\6"PD$+%%E 8>#[GU'K M+@J'DQ/5ITS'=:;C7BDCFG-8V0TQ>P4,:]JP5\#O9H^DR2UYAR^UI0BTS&!K MKA8K'!I2P4=C^19=LZ/9JG(99]Q(>NH'4]Q2N8N:>'[0$C"R<'FAU_H8:PL7 M#L.97>=)+QM4$ M]Y\QY^\F?Z< 7J_^*W-R:4D+F9S(['>N>.VLE[GA&A7VQFF MCJI=&*#.U=SIW,;^H)H;F+4_+&O_SVA2*F@X$MBA*1PYJ3S2OQA>47=/>)F=O>D"PH M#[=1D0WEME%K"RIL@$JYG$9_ ->VK6G,)*1;Y*J\\M76NOE[,"U/R[["]X_8 M8H]TLVCZD1-]V6E^)6++8(-/Z09"N7<3F*DHF[=RH/C>=">O7$&O8QYWT/!2 MH0'P?L.Y.@YT@+J%7OX%4$L#!!0 ( %R *5-6[E"-_ ( #() 9 M>&PO=V]R:W-H965TJR12 MDVA;IW:KVG7],.V# Q>P:FQFF]!*^_&S@5*F$MI-ZQ>PC9_GGKNS[YCG7-S* M&$"ANX0RN;!BI=)CVY9!# F6 YX"TU]V7"18Z:F(;)D*P&$!2JCM.<[83C!A MUG)>K%V(Y9QGBA(&%P+)+$FPN%\!Y?G".-Z!E#L^$8@EXTQ,JYL.;\UD]-P83E&$5 (E*' M^K6'-5!JF+2.GQ6I5=LTP.;X@?U]X;QV9HLEK#F](:&*%];40B'L<$;5)<\_ M0N70R/ %G,KBB?)R[UAO#C*I>%*!M8*$L/*-[ZI - #N\ # JP#>2P%^!?!? M"AA6@&$1F=*5(@X;K/!R+GB.A-FMV9U"M2 MHH G6\)PD8S>9RP$-@GIH]X&%"94]M$[='VU0;VC/CI"A*&O,<\D9J&8[GML#7W?!/&1T@WST(WSP#Q^P0W-;1JT/H MU2'T"C[_N1">!#\S(DD1PN]G>@V=*DCDCPX;?FW#+VP,#]CXP'F8$TK;@E4B MQP727//]TO7'_F@\G=O[9E3:]GD3=^;7^_Z0-JRE#3NEG659TG2]P]M133EZ MM8B.:QOC3ME?<@9"QB359UF! *E0#TN$40HB *;Z;<>ZF])UG('CO.D0-ZG% M33J93J)(0(05H!TF NTQS0#Q';K1I?C&M 2D"T-PJZNFCH^ L$WKY$FZ1X[N M!NW)GM;"IIW"UIPIPB(='Y3B>UW_E30#O*70IJ$D&S4T3-V&A/+\3I\(G1W4 M.:MUSO[UOJQF3T3IZS(9MAMTG<="ZOS5/4"_T#F^(TF6=!P(MU&GW5>[$^YC M*7.]_YG?BJV9.YVZ)\FS&_W)_$WH^A\1)A&%G<8Y@XE.AB@;=#E1/"U:UI8K MW0"+8:Q_:D"8#?K[CG/U,#%=L/Y-6OX&4$L#!!0 ( %R *5,P)[0($ , M )8) 9 >&PO=V]R:W-H965T.YFCJIUIM3UU5Q"AE5/;&!'-^LA,RHQJEFSW)S[C9;X MEB%.S\X+A2M*D5AD2Y93>QC'5Q(X0S:L!'+&N8CWZV)%Y@*// %I%T[(\0(T M95R=D(_D[F9!CH].R!%A.;E-1:%HGJB)JU&F(7/C4M+Y7E+0(NEKP7LD]#^0 MP O\!OB\&_Z-RA[Q1JWPQ1OL-&]C=]';RN"@,CBP\<*W##Z+'PJFF#7RUR6N MD0L-F?K=P1%6'*'EZ+=P?!8BV3'.F[S>(R.+-$U@._/#*!Q$HXF[K;O2M"\8 M^N.PVO=*6K^2UN^4=ED463WUCFP'5,_.X8A[_:QW/QP>$6,;#?C.A[[VT/^\=1K?G M6<)?.=R6IE]KNGYW>94'RQE=,HX5#,WD_@'YQ\%XV,+^TI'\H)-] 2M _H1H M^EA)>&H4$!P*P-[14MS^2[_RNQO6K="4XY53NTO(AK*D4<-A9QJ,0N]O#6[M M#C1?+'@-K%FN"(<5XKS>$).0^X^ _42+C;T6ET+C)6N'*7XX@30;\/U*"/T\ M,3=M]2DV^P-02P,$% @ 7( I4UW:R&+; @ _ D !D !X;"]W;W)K M&ULM59=3]LP%/TK5H2F(FTD3MNTL+82I4-#8A+B M8WN8]N FMXV%/X+MM/#O9SLA+8*F#\!+8CL^YY[K$U][M);J7N< !CUR)O0X MR(TI3L)0ISEPHH]D <)^64C%B;%=M0QUH8!D'L19&$=1$G)"13 9^;$K-1G) MTC JX$HA77).U-,4F%R/ QP\#US396[<0#@9%60)-V#NBBME>V'#DE$.0E,I MD(+%.#C%)U.<.("?\9O"6F^UD4ME+N6]ZUQDXR!RBH!!:AP%L:\5G %CCLGJ M>*A)@R:F VZWG]G/??(VF3G1<";9'YJ9?!P, Y3!@I3,7,OU3Z@3ZCN^5#+M MGVA=SXT"E);:2%Z#K0).1?4FC_5"; %BO ,0UX#8ZZX">94S8LADI.0:*3?; MLKF&3]6CK3@JG"LW1MFOU.+,9%IJ.Z(U2B6?4T'\4G5.TX>2*LC010;"T 5U M36&(6-(Y W2J-1A]B#HS,(0RV_J&+LN2(X_3U),<("K0;2Y+342F1Z&Q:EW, M,*V532ME\0YEOX@Z0M'P*XJC&-_=S%#GX/ E2VAS;1*.FX1C3]O=E_"VUK^7 M=@Q=&.#Z7TN,;A.CZV/T=L0X)U2A%6$EO)5VA4T\UFV:U23N'D?1*%R]$;+7 MA.RUAORA#;7_J/6)T06@CEW[)R!*'[ZEH)TJJ9 MZ]!O1/5;F<[\_PO*;E_F M_RR=TZ*-.&F(DT\S<=#$&+S#Q,$K$W'TT\;D0=MS+- M8&5K=V%%&4AS(9E:)/,Q%OU3?\#AMK\ L?HYV;$6^*#(X_SLD] M7/V]5N)-8<+ME>E6D0R0(!PT^D)X\1T9-V(/Y/O6 )LRA'N?9^JFKN#VPK+' MU/XK4Y.=EFY*#DX^T-)VKNYN2\.ML]S=B^PQN*1"(P8+2Q4=#6QRJKIJ5!TC M"W^\SZ6QQ=8W&ULO5913]LP M$/XK5L0#2$!BITT;U%:",C0F)E5T; _3'DSB-A9.'&RGA7\_VTG3T(:P3;"7 MQG;NN_ONR_EZHS47#S(A1(&GE&5R["1*Y6>N*Z.$I%B>\IQD^LV"BQ0KO15+ M5^:"X-B"4N8BSPO<%-/,F8SLV4Q,1KQ0C&9D)H LTA2+YPO"^'KL0&=S<$N7 MB3('[F24XR69$W67SX3>N;67F*8DDY1G0)#%V#F'9U/8,P!K\9V2M6RL@4GE MGO,'L[F.QXYG&!%&(F5<8/U8D2EAS'C2/!XKITX=TP";ZXWW*YN\3N8>2S+E M[ >-53)VA@Z(R0(73-WR]6=2)=0W_B+.I/T%Z\K6_!(<'1^! 0\&WA!=2&\N1JS1;$].-*F87)3/T"K,O M!3L%/CP&R$.P!3Y] XZSU^"NUJ@6"M5"(>O/?\7?)O5C,&-8ZV(4^+11 /R\ MT>;@6FLF?W4$\^M@O@W6>R/82YV/P5)PV2IEZ2ZP[LS-74T"O]_KC]Q54[$6 M*\\+_=KJ!==>S;77R?4\BHJT8+I>8GU_="_1!62JI8UFZ:G?('#B!S#P=WBV MF7GA<-!.M%\3[?^3J!E1;5S[>R30P!^B':HM5B'T@G:F0<+NTST"$B$,=#O M%YRKS<8,&?50.?D-4$L#!!0 ( %R *5-Z'O>")P, &D) 9 >&PO M=V]R:W-H965TR2!!5UQ\R WGZ',)[+V M8LFU>Y)-B0T\$J^TD5E)Q@@R)HHW?2[KL$- ._6$9DEH'A+:)PBMDM!ZJX=V M26B_U4-4$J*W$CHEH>-J7Q3+57I,#1WVE=P09=%HS0[<=CDV%I@)*ZR94?B5 M(<\,9ZL\YX!*,923!1-4Q Q'VE#C5@D3A7JM#"Z^4:6HE<(EN1B#H8SK2_*1 M/,[&Y.+#)?F :'+/.$>P[OL&X[->_+B,Y;:(I7DBEA:YE\(L-;D3"20U_/%Y M?N<,W\>Z5,5I;HMSVSQK\.N*-T@KO"+-H!G6Q#-Z.SVH2^=]WN_>YWWR"IV* M4][W:MFJA-9R]EHG['U7*17LKQ/2%1FA0"1G2:$K*A(R5:"M"MV"7)!)I<79 M5HN:_+J9:Z/P-/I])J)V%5';1=0^$=$8\"A&#\XC/.-1K:%.M(653\Z*/:?7 MPU8CZOOK72$<8]J-Q@KBO$7I)1E61T-LD'L-V%B93D MH-R?+&(@**Q9'X>]NZ+M_S=?7$+NJ4J9T(3# ET%C2YJ0!6-O9@8F;M&-)<&VYH; M+O$N!,H"\/M"2K.=6 ?5[6KX#U!+ P04 " !<@"E3S"LK<_," "]" M&0 'AL+W=OLJ ^MU#8A M"0$J0&J!:IO6#95U>YCV8!)#K#IV9CNEVU^_LQ-2?@2&MA=B.]]W=]_=X4M_ M)>2S2@G1Z#5C7 V<5.O\QG55G)(,JVN1$PYO%D)F6,-6+EV52X(32\J8ZWM> MY&:8R+0C/*R50B5609EK_N"!.K@=-RU@>/=)EJ<^ .^SE>DAG1 M3_E4PLZMK20T(UQ1P9$DBX%SV[J91 9O 5\I6:F--3)*YD(\F\W[9.!X)B#" M2*R-!0R/%S(BC!E#$,;/RJ93NS3$S?7:^KW5#EKF6)&18-]HHM.!TW500A:X M8/I1K-Z12D_;V(L%4_87K2JLYZ"X4%ID%1DBR"@OG_BURL,& >PT$_R*X.\2 MP@.$H"($IWH(*T)XJH=V1;#2W5*[3=P8:SSL2[%"TJ#!FEG8[%LVY(MRTR$M!9X>SHH\9P0*KS%#"\HQCRFLE,;:GB+*RV8T53W_2* F:"24OD#G8Z(Q M9>H"7:&GV1B=GUV@,X"C+ZDH%.:)ZKL:(C1^W+B*YJZ,QC\038 >!->I0A.> MD*2!/S[.CX[P7WVJ(9W0ZW6N2\W_>)__L M?2L90=TK@;47'+#W62XQI[]M+UQ"%W E&$W*UH!ZHZDDRC22/1 +=%^WTVS= M3@I]OYTK+>%^^'$DHK".*+01A8CLI30.,&4,_; 4W^ MI2&=4JHZ,J/\%P%*?7-=HOF1?N MUK4!%'9VZ[H/BGI[==T'=8*]NKH;]W%&Y-(.0H5B47!=_MWJTWK6WMH1LW-^ MU[H9M1K.QS";RU'Z9KX<[ ]8+BE7D+<%N/*N.U <60[+4S MD%9)I'Q5ZZ2J4=-N#],>''""5;"I;9INOWZV(2P!@KKM!>S+N>?>-#4LEA!(4 M"L4 Y>L-S5&2*"*9QFO):50AE>/Q^,!^J[5++1O(T9PFWW DXK$Q-$"$MC!/ MQ"/=?T:EGH'B"VG"]1/L2ZQE@##G@J:EL\P@Q:1XP_>R#D<.DJ?=P2D=G+J# M=\;!+1W$64,#)B-$]8 HMV=1 5U][RWIAHOID M+9C\BJ6?F*SS+$N07'@!$[#%!)(0RQ$74&@KP*1H1K6JO0<1(R9-(4T1Z*%W MV:T<]2\ 0:(/>@LD($YX'UR"Y_4"]#[UP2<)!D\QS3DD$1^90J:L IMAF=ZL M2,\YDYX+[BD1,0=+$J&HQ7_1[>]W^)NR5%6]G$.]9DXGX9<\N0*N?0$$TP1'1:_(]08K MAKCJ+&V@6W!;]=?ZT%\3IC+PS&=T1@6104?9H6\,5 M!+XF4+OHVV3@NB/S[7@1FYC /X4LFI!KSS[%+)L8_XCG1."@$CCH%#@-7W/, ML:[H3AX#'/1"R@4O?L(VO07?X"B)2]OW!S7%390SK"EN(0I\RZMI;D'Y9S3[ ME6:_4W/'KM,FV&]D8'OUY9LW09?7#<5-D.L&04UP"Y-C7P_;)0>5Y*!3\A-5 M^S'].^%!H]U.J3YN:_:9?3.W6^P+>4\IKA5_Z(M+SCUD._6')&@K0UE7@5PD M5EP(P40&JV]OD-U!+ P04 " !< M@"E3K<=@[;0" !O!@ &0 'AL+W=O]#)5#56<(D/&DQ354S_FZ-0ZUDP"#8;C[PH MK=L(DVG-"ERB?:H?-%EACY+Q"J7A2H+&?!;<#*X78^?O'7YS7)NM-3@E*Z6> MG?$]FP61(X0"4^L0&+U><(%".""B\;?##/HK7>#V>H-^Y[63EA4SN%#B#\]L M.0NN L@P9XVPCVK]#3L]GF"JA/%/6'>^40!I8ZRJNF!B4''9OMEKEX>M ,(Y M'!!W ?%^P.A(P+ +&'JA+3,OZY99EDRU6H-VWH3F%CXW/IK4<.FJN+2:3CG% MV639U+5 *HME G(NF4PYK8QEUN\"EVVKN)R?[G@OF"GACMH OK_YG,'I+5K& MA3F#=KR1/8\_!/S1B L8#KY ',6# WP6GP^//J S[*LP]'C#(W@^E37C M&5 B@56JD=90SE+1D%Z7/%LB5,A,H]NRJ!P$F0B"LQ47W'(TUQ\P&?5,1I[) MZ B3GS5J*J0L('6<^*QW?QX22[C">7W93NU[YTF MH\E5[[1#>]S3'G^2=IL5[;[>_MSFJ;M\'N#:4?Q/=,%EX:4Y00975P2,]V.M]:PJO838J4LS1N_+.F/ M@-HYT'FNE-T8[H+^'Y/\!U!+ P04 " !<@"E3PDGP68@# "X#0 &0 M 'AL+W=OY5\Y+8\/LX/L<=4VK SX(+/?=R8\IKW]=I3@NBKV1)A;VSDJH@QD[5VM>EHB2KDPKN8P@C MOR!,>(M9?>U!+6:R,IP)^J" KHJ"J%]O*9>;N8>\[86/;)T;=\%?S$JRIDMJ M/II<26(_7NBMY1S5\GB^-$6];J>+G$XWE9_5R_>+N:1:'HK^5>6F7SN33V0 MT16IN/DH-^]INZ#0U4LEU_4OV+2QT -II8TLVF2+H&"B^2<_6R(&"6AR( &W M"?A/$X(V(:@7VB"KEW5'#%G,E-P Y:)M-3>HN:FS[6J8<#(NC;)WF&%OJ?(]V"KEM0 M=YLK)<=1I6A45)\921-H5N*=T#&E3*1P@N,1A@&"X@W0D#B5A/$G& MH88=U/#_$"RH&0,=[H&)8QC@9 ?S2%@40QB,0XXZR-%1R$NY,ANB:/UHZNTD MHT_6A$MKJ0:D4AM]9/?%7:?X#'M]VG6;OLA>G^ZQC"*$]K;Z2!BV8H3C8B0= MZ.3$5O]1,67I>;^\ :5=P$IR)H^1CV#OQ? ,]*.!]Z,7$: MNT-MG.PJ,!H7 MH@D:EP#UEHSPGXG0O"&ILB<*7CN.SEEY5(S>B%%P#C%Z"T4G//2_BK%OE!$* MXBG:%6,D#J)@>DB,WE#1"4?=BM$ZDAT9FN9"A=$\_O=QA/\>ZK;20NB1)\P)E0[Z?HA*%NE3"*9!0(4M"CST+O>2@Y@P"X-T(, M7T2 MNRS8Q!.(-SA?S0L&(0UL/W!L=I]T_Q-U)H)#3A=V3QX%5L!5?.9T$R, M+.N3]J,TUI7J86X_K:AR ?;^2DJSG;C#>_>QMO@74$L#!!0 ( %R *5,A M-W5UG@( # ' 9 >&PO=V]R:W-H965T*$@;7 LFJ++'XO0#*ZYGC.3O##@[K;70N_&IE,UIS? MF\UE-G/&)B"@D"K#@/7K$99 J2'283RTG$XG:8#]]8[]D\U=Y[+&$I:<_B"9 M*F;.F8,RV."*JAM>?X$V'QM@RJFT3U0WOM.I@])**EZV8!U!25CSQD]M'7H MS3,,\%N _QH0[@$$+2!XKT+8 L+W*DQ:@$W=;7*WA4NPPG$D>(V$\=9L9F&K M;]&Z7H29/KE50G\E&J?B2Z8PR\F: L)2@I((LPSEG&'\:<'\*ZN1%<.?U>.A7^0\&M%1RCP/B!_['L#\2S?#Q\/I?-_ZJM_ M5G]1C*#KC<#R!7OX/N^ZP+1$KU'F3:,D1*:4RTH ^CE?2R7T3__K@&S8R896 M-MPC.R^Y4.0/MH,$GO1$E##46@W+N64QX_ Q]L]'D\A][)_7@%/XVBEYZS29 MCL*73JNW3N'9R.N<7J0ZZ5*='$SUN<+I0T7$\"\P>2,1V M]DJ4\HJIYL0[:S?>YW:JO;(OO(NE-V!/]'703.]G^N8NN<(B)TPB"ALM-1Y- M=<"BF<_-1O&M'4!KKO0XL\M"7VD@C(/^ON%<[39&H+LDX[]02P,$% @ M7( I4_=&T$S0! PQ0 !D !X;"]W;W)K&UL MQ5A=;Z,X%/TK5C0/,U(W8)//41JI33]'[6PUV6D?5OO@$"=8!4QMD[32_OB] M)A1( V[F(]H^-!BXYQX?7Q_;C-9"/JJ ,8V>HS!6QZU Z^2SXR@_8!%5;9&P M&)XLA(RHAJ9<.BJ1C,ZSH"ATB.OVG(CRN#4>9??NY'@D4AWRF-U)I-(HHO+E ME(5B?=S"K=<;W_@RT.:&,QXE=,FF3']/[B2TG )ESB,6*RYB)-GBN'6"/U]Z MQ 1D;]QSME:5:V2Z,A/BT32NY\H:[!\T6HLO]HG;_K MMI"?*BVB/!@81#S>_-+G7(A* ,$- 20/(/L&>'F MV] )P_HO GPFOK0S0.Z M^V;HY0&]?0/Z>4 _&ZR-NMG0G%%-QR,IUDB:MP'-7&3CFT7#B/#8E.)42WC* M(4Z/)R**N(;:T@K1>(Y\$6L>+UGLH[\"D2J(5$?H@VG?\C"$&E,C1P,]D\3QE2( M5P-W\1ZI$.#P>P)=VE%N*9!R!Q84!VJH*"12%!+)8+T&V!NA%)IL5<_?-_ . MNM8L4O]8,GA%!B_+T&G(\&?"3"G&2Q0R,!\4"XU>P*Q]*&'(R.8HC>=<^2*- M-31H9"[J!FV39IBE,5:]&O>\-AXYJQIRG8)2.T*:R:B.FST+Q@!*I;*H MV2T(=ZU0L,CHD"&Q0'Y(>50W7R\V"+V*4)Y;+U.OR-JS9OV:9KX!6>=,\M7& M6?+YI="_J'FJ33; W0H94G#93&G;&UML^P7;OI7M RS&#V93@*YCE4IF%7Y0 M@ X.-%&&18;A+P_M<%>K;KU8V"V7$G<_N8Y +]_2$5Q9G?"!Q,*E<6'RRW+E M$%6]FN0J[0S;_>R"+W0 ZR>7@JVF\I=*OW V%\BN<\0[)2W.U6[A'9W[=AM#QK4+8T&[^LTAD&4 M+;D*:4ECM6!2@B'#9J54FY9J@PW9%NESO.LSN#-LX%M:#;9[S3T-4_9*ERK% M]'YL:QGV=XR[T^\W,"Q]"P_L]9I*'8"D5XR&4+A3NH)*4E"GV:*&[GZTMG*C>'K,K<=1L62%):'L'_4^'FB;=,K-O$M[+OL]OG[RS< M/%554=QOE+1T6O*.T_Y$Y8*8TW2FV%,*9R-TOF)O]Y+;7$H;)H>R85+:,+'; M\"U]YE$:H62KJ.M.9&1WB]=I6-A(:;W$;KTU<^G^_/2U.&II]&IH-/$H+978 M+?4F!0WV,R-2NB YU/:-E(9'[!NX EZCA+YL#N=P06=AW2!>Y&C5%738QL.M MO^VM\F5-R*#I".25)NK93?2MX#"'\E*T'?]*9_0.M1GT2C?S[&[V8])?>KN& M1=[:E5/Y.F,^[\$!?,EC!0?%!02Y[3[,0;GY8K9I:)%D'VQF0FL199&ULI5;;;N,V$/T50M@"#K!KW2\) M; /Q)=TML$"PV;0/11]H:6P1D4B7I&)OO[XDI:AV+$LN]L4F1W/F\ R'Y$SV MC+^('$"B0UE0,;5R*7=WMBW2'$HLQFP'5'W9,%YBJ:9\:XL=!YP94%G8GN-$ M=HD)M6838WODLPFK9$$H/'(DJK+$_,<<"K:?6J[U9OA&MKG4!GLVV>$M/(%\ MWCUR-;/;*!DI@0K"*.*PF5KW[MU#HOV-P^\$]N)HC+22-6,O>O(EFUJ.7A 4 MD$H= :N_5UA 4>A :AE_-S&MEE(#C\=OT1^,=J5EC04L6/$'R60^M1(+9;#! M52&_L?UG:/2$.E[*"F%^T;[Q=2R45D*RL@&K%92$UO_XT.3A"*#B= .\!N"] M!P07 'X#\*]E"!I <"U#V #":P%1 XA,[NMDF4POL<2S"6=[Q+6WBJ8'9KL, M6B684%U83Y*KKT3AY.P+35D)2.(#"#1:@L2D$#?H$WI^6J+1AQOT 1&*ON>L M$IAF8F)+1:JA=MH0S&L"[P*!C[XR*G.!5C2#K ._[,='/7A;B6T5>V^*YUYO MP-^J8HQ\]R/R',_M6,_B>KC3)>?GV%<_Q_XP ,?T$OM)+OVV>GP3S^^OGN_X M@)9$I 43%0?TY_U:2*[NC+]Z*(*6(C 4P6"!HC50V!#958-UC,C$T'?IZ\R_ MC>*)_7J\L>=.8>"?^BS/?>+ 34Z=5AUL7MCZG,@,6YEAK\S59@/FDC5*.9;0 M);,_QBATQHGSRTU740\@XV0<=2.70YS^)>1J .D%8^<,>9*\J$U>]#^3]Q'M M.%$O)2E^H*Q2=H;@D((0QX6$U,NF+MCTY9-^FS*D"DV]UP*;)P\.>@QHU#AW M*9SW+VODA9=RLQA 1M[X]L)^#'$FEY"K 608CX/^_8C;_8A[0_W*F&ULM55=;]HP%/TK M5U$?6JEMOB"!"B*MH&I,3$*EW1ZF/9CD!JPZ-K,=:/?K9R7]N#K9!/:H6HX;E@7 V=E=;K&]=5Z0H+HJ[%&KF9R84LB#9=N7356B+) M*E+!W,#S(K<@E#O)H!J;R60@2LTHQYD$518%D2^WR,1VZ/C.Z\ ]7:ZT'7"3 MP9HL<8[Z<3V3INZW7]7OJMA-+ NB<"383YKIU=#I M.9!A3DJF[\7V*^[BZ5J]5#!5?6%;8^/8@;146A0[LG%04%[_R?,N#WL$OW.$ M$.P(P4<)X8X05H'6SJJPQD239"#%%J1%&S7;J')3L4TTE-M=G&MI9JGAZ63" M,UQHS#@J!>=S4R19R1!$#E/!EU<:90%C@[B \S%J0IFZ@"MXG(_A_.P"SH!R M>%B)4A&>J8&KC2.KZZ:[U6_KU8,CJW\KV36$_B4$7N"WT$?OT D_1G=-'IID M!$TR@DJO]2^8=^)7%*N@&%N:-YU;+9+UN]"W=%B75VM"Z'-15TU5^8I16D!9CX7 M0K]V[&W=/,[)/U!+ P04 " !<@"E3&%V$0<($ !0%@ &0 'AL+W=O MM?'8]V4CT4 M*\8T^IEGHKCHK;1>OP^"(EFQG!9]N6;"?+.0*J?:G*IE4*P5HZEKE&N.1NW:KQB.YT1D7[%:A8I/G5#U.6"9W%SW<>[YPQY M:!VQC"7:2E#SL653EF56R?CX48GVZCYMP^;QL_I'-W@SF#DMV%1F?_)4KRYZ M9SV4L@7=9/I.[CZQ:D #JY?(K'#_T:Z\=TAZ*-D46N958^,@YZ+\I#^K(!H- M"#[0@%0-7!!!V9%S>44U'8^4W"%E[S9J]L -U;4VYKBP3^5>*_,M-^WT>"92 M-ME)CF@.40W4NA5@3X8 M\?3?[0/CKS9)GDU.""CX>9/U481/$ D)_G9_A8Y^.P9DHWKLD9.-#LA>F9&C MF2BTVI@ZT^BO:W,#FFF6%W\#\G$M'SOY^(#\A\6"N9I#7&BF6*&1"9>A-5.) MZ<[4_+YH84W2CT[? =X&M;<."I"UOCRL,\VKJ%C]FI8@F M9M55IOR2:B:>2"3L(EWB"43P&Z?;(ABVI$L\NPC,K@/IMM8N\7PBG:RNB(<1 M@=="_R-=6+"-%<1CC,#4N6-;F6VMF:DA!-?H(TUXQO7CRRK8,XD,.\G8 XC MBY^IS'.NG?:"M2U=6[1,\89@O)Y:!(8,&&]["7L$D?,NXHT\@2)X3?2J>%NT MPGX,QAMY;$4P9:I0+Y>*,>?M"=VS9&-_ZUPB3^@/IG)T+:FHDX&54%Y,7C*X)I4Z6\J"R=()K+C=![7<6_OF"1 M ?B&%7E613"K]CQM%[M<5+,+&JTG5=0)J2)/J@BFR[TVOP+IJUZU6Q1Q_RP& M)Y3G503SJC5B<^$@TR 'GF11)R2+/R93Y4/\HN/__8?-#;YYP9=943-D;S/<+*?7SB>V@WD0>_P-02P,$% @ 7( I4T&PN83@ P MFQ !D !X;"]W;W)K&ULS5C?;]LV$/Y7"*$/ M";!&HGX[L TD=K:U6+&@;M>'8@^,=;:$2*1'TG&ROWXDI4BV)&M!"P-^B47J MNX]W]QUY8L8[QA]%"B#1IWXG*U3 MJ2?LZ7A#UK ^75SS]7(KEF2K J,D81A]7$NL'7=WBD#0SBKPQV8N\9Z5 > M&'O4@P_)Q'*T1Y##4FH*HGZ>8 9YKIF4'_]4I%:]IC;)V#-0//T&;F7@M@W\(P9>9>"]=06_,O#?ND)0&9C0[3)VD[@YD60ZYFR' MN$8K-OU@LF^L5;XRJ@ME(;EZFRD[.5U(MGQ\KU.=H"4K5/T)8A2\6)2E@]@* MB91P0#T@#DNVIMF_D%RBBSE(DN7B$KU'7Q=S=/'N$KU#&45?4K85A"9B;$OE ML5[77E;>W9;>N4>\\] G1F4JT!U-(.FQGP_;AP/VMLI4G2[W-5VW[B#AQVU^ MA3S\"W(=%_?X,WN[N=,7SL^M?O?#JQ\DPZMKQS-\WK':T651UH\D>CA!>WC[LF+F;[9$9Z@[W\H2O1!0B'^'G#(KQWRC4/^$8>^,$ER)(Z5 M-#SK9^@KPY(W-+SZ;'V:XB#$T=A^VA>W!X5]+SY$S;LH-XZ"%NJNARN./;]& M'20@J!,0#"9@QH34&Y;#$] M#*0TK!G#\] XJAV*3J1QR1OL9=QSPI8LLR[( M=<*@I7 7%/@1;@G M&F.GZ4K.B52NB \4#$.G)7,/"L>XO9-[4'[LMW=RWXI1%/8KC?<:,QY. 2Q3 MRG*V?C&")VI+YVRCDSZ48;>A=\]$]*:=8.]4HGO=S1:.O+;H793KMU'S'E08 M.6%;]"XJ\+%S1/2F@>'A#O8;4. J"5IQDJCOO4Q(3O2W]%"&F_: @S,1O>DO M.#R5Z&%7*#P*VZ)W48$3NFW1NRB,O5'[3.^!1=@]IGK3TO!P3_M3IL#[0SUD M;/H$CL]$Z*;)X-&IA!YUOI4ZY_G_0N8]$,]WVP(/\92!VWN7K0+XVMQRA0IF M2V7Y[5S/UC?I&W-_;,W?XNL9[IF?ZYNWN=PU].6U_1/AZXP*E,-*+>5<1:H0 M>7D3+@>2;&UL MS5;;;MLX$/V5@9 "";"U1/D6%[:!7+K;%)O"J-'M0]$'6J(M(A2I)2D[*?;C M.Z1DV<4JD,C^_W MZ'_ZX#&8%37L1HG//+79++@,(&5K6@K[4>W>L3J@H<-+E##^'W;5V?$D@*0T M5N6U,3+(N:RN]+%.Q)%!/'[&(*X-8L^["?]YPK@V-8%N#DNP!6F7VX8O@$65D]P?&Y!G_SVU8[J%+[\ MC9!P9UENOG80&C:$AC\=M0\2J'-CX!Q+7^7VHJWR%>K0HSHMV,[CP60\C*;A MMH7-J&$SZF3S%R;!0DHM@S7E&K94E S^@[,V"A74Y)A"W!NT$Q@W!,:_V 3( MYIY+GI=Y1_8O&W>7+Z,=)@VA26?\%>@6(^=R ]J)G(&"Z00]HFRWE:$;,.I% MT:L.8B0Z2%?T&TI#'T^4AAQI)7D9Q2'Q@5+\N\MS A&_YZ&+WK:OJK%E85?N):*8OSF[_-<&)FVAW MYVNE['[A'#0S^/P[4$L#!!0 ( %R *5,<5,$RL@0 !44 9 >&PO M=V]R:W-H965T=S^;9("H2#QC>W%@_%UL 23Z M"(-(W(ZV4NZ^&(9PMQ!2,68[B-27->,AE:K+-X;8<:!>*A0&!IE,'".D?C1: M+M*Q9[Y '6Y'>'0<>/$W6YD,&,O%CF[@%>3;[IFK MGE%H\?P0(N&S"'%8WX[N\)<',DT$TAD_?3B(2ALEKJP8>T\Z?WNWHTF"" )P M9:*"JK\]/$ 0))H4CG]SI:/"9B)8;1^U_YDZKYQ940$/+/CE>W)[.YJ-D =K M&@?RA1W^@MPA.]'GLD"DO^B0SYV,D!L+R<)<6"$(_2C[IQ\Y$14!8K<(D%R MG E@IT7 S 7,U-$,6>K6(Y5TN>#L@'@R6VE+&BDWJ;3RQH^297R57'WUE9Q< MODKFOM\D1'C(9:&*#D%3?B_3+XCM2K9]^7F%+A]!4C\05^@&O;T^HLN+*W2! M#"2VE(- ?H3>(E^*Z\K /UL6"QIY:O#BI+\PI'(A 6*X.=S[#"YI@>N@;RR2 M6X&>(@^\!OD'O3PF&@6&XJX@D!P)O"=:C5_C8(Q,?(W(A. F0!WB-&H3/X%C M%NMIIOK,%GW?XW %_/??L#/Y@ZWSY1/H,EN-*XT%J[!@I1:L%@L_8BFD6CT_ MVERC%6S\*%)-M9<"&KF +M4"-QK+R,QTVZGN),7LE]B96@MCWX#(+A#96D1/ M'\!=/XG@#N-VS?@-(7:S<:ZC&?P)D5<&9]UH^N@D[*9G7SIDV:S<\+ M\W/MEGFAT0:0VBR0QQ':<=\%H=DK>%*FUXG6M_OS#7*=9'$_C,/4U5AX: <\ M<[G1XUS_K.KRN"UH<27MX\&XZ,<07'E=P15@,S(V6V(!DQ(9Z;>;!S-%ZH@T M5)49%9N] 0VCR*P#LJRQ;;8@*C,PUJ?@IY,T,Y@GJX.GO)!:0P*OS-6X(UF? M8Q]&J=T5=3GXSGFG\,MLCQUMLOB5G@O!NT%T#UP==,^RABYIE.D9Z_/S#W4, M.Z\C/;B9UGTV\=AR6GPNTS/NE9_S^MH#R*P.A)ACIXW\,E'C^8#8Z8MFWD + M&3O.>-,)C/S+(LU3)M-L=-R82!EW2/Z:XXVFFB;(WUS0OV2<^K;*>BR MCA)]'3V)E%:0C8BF-1KMN6.=9RFC\O 2 M^D[U%"Q6 P-IA@MWKSNTI<> MHYR>/9A]HUR=R 4*8*U$)^.I8H-G;U!91[)=^HRS8E*R,&UN@7K DPGJ^YHQ M>>PD!HJ7P.5_4$L#!!0 ( %R *5-S5D.V3@0 (L3 9 >&PO=V]R M:W-H965T=&+E-J\]3RYC&A*9)]O*-,]*RY2HO2C6'MR(R@)K5&:>-CW R\E M,>O-IO;=C9A->::2F-$; 3)+4R(>+VG"=Q<]U'MZ<1NO(V5>>+/IAJSI'55? M-S="/WFEES!.*9,Q9R#HZJ(W1V\O\<08V!'W,=W)6AO,4A:E5S1)C"?-\;-PVBOG-(;U]I/W#W;Q>C$+(ND53[[%H8HN>I,> MA'1%LD3=\MW?M%C0R/A;\D3:7]@58_T>+#.I>%H8:X(T9OD_^55L1,U@T&: M"P-LN?.)+.4[HLAL*O@.A!FMO9F&7:JUUG Q,U&Y4T+WQMI.S>X47SZ\,>L* M8&GY9VB9T._\F2 M/@S0&6 ?H[_ *S#S7X?_0;EU ^M_V.*_MD%V%^&KWB"7XV'I>&@=#]IB8@B+ MF%S58S(7@K UU4FA8/$(]7$WY-&^GN^(",_@_<_,!.L3TXB9Z9!PK2(J0$6$ MP?7&N)-G\(6SK5X%U19?LG2A^_DJ=ROA^RU/$M!'WWC\X5C6J%S6R+E?UYF2 M2I^-F*W/8$'7,6.ZJ7,J(6Q)X40?GSPVI_ ?[(M2'O1\DI&=Q-2<[0Q-!GCJ M;?>@!25:X$3[J/?5Q/%0AJ#)@(/1?H9QR3!V,MS;0!R,,&X@O!E,!OL1)B7" MQ(F@@[VB<1>*29,"^2T4YR7%^>'GA-K_SH?DO,&% X3V"U9#JJ) %UT(0]N=Z5<]0\8T$_"%HP M*WE ;GUH2+W-9I?6HZKLH_'K*RI_KO:H$A/D5I,CZ3UJ:@PZ;SMXE<8@M\AT M57S45!1_/P.NY 3[QU3\PMMSL44M9QM7E1Z[*WUWT2\#UY>E_X/IBJT@3<01->KO?% M;+\?K]^_!KW:_4A*Q=K> DE8\HRI_*JD?%O>-,WS^Y5J>'Y-]9D(G182$KK2 MIGY_K,^1R&]^\@?%-_:V9<&5XJEM1I2$5)@!NG_%N7IZ,!.4]V^S_P%02P,$ M% @ 7( I4RO57DOB @ P 8 !D !X;"]W;W)K&ULE57;3ALQ$/T5:\4#2"E[R8VB)!()1045"85"'ZH^3'8G60NO'7Q) M:+^^8V^RA!(B]27KR\R9QR8OL0)SJI8H M:6>N= 66IGH1FZ5&*$)2)>(L27IQ!5Q&HT%8N].C@7)6<(EWFAE75:!_CU&H M]3!*H^W"E"]*ZQ?BT6 )"[Q'^["\TS2+&Y2"5R@-5Y)IG ^CB_1\W/?Q(>"1 MX]KLC)E7,E/JR4^NBV&4>$(H,+<> >BSP@D*X8&(QO,&,VI*^L3=\1;]*F@G M+3,P.%'B!R]L.8S.(E;@')RP4[7^BAL]78^7*V'"+UMO8I.(Y$%:@@N'C$NV?=2.0.R,(/8 M$@>/%.>;>N.Z7O9!O1Z[)>C2L"^RP.)M?DS<&P'95L X.PAXX\0I:ZI9@;U"F8"V;5<.NMCE,PI.]C78A,0N1.UES^G2@A&EVL-NOAU@'2G M(=T)I#L?D!Z# )DC \/4G-V =/3.&G/V'5:-UPMX_OVN1LD@7NVAT&TH= ]2 MV+DX^9N+H\F(A>1_R#JP]!B?'3?<[^RC5=?H[M Z2SO]_868E$"]_ M?>>O=WZ'%6W8$CWK@GH.+7C^2O "+$V,I4_E99&SU!)K58;1*Z# BAIBZ3O5 MRA>@.;TFH8PYV2>N]TYB:4BMD[9N,,UJTYXOZJ[T&E[W]EO0"TYN"9Q3:G+:)_6Z[I?UQ*IEZ%$S M9:GCA6%)?S&H?0#MSY6RVXDOT/QIC?X"4$L#!!0 ( %R *5.+'ZR')P, M X3 - >&PO7=$2Z\0<2.+J)2MF(/%Z^_;E4YN9-X)X7 M[R\N.H_O;O;MEQ7PCH1>TOX1I%<=>Z',%8K1Q\?1'R+'J*^/HC[ C!$/=HE; MHAW'L$[:>)@IV>8N(LY@F6G.@B#>JIY[A9?N1[7"OLJV<=2!CLFE:0773T;@.\&^S M.>YMVMZK>(."/RGS>6FG(ZL^%!F[TRSCJZJ_RAH!&'L79Z=%(=:?!)_+G+G) M'QUP/*0;OV"A-'^VT:!49M; - F>F#9\MFWYI6GQP%9F4TZK#-?<.T/-?W>= MYTPR3<6V:%O[I[S*KU8<7?\KR=6ORKY@K\9Z!SUUD?US$!F?@\BSJ,G!Z8N, MDI/4&-;[]]8A8>>(T%@#.(J-R'I1;?LK3*\;-^= &XO+E*U8.JF[ M>CZMFH%MV*CU!0[[R&UU^1',QV%^!# L#J8 \W%>6)S_:3X#=#X.P[0-O,@ M]1F@/L[+ATRJ&XOC]TGLY9]IDD11'&,K.IEX%4RP=8MC^/C9,&W@@<6!2'^V MUGBV\0HY7 =83@]5"#93O!*QF>)K#8A_W< C2?S9QN* !Y8%K'8@OC\.U)3? M)XH@JY@V[ W&D23!$*A%?XW&,;(Z,=S^_&!O210EB1\!S*\@BC $WD8-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( %R *5.A.MCV MO , $L> / >&PO=V]R:V)O;VLN>&ULQ9E;3]LP%(#_BI6G\<#:7%HN MHD@;B*T28H@B7BNK?$\O^, M,HNF8QAP*:WS;8]V? Z,6P&=NU+MS9547MA+[L4W:^J-U*MF&'B*$7J,-@Z[ MSRZ(I_9_PFB62UF(2U/4E="^BZ,5J@'4;BTW+F*:5V(679BML.R6KT3S4/ K M\[)[0 ]D*%SV5$*#G970KM1,D*:#%*EL!1LIPKK@O!$&1"0"8#0OY, M$&1*0*:#0+8X\*<(,B,@LP$A>Y&<$)"3(2%3!#DE(*=A(1=U57'[PLR2Y;63 M6CC'N 9*N=)R*1'D$0%Y%!;R!L:5NC"58)^4<>Z ;2#[N#6W./T<$X#'80&_ M[D('C+G4;0=$=D*0G82>W\U&-0L7_ 1VT9!I)'S;LYSC,96^QV$QY\"G5\V/ M,NXSA;LTSW'F)0RX@&MM_RA])8'_@-+AOJA/RTN#>" ME%&2T$8A\R/>\">46)+ 8B'SXV5OHBG;)(%MLS\_WG!K>7,I@C$IVR2!;;,? M\Q;ZR@J*&).R33*(;;X4OVII8<%C3,HWR:"^P4LHI7R3!O8-C9EA3,HW:6#? MT)@3C$F9)PUM'A)SBC')B[' YJ$QCS F9:$TL(7(O5#_EI&R4!K80C1F;Z53 M%DH#6X@\\K-#C$E9* UL(7SH;R3NN52]C5%*R2<-+)_^OG'E[EWH[CWN^6]02P,$% M @ 7( I4[@VQ-RI 0 +AL !H !X;"]?/L@*.!8*=*@ M/96UMCS^&W^RUK.O4)7I4)_C_M#$WN54G>.\V*?4?#@7U_MP*F._;L+Y=F5; MMZZ-N$_$^OM]K .G_7Z^Q3.Z8_! M[J=NCW$?0BIZJ[+=A30OW*5ZGH[N?I#^;7+16V[F1;O<2.%R!RD$:?X@@R#+ M'^0AR.BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H; MZFT$>AOJ;01Z&^IM!'I;9[.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O M0[V-0&^/>GL"O3WJ[0GT]JBW)]#;H]Z>0&_?V>PFT-NCWOZ=>L=TK4)\]CS6 M^/QW4IUN]X;GX^_+Q\G."W7'V<'OL<4O4$L#!!0 ( %R *5-3V2LIL@$ M %,; 3 6T-O;G1E;G1?5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQG=(? M 9>VUY9#7\!--B0BB2W;4'C[.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75 MN%E4>&\>&'-I0;5RL3;4A)U7T<$A#IU=C2M* MXX:A(&)G'=J=GPT.?:\;LK;,:+!0UK^H.E2Q;<6H?K_=!VU&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( %R *5,O6AX>4P4 M H6 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I4U!I M\J , P 5PH !@ ("!,Q0 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ 7( I4X?CB/B?" 8"4 !@ M ("!O"0 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ 7( I4_NKN#]I!P O!$ !@ ("!LS@ 'AL M+W=O&UL4$L! A0#% @ 7( I4[GZAY78 P ^0@ !D ("! MWT8 'AL+W=O&PO=V]R:W-H965TM8 !X;"]W;W)K&UL4$L! A0#% M @ 7( I4P02-!"T!P :!, !D ("!UUT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I4VEQJ)^P M!@ JA$ !D ("!X7, 'AL+W=O@ >&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I4P0V7?6>! 9@L !D M ("!!(, 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 7( I4V241.$6!0 -@P !D ("!UHX M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M7( I4ZW&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I4UW:R&+; @ M_ D !D ("!<:4 'AL+W=O&PO=V]R:W-H965T")P, &D) 9 " @&UL4$L! A0#% @ 7( I4\PK*W/S @ O0@ !D M ("!)Z\ 'AL+W=O&PO=V]R:W-H M965TU !X;"]W;W)K&UL4$L! M A0#% @ 7( I4\))\%F( P N T !D ("!HK@ 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I M4V"^R+E6 P 8@L !D ("!/<0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I4T&PN83@ P FQ M !D ("!L,\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 7( I4W-60[9.! BQ, !D M ("!2MP 'AL+W=O2^(" # !@ &0 @('/X >&PO=V]R:W-H965T MCC !X;"]S='EL97,N>&UL4$L! A0#% @ 7( I4Y>* MNQS $P( L ( !.N< %]R96QS+RYR96QS4$L! A0# M% @ 7( I4Z$ZV/:\ P 2QX \ ( !(^@ 'AL+W=O MWM !;0V]N=&5N B=%]4>7!E&UL4$L%!@ U #4 :@X -#O $! end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 142 318 1 false 44 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed consolidated balance sheets Sheet http://healthequity.com/role/Condensedconsolidatedbalancesheets Condensed consolidated balance sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed consolidated balance sheets (Parenthetical) Sheet http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical Condensed consolidated balance sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited Condensed consolidated statements of operations and comprehensive income (loss) (unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited Condensed consolidated statements of stockholders' equity (unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed consolidated statements of cash flows (unaudited) Sheet http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited Condensed consolidated statements of cash flows (unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - Summary of business and significant accounting policies Sheet http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies Summary of business and significant accounting policies Notes 7 false false R8.htm 2104102 - Disclosure - Net income (loss) per share Sheet http://healthequity.com/role/Netincomelosspershare Net income (loss) per share Notes 8 false false R9.htm 2107103 - Disclosure - Business combination Sheet http://healthequity.com/role/Businesscombination Business combination Notes 9 false false R10.htm 2112104 - Disclosure - Supplemental financial statement information Sheet http://healthequity.com/role/Supplementalfinancialstatementinformation Supplemental financial statement information Notes 10 false false R11.htm 2119105 - Disclosure - Intangible assets and goodwill Sheet http://healthequity.com/role/Intangibleassetsandgoodwill Intangible assets and goodwill Notes 11 false false R12.htm 2123106 - Disclosure - Commitments and contingencies Sheet http://healthequity.com/role/Commitmentsandcontingencies Commitments and contingencies Notes 12 false false R13.htm 2125107 - Disclosure - Income taxes Sheet http://healthequity.com/role/Incometaxes Income taxes Notes 13 false false R14.htm 2127108 - Disclosure - Indebtedness Sheet http://healthequity.com/role/Indebtedness Indebtedness Notes 14 false false R15.htm 2131109 - Disclosure - Stock-based compensation Sheet http://healthequity.com/role/Stockbasedcompensation Stock-based compensation Notes 15 false false R16.htm 2137110 - Disclosure - Fair value Sheet http://healthequity.com/role/Fairvalue Fair value Notes 16 false false R17.htm 2202201 - Disclosure - Summary of business and significant accounting policies (Policies) Sheet http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies Summary of business and significant accounting policies (Policies) Policies 17 false false R18.htm 2305301 - Disclosure - Net income (loss) per share (Tables) Sheet http://healthequity.com/role/NetincomelosspershareTables Net income (loss) per share (Tables) Tables http://healthequity.com/role/Netincomelosspershare 18 false false R19.htm 2308302 - Disclosure - Business combination (Tables) Sheet http://healthequity.com/role/BusinesscombinationTables Business combination (Tables) Tables http://healthequity.com/role/Businesscombination 19 false false R20.htm 2313303 - Disclosure - Supplemental financial statement information (Tables) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationTables Supplemental financial statement information (Tables) Tables http://healthequity.com/role/Supplementalfinancialstatementinformation 20 false false R21.htm 2320304 - Disclosure - Intangible assets and goodwill (Tables) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillTables Intangible assets and goodwill (Tables) Tables http://healthequity.com/role/Intangibleassetsandgoodwill 21 false false R22.htm 2328305 - Disclosure - Indebtedness (Tables) Sheet http://healthequity.com/role/IndebtednessTables Indebtedness (Tables) Tables http://healthequity.com/role/Indebtedness 22 false false R23.htm 2332306 - Disclosure - Stock-based compensation (Tables) Sheet http://healthequity.com/role/StockbasedcompensationTables Stock-based compensation (Tables) Tables http://healthequity.com/role/Stockbasedcompensation 23 false false R24.htm 2338307 - Disclosure - Fair value (Tables) Sheet http://healthequity.com/role/FairvalueTables Fair value (Tables) Tables http://healthequity.com/role/Fairvalue 24 false false R25.htm 2403401 - Disclosure - Summary of business and significant accounting policies (Details) Sheet http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails Summary of business and significant accounting policies (Details) Details http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies 25 false false R26.htm 2406402 - Disclosure - Net income (loss) per share (Details) Sheet http://healthequity.com/role/NetincomelosspershareDetails Net income (loss) per share (Details) Details http://healthequity.com/role/NetincomelosspershareTables 26 false false R27.htm 2409403 - Disclosure - Business combination (Narrative) (Details) Sheet http://healthequity.com/role/BusinesscombinationNarrativeDetails Business combination (Narrative) (Details) Details http://healthequity.com/role/BusinesscombinationTables 27 false false R28.htm 2410404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details) Sheet http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails Business combination (Preliminary Allocation of Consideration) (Details) Details http://healthequity.com/role/BusinesscombinationTables 28 false false R29.htm 2411405 - Disclosure - Business combination (Acquired Identified Intangible Assets) (Details) Sheet http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails Business combination (Acquired Identified Intangible Assets) (Details) Details http://healthequity.com/role/BusinesscombinationTables 29 false false R30.htm 2414406 - Disclosure - Supplemental financial statement information (Property and equipment) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails Supplemental financial statement information (Property and equipment) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 30 false false R31.htm 2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails Supplemental financial statement information (Narrative) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 31 false false R32.htm 2416408 - Disclosure - Supplemental financial statement information (Lease Cost) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails Supplemental financial statement information (Lease Cost) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 32 false false R33.htm 2417409 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails Supplemental financial statement information (Other income (expense), net) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 33 false false R34.htm 2418410 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details) Sheet http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails Supplemental financial statement information (Supplemental Cash Flow Information) (Details) Details http://healthequity.com/role/SupplementalfinancialstatementinformationTables 34 false false R35.htm 2421411 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails Intangible assets and goodwill (Schedule of intangible assets) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 35 false false R36.htm 2422412 - Disclosure - Intangible assets and goodwill (Narrative) (Details) Sheet http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails Intangible assets and goodwill (Narrative) (Details) Details http://healthequity.com/role/IntangibleassetsandgoodwillTables 36 false false R37.htm 2424413 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 37 false false R38.htm 2426414 - Disclosure - Income taxes (Details) Sheet http://healthequity.com/role/IncometaxesDetails Income taxes (Details) Details http://healthequity.com/role/Incometaxes 38 false false R39.htm 2429415 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details) Sheet http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails Indebtedness (Schedule of Long-term Debt) (Details) Details http://healthequity.com/role/IndebtednessTables 39 false false R40.htm 2430416 - Disclosure - Indebtedness (Narrative) (Details) Sheet http://healthequity.com/role/IndebtednessNarrativeDetails Indebtedness (Narrative) (Details) Details http://healthequity.com/role/IndebtednessTables 40 false false R41.htm 2433417 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details) Sheet http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails Stock-based compensation (Summary of share based compensation recognized) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 41 false false R42.htm 2434418 - Disclosure - Stock-based compensation (Narrative) (Details) Sheet http://healthequity.com/role/StockbasedcompensationNarrativeDetails Stock-based compensation (Narrative) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 42 false false R43.htm 2435419 - Disclosure - Stock-based compensation (Stock option activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails Stock-based compensation (Stock option activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 43 false false R44.htm 2436420 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details) Sheet http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails Stock-based compensation (Restricted stock unity activity) (Details) Details http://healthequity.com/role/StockbasedcompensationTables 44 false false R45.htm 2439421 - Disclosure - Fair value (Details) Sheet http://healthequity.com/role/FairvalueDetails Fair value (Details) Details http://healthequity.com/role/FairvalueTables 45 false false All Reports Book All Reports hqy-20210731.htm exhibit311-ceo302xfy22q2.htm exhibit312-cfo302xfy22q2.htm exhibit321-ceo906xfy22q2.htm exhibit322-cfo906xfy22q2.htm hqy-20210731.xsd hqy-20210731_cal.xml hqy-20210731_def.xml hqy-20210731_lab.xml hqy-20210731_pre.xml http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20210731.htm": { "axisCustom": 1, "axisStandard": 19, "contextCount": 142, "dts": { "calculationLink": { "local": [ "hqy-20210731_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20210731_def.xml" ] }, "inline": { "local": [ "hqy-20210731.htm" ] }, "labelLink": { "local": [ "hqy-20210731_lab.xml" ], "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20210731_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml" ] }, "schema": { "local": [ "hqy-20210731.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 398, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 25, "keyStandard": 293, "memberCustom": 16, "memberStandard": 28, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20210731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Supplemental financial statement information", "role": "http://healthequity.com/role/Supplementalfinancialstatementinformation", "shortName": "Supplemental financial statement information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119105 - Disclosure - Intangible assets and goodwill", "role": "http://healthequity.com/role/Intangibleassetsandgoodwill", "shortName": "Intangible assets and goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123106 - Disclosure - Commitments and contingencies", "role": "http://healthequity.com/role/Commitmentsandcontingencies", "shortName": "Commitments and contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Income taxes", "role": "http://healthequity.com/role/Incometaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Indebtedness", "role": "http://healthequity.com/role/Indebtedness", "shortName": "Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131109 - Disclosure - Stock-based compensation", "role": "http://healthequity.com/role/Stockbasedcompensation", "shortName": "Stock-based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Fair value", "role": "http://healthequity.com/role/Fairvalue", "shortName": "Fair value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Summary of business and significant accounting policies (Policies)", "role": "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies", "shortName": "Summary of business and significant accounting policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Net income (loss) per share (Tables)", "role": "http://healthequity.com/role/NetincomelosspershareTables", "shortName": "Net income (loss) per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Business combination (Tables)", "role": "http://healthequity.com/role/BusinesscombinationTables", "shortName": "Business combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed consolidated balance sheets", "role": "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "shortName": "Condensed consolidated balance sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Supplemental financial statement information (Tables)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationTables", "shortName": "Supplemental financial statement information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320304 - Disclosure - Intangible assets and goodwill (Tables)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillTables", "shortName": "Intangible assets and goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328305 - Disclosure - Indebtedness (Tables)", "role": "http://healthequity.com/role/IndebtednessTables", "shortName": "Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2332306 - Disclosure - Stock-based compensation (Tables)", "role": "http://healthequity.com/role/StockbasedcompensationTables", "shortName": "Stock-based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338307 - Disclosure - Fair value (Tables)", "role": "http://healthequity.com/role/FairvalueTables", "shortName": "Fair value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "iec8aaf532cf04a4a82a97c6c16bdf7ba_D20210308-20210308", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Summary of business and significant accounting policies (Details)", "role": "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails", "shortName": "Summary of business and significant accounting policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ia372d309fd8b401b92893d732e57aaa3_D20210201-20210430", "decimals": "INF", "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNetOfTax", "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Net income (loss) per share (Details)", "role": "http://healthequity.com/role/NetincomelosspershareDetails", "shortName": "Net income (loss) per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Business combination (Narrative) (Details)", "role": "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "shortName": "Business combination (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Business combination (Preliminary Allocation of Consideration) (Details)", "role": "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "shortName": "Business combination (Preliminary Allocation of Consideration) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i0bed04a9768f47928f6bcd9b870e8abb_I20210308", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "iec8aaf532cf04a4a82a97c6c16bdf7ba_D20210308-20210308", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Business combination (Acquired Identified Intangible Assets) (Details)", "role": "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "shortName": "Business combination (Acquired Identified Intangible Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "iec8aaf532cf04a4a82a97c6c16bdf7ba_D20210308-20210308", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed consolidated balance sheets (Parenthetical)", "role": "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical", "shortName": "Condensed consolidated balance sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Supplemental financial statement information (Property and equipment) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails", "shortName": "Supplemental financial statement information (Property and equipment) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Supplemental financial statement information (Narrative) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails", "shortName": "Supplemental financial statement information (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Supplemental financial statement information (Lease Cost) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails", "shortName": "Supplemental financial statement information (Lease Cost) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Supplemental financial statement information (Other income (expense), net) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails", "shortName": "Supplemental financial statement information (Other income (expense), net) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeNonoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Supplemental financial statement information (Supplemental Cash Flow Information) (Details)", "role": "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails", "shortName": "Supplemental financial statement information (Supplemental Cash Flow Information) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Intangible assets and goodwill (Schedule of intangible assets) (Details)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails", "shortName": "Intangible assets and goodwill (Schedule of intangible assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Intangible assets and goodwill (Narrative) (Details)", "role": "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails", "shortName": "Intangible assets and goodwill (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ic6b491ddcccc4d41a1f3ed0ec6e76d7b_I20210430", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424413 - Disclosure - Commitments and contingencies - Narrative (Details)", "role": "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "shortName": "Commitments and contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ic6b491ddcccc4d41a1f3ed0ec6e76d7b_I20210430", "decimals": "-5", "first": true, "lang": "en-US", "name": "hqy:LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Income taxes (Details)", "role": "http://healthequity.com/role/IncometaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "iecd503fbb7634c929c185cc5ca43e2d9_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429415 - Disclosure - Indebtedness (Schedule of Long-term Debt) (Details)", "role": "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails", "shortName": "Indebtedness (Schedule of Long-term Debt) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "iecd503fbb7634c929c185cc5ca43e2d9_I20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "shortName": "Condensed consolidated statements of operations and comprehensive income (loss) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430416 - Disclosure - Indebtedness (Narrative) (Details)", "role": "http://healthequity.com/role/IndebtednessNarrativeDetails", "shortName": "Indebtedness (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i42eb8ae6b79e49caae3073b064157a31_I20210731", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433417 - Disclosure - Stock-based compensation (Summary of share based compensation recognized) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails", "shortName": "Stock-based compensation (Summary of share based compensation recognized) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ib084ccf8e9a14a8ca267905976191a85_D20210501-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i46bce1a211dd43edb1ad9d6995b23ac4_D20210201-20210731", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434418 - Disclosure - Stock-based compensation (Narrative) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "shortName": "Stock-based compensation (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i46bce1a211dd43edb1ad9d6995b23ac4_D20210201-20210731", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "ia4371f27b56b46a499bbe7585743e025_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435419 - Disclosure - Stock-based compensation (Stock option activity) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails", "shortName": "Stock-based compensation (Stock option activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i3822ab43074348eab7adb4651c99e315_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Stock-based compensation (Restricted stock unity activity) (Details)", "role": "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "shortName": "Stock-based compensation (Restricted stock unity activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i3822ab43074348eab7adb4651c99e315_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "if50f6949fa2c49a588e8005678bac358_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Fair value (Details)", "role": "http://healthequity.com/role/FairvalueDetails", "shortName": "Fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "if50f6949fa2c49a588e8005678bac358_I20210131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i6304b16b37f74ce38fcff77506320604_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed consolidated statements of stockholders' equity (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "shortName": "Condensed consolidated statements of stockholders' equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i6304b16b37f74ce38fcff77506320604_I20200131", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed consolidated statements of cash flows (unaudited)", "role": "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "shortName": "Condensed consolidated statements of cash flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Summary of business and significant accounting policies", "role": "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies", "shortName": "Summary of business and significant accounting policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Net income (loss) per share", "role": "http://healthequity.com/role/Netincomelosspershare", "shortName": "Net income (loss) per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Business combination", "role": "http://healthequity.com/role/Businesscombination", "shortName": "Business combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20210731.htm", "contextRef": "i9b5f60b43c5343259e8f4237ac73bfbf_D20210201-20210731", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 44, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "hqy_AcquiredHSAIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquired HSA Intangible Assets [Member]", "label": "Acquired HSA Intangible Assets [Member]", "terseLabel": "Acquired HSA portfolios" } } }, "localname": "AcquiredHSAIntangibleAssetsMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "hqy_AmortizationOfAcquiredIntangible": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Acquired Intangible", "label": "Amortization Of Acquired Intangible", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfAcquiredIntangible", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired And Liabilities, Assets", "label": "Asset Acquisition, Assets Acquired And Liabilities, Assets", "terseLabel": "Value of HSA assets transferred in portfolio acquisition" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssets", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "domainItemType" }, "hqy_ContractWithCustomerRecognitionTermInterchangeArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Recognition Term, Interchange Arrangement", "label": "Contract With Customer, Recognition Term, Interchange Arrangement", "terseLabel": "Deferred revenue interchange arrangement recognition term" } } }, "localname": "ContractWithCustomerRecognitionTermInterchangeArrangement", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement [Member]", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Axis]", "terseLabel": "Debt Covenant Period [Axis]" } } }, "localname": "DebtCovenantPeriodAxis", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "hqy_DebtCovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Debt Covenant Period [Axis]", "label": "Debt Covenant Period [Domain]", "terseLabel": "Debt Covenant Period [Domain]" } } }, "localname": "DebtCovenantPeriodDomain", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period Four", "label": "Debt Covenant Period Four [Member]", "terseLabel": "Debt Covenant, Acquisition Holiday Provision" } } }, "localname": "DebtCovenantPeriodFourMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtCovenantPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant Period Two", "label": "Debt Covenant Period Two [Member]", "terseLabel": "Debt Covenant, Beginning July 31, 2021" } } }, "localname": "DebtCovenantPeriodTwoMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "label": "Debt Instrument, Covenant Description, Acquisition Threshold For Maximum Total Net Leverage Ratio", "terseLabel": "Acquisition threshold for maximum total net leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionAcquisitionThresholdForMaximumTotalNetLeverageRatio", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_DebtInstrumentCovenantDescriptionInterestCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "label": "Debt Instrument, Covenant Description, Interest Coverage Ratio", "terseLabel": "Minimum interest coverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionInterestCoverageRatio", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_DebtInstrumentCovenantDescriptionLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant Description, Leverage Ratio", "label": "Debt Instrument, Covenant Description, Leverage Ratio", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantDescriptionLeverageRatio", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "pureItemType" }, "hqy_ExerciseofStockOptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Exercise of Stock Options Receivable", "label": "Exercise of Stock Options Receivable", "terseLabel": "Exercise of common stock options receivable" } } }, "localname": "ExerciseofStockOptionsReceivable", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member]", "label": "Fifth Third Bank Health Savings Accounts Portfolio Acquisition [Member]", "terseLabel": "Fifth Third Bank HSA portfolio Acquisition" } } }, "localname": "FifthThirdBankHealthSavingsAccountsPortfolioAcquisitionMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_FollowOnEquityOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow On Equity Offering [Member]", "label": "Follow On Equity Offering [Member]", "terseLabel": "Follow on equity offering" } } }, "localname": "FollowOnEquityOfferingMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "hqy_FurtherHealthSavingsAccountPortfolioAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Further Health Savings Account Portfolio Acquisition", "label": "Further Health Savings Account Portfolio Acquisition [Member]", "terseLabel": "Further Health Savings Account Portfolio Acquisition" } } }, "localname": "FurtherHealthSavingsAccountPortfolioAcquisitionMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive Plan [Member]", "label": "Incentive Plan [Member]", "terseLabel": "Incentive Plan" } } }, "localname": "IncentivePlanMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "label": "Increase (Decrease) In Operating Lease Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilityNoncurrent", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset", "negatedTerseLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Amount", "terseLabel": "Operating lease not yet commenced undiscounted amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted, Term", "label": "Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted, Term", "terseLabel": "Operating lease not yet commenced undiscounted, term" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedTerm", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "hqy_LossContingencyNumberOfLawsuits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency Number Of Lawsuits", "label": "Loss Contingency Number Of Lawsuits", "terseLabel": "Number of derivative lawsuits" } } }, "localname": "LossContingencyNumberOfLawsuits", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hqy_LuumAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Luum Acquisition [Member]", "label": "Luum Acquisition [Member]", "terseLabel": "Luum Acquisition" } } }, "localname": "LuumAcquisitionMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "hqy_NumberOfHSAMembersTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of HSA Members Transferred", "label": "Number Of HSA Members Transferred", "terseLabel": "Number of HSA members transferred in portfolio acquisition" } } }, "localname": "NumberOfHSAMembersTransferred", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "hqy_OtherNonoperatingIncomeExpenseMiscellaneous": { "auth_ref": [], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Nonoperating Income (Expense), Miscellaneous", "label": "Other Nonoperating Income (Expense), Miscellaneous", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpenseMiscellaneous", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PaymentsForAssetAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments For Asset Acquisition", "label": "Payments For Asset Acquisition", "terseLabel": "Purchase price for HSA portfolio" } } }, "localname": "PaymentsForAssetAcquisition", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_PaymentsToSettleClientHeldFunds": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Settle Client Held Funds", "label": "Payments To Settle Client Held Funds", "negatedTerseLabel": "Settlement of client-held funds obligation, net" } } }, "localname": "PaymentsToSettleClientHeldFunds", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Restricted Stock Units [Member]", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance restricted stock units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]", "label": "Recently Adopted Accounting Pronouncements [Policy Text Block]", "terseLabel": "Recent adopted accounting pronouncements and Recently issued accounting pronouncements not yet adopted" } } }, "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hqy_SalesandMarketingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales and Marketing [Member]", "label": "Sales and Marketing [Member]", "terseLabel": "Sales and marketing" } } }, "localname": "SalesandMarketingMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Grants In Period, Fair Value", "terseLabel": "Grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Exercised", "terseLabel": "Exercised, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitExercised", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Lower Range Limit, Outstanding", "periodEndLabel": "Ending balance, minimum (in usd per share)", "periodStartLabel": "Beginning balance, minimum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimitOutstanding", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Exercised", "terseLabel": "Exercised, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitExercised", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "label": "Share-Based Compensation, Shares Authorized Under Stock Option Plans, Exercise Price Range, Upper Range Limit, Outstanding", "periodEndLabel": "Ending balance, maximum (in usd per share)", "periodStartLabel": "Beginning balance, maximum (in usd per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimitOutstanding", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "hqy_SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Shares Available for Grants, Percentage of Capital Stock Outstanding, Percentage", "terseLabel": "Percentage of capital stock" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAdditionalSharesAvailableforGrantsPercentageofCapitalStockOutstandingPercentage", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "hqy_StockIssuanceCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issuance Costs Incurred But Not Yet Paid", "label": "Stock Issuance Costs Incurred But Not Yet Paid", "terseLabel": "Follow-on equity offering costs accrued during the period" } } }, "localname": "StockIssuanceCostsIncurredButNotYetPaid", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "hqy_StockIssuanceCostsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issuance Costs Payable", "label": "Stock Issuance Costs Payable", "terseLabel": "Other offering expenses payable" } } }, "localname": "StockIssuanceCostsPayable", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hqy_TechnologyandDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology and Development [Member]", "label": "Technology and Development [Member]", "terseLabel": "Technology and development" } } }, "localname": "TechnologyandDevelopmentMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "hqy_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Facility [Member]", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "hqy_WageWorksInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WageWorks Inc. [Member]", "label": "WageWorks Inc. [Member]", "terseLabel": "WageWorks, Inc" } } }, "localname": "WageWorksInc.Member", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WageWorksInsurersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "WageWorks Insurers [Member]", "label": "WageWorks Insurers [Member]", "terseLabel": "WageWorks Insurers" } } }, "localname": "WageWorksInsurersMember", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "hqy_WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "label": "Weighted Average Number Of Shares Used In Computing Net Income Per Share Attributable To Common Stockholders, Basic And Diluted [Abstract]", "terseLabel": "Weighted-average number of shares used in computing net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesUsedInComputingNetIncomePerShareAttributableToCommonStockholdersBasicAndDilutedAbstract", "nsuri": "http://healthequity.com/20210731", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r47", "r49", "r95", "r96", "r220", "r253" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r219", "r252", "r267", "r269", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r459", "r461", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r219", "r252", "r267", "r269", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r459", "r461", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r151", "r262", "r264", "r425", "r458", "r460" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r151", "r262", "r264", "r425", "r458", "r460" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r219", "r252", "r265", "r267", "r269", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r459", "r461", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r219", "r252", "r265", "r267", "r269", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r459", "r461", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r48", "r49", "r95", "r96", "r220", "r253" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r23", "r154", "r155" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $5,824 and $4,239 as of July 31, 2021 and January 31, 2021, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r186" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental financial statement information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Supplementalfinancialstatementinformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r304", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r99", "r100", "r101", "r301", "r302", "r303", "r372" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital:" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r270", "r272", "r306", "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r272", "r294", "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r29", "r156", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r64", "r81", "r239", "r400" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r81", "r174", "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r352", "r353", "r354", "r355" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Purchase price for VEBA assets" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r92", "r140", "r143", "r149", "r161", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r357", "r360", "r380", "r413", "r415", "r433", "r447" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r11", "r46", "r92", "r161", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r357", "r360", "r380", "r413", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r274", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Customary Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r266", "r268" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r266", "r268", "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Ownership interest (as a percent)" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r333" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "negatedLabel": "Acquisition gains (costs), net" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r345", "r346", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Aggregate fair value of WageWorks stock acquired" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r80", "r350" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r344", "r347", "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent payments payable" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Businesscombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Merger integration" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "negatedLabel": "Current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r337", "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total consideration paid" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r338" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r85", "r86", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable or accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r30", "r83" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r77", "r83", "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Ending cash and cash equivalents", "periodStartLabel": "Beginning cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r77", "r389" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r193", "r437", "r452" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r200", "r474" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Commitmentsandcontingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r99", "r100", "r372" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock:" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value, 900,000 shares authorized, 83,608 and 77,168 shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54", "r61", "r440", "r454" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r175", "r179", "r342" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Computer software intangible asset" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r89", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenue recognition" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r66", "r425" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditAndDebitCardMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Card issued to user to facilitate payment for purchase of product and service paid directly to merchant by issuer, or from user's checking account.", "label": "Credit and Debit Card [Member]", "terseLabel": "Interchange revenue" } } }, "localname": "CreditAndDebitCardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships", "verboseLabel": "Acquired customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r90", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r233", "r240", "r241", "r243", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Indebtedness" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Indebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r91", "r97", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r246", "r247", "r248", "r249", "r401", "r434", "r435", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate borrowing spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r19", "r244", "r435", "r446" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Term loan facility" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40", "r217" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41", "r91", "r97", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r246", "r247", "r248", "r249", "r401" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r91", "r97", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r229", "r230", "r231", "r232", "r234", "r235", "r236", "r237", "r238", "r239", "r242", "r246", "r247", "r248", "r249", "r255", "r256", "r257", "r258", "r398", "r399", "r401", "r402", "r445" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Facility term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r33", "r229", "r400" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Less: unamortized loan issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r312", "r313" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r82" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r81", "r184" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r81", "r138" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Acquired developed technology", "verboseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Stockbasedcompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r62", "r108", "r109", "r110", "r111", "r112", "r117", "r119", "r124", "r125", "r126", "r130", "r131", "r373", "r374", "r441", "r455" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net income (loss) per share:", "verboseLabel": "Net income (loss) per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r62", "r108", "r109", "r110", "r111", "r112", "r119", "r124", "r125", "r126", "r130", "r131", "r373", "r374", "r441", "r455" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Netincomelosspershare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r308", "r315" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Effective tax rate, primarily due to excess tax benefit on stock-based compensation expense (benefit)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r55", "r56", "r57", "r99", "r100", "r101", "r104", "r113", "r115", "r133", "r165", "r254", "r259", "r301", "r302", "r303", "r323", "r324", "r372", "r390", "r391", "r392", "r393", "r394", "r395", "r464", "r465", "r466", "r488" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Fairvalue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r375", "r379" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r375", "r379" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Change in the Fair Value of the Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value recognized in the condensed consolidated statement of operations and comprehensive income (loss)" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Contingent consideration recognized at acquisition" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance as of July 31, 2021", "periodStartLabel": "Balance as of January 31, 2021" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/FairvalueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialServiceOtherMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Financial assistance, including, but not limited to, management and maintenance of depositor account, credit card, merchant discount, trust, investment and insurance, classified as other.", "label": "Financial Service, Other [Member]", "terseLabel": "Custodial revenue" } } }, "localname": "FinancialServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r180" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r175", "r177", "r180", "r182", "r426", "r430" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r180", "r430" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Amortizable intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r175", "r179" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r180", "r426" ], "calculation": { "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Amortizable intangible assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Fair value" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r169", "r170", "r415", "r432" ], "calculation": { "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails", "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r171" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Intangibleassetsandgoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r172", "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Additions to goodwill due to measurement period adjustments" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r65", "r92", "r140", "r142", "r145", "r148", "r150", "r161", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r380" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r140", "r142", "r145", "r148", "r150", "r431", "r438", "r443", "r456" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r93", "r316", "r319", "r320", "r325", "r327", "r329", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Incometaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r94", "r114", "r115", "r139", "r314", "r326", "r328", "r457" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax payments (refunds), net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accounts payable, accrued liabilities, and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r120", "r121", "r122", "r126" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted-average dilutive effect of stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r173", "r178" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r58", "r137", "r397", "r400", "r442" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r75", "r78", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r68" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r410", "r411" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net operating lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r92", "r144", "r161", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r358", "r360", "r361", "r380", "r413", "r414" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r92", "r161", "r380", "r415", "r436", "r450" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r92", "r161", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r358", "r360", "r361", "r380", "r413", "r414", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r19", "r20", "r92", "r161", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r358", "r360", "r361", "r380", "r413", "r414" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r19", "r435", "r446" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term line of credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Commitment fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Effective interest rate percentage" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, amount" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r19", "r230", "r245", "r246", "r247", "r435", "r448" ], "calculation": { "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term debt, net of issuance costs" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of issuance costs" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r203" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Settle of claims" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r77" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r77", "r79", "r82" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r50", "r52", "r57", "r60", "r82", "r92", "r103", "r108", "r109", "r110", "r111", "r114", "r115", "r123", "r140", "r142", "r145", "r148", "r150", "r161", "r205", "r206", "r207", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r374", "r380", "r439", "r453" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Numerator (basic and diluted):" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r102", "r103", "r104", "r105", "r106", "r107", "r110", "r116", "r130", "r158", "r159", "r162", "r163", "r164", "r165", "r166", "r167", "r204", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r321", "r322", "r323", "r324", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r412", "r427", "r428", "r429", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r484", "r485", "r486", "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r85", "r86", "r87" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": { "auth_ref": [ "r85", "r86", "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed", "terseLabel": "Contingent consideration recognized at acquisition" } } }, "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r68" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r140", "r142", "r145", "r148", "r150" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r405" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r404" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r404" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r406", "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r403" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r7", "r98", "r134", "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of business and significant accounting policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Summaryofbusinessandsignificantaccountingpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r45", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net", "totalLabel": "Total other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/SupplementalfinancialstatementinformationOtherincomeexpensenetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r71" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Purchases of software and capitalized software development costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r70" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r71" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Acquisition of intangible member assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r71", "r352", "r353", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Maximum purchase price" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r274", "r295" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21", "r251" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r251" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CondensedconsolidatedbalancesheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2021 and January 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r72" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from follow-on equity offering, net of payments for offering costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "auth_ref": [ "r76", "r160" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Proceeds from Sale of Equity Securities, FV-NI", "terseLabel": "Proceeds from sale of equity securities" } } }, "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r72", "r296" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r32", "r187" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r31", "r185" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r187", "r415", "r444", "r451" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r187" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r185" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r73" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Principal payments on long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r310", "r424", "r477" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Technology and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r259", "r304", "r415", "r449", "r468", "r473" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r99", "r100", "r101", "r104", "r113", "r115", "r165", "r301", "r302", "r303", "r323", "r324", "r372", "r464", "r466" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r135", "r136", "r141", "r146", "r147", "r151", "r152", "r153", "r261", "r262", "r425" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "verboseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues [Abstract]" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "verboseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails", "http://healthequity.com/role/IndebtednessScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r409", "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from follow on offering" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock, shares (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Offering price per share (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r335", "r336" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails", "http://healthequity.com/role/BusinesscombinationNarrativeDetails", "http://healthequity.com/role/BusinesscombinationPreliminaryAllocationofConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r41", "r97", "r246", "r248", "r255", "r256", "r257", "r258", "r398", "r399", "r402", "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings (Loss) Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r272", "r293", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Share Based Compensation Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r175", "r179", "r426" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r175", "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-lived Intangible Assets", "verboseLabel": "Schedule of Acquired Identified Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationTables", "http://healthequity.com/role/IntangibleassetsandgoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other Income (Expense), Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r32", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationPropertyandequipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Preliminary Allocation of Consideration" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r274", "r295" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r278", "r288", "r290" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r80" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Performance units awards (in shares)", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, ending balance (in usd per share)", "periodStartLabel": "Outstanding, beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails", "http://healthequity.com/role/StockbasedcompensationSummaryofsharebasedcompensationrecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant under incentive plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, weighted-average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r280", "r295" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number\u00a0of options (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Opening balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest, aggregate intrinsic value (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest, weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r271", "r277" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails", "http://healthequity.com/role/StockbasedcompensationRestrictedstockunityactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Beginning of Period [Abstract]", "terseLabel": "Range of exercise prices" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable, weighted-average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding stock options, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest, weighted average contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and software development costs" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r44", "r55", "r56", "r57", "r99", "r100", "r101", "r104", "r113", "r115", "r133", "r165", "r254", "r259", "r301", "r302", "r303", "r323", "r324", "r372", "r390", "r391", "r392", "r393", "r394", "r395", "r464", "r465", "r466", "r488" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r133", "r425" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r21", "r22", "r254", "r259", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/StockbasedcompensationStockoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Other issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r21", "r22", "r259", "r273", "r289" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock upon exercise of stock options, and for restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r26", "r27", "r92", "r157", "r161", "r380", "r415" ], "calculation": { "http://healthequity.com/role/Condensedconsolidatedbalancesheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets", "http://healthequity.com/role/Condensedconsolidatedstatementsofstockholdersequityunaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedbalancesheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r407", "r411" ], "calculation": { "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedTerseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SupplementalfinancialstatementinformationLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r396", "r416" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r396", "r416" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r396", "r416" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/CommitmentsandcontingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/SummaryofbusinessandsignificantaccountingpoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow data:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofcashflowsunaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Acquired trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IntangibleassetsandgoodwillScheduleofintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trade names & trademarks" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/BusinesscombinationAcquiredIdentifiedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r311", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Gross unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact the effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IncometaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/IndebtednessNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r126" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator (diluted):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r117", "r126" ], "calculation": { "http://healthequity.com/role/NetincomelosspershareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "netLabel": "Weighted-average common shares outstanding (in shares)", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/Condensedconsolidatedstatementsofoperationsandcomprehensiveincomelossunaudited", "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator (basic):" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://healthequity.com/role/NetincomelosspershareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r480": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r481": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r482": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r483": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" } }, "version": "2.1" } ZIP 63 0001428336-21-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-21-000035-xbrl.zip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

_(9S(NI#E=Z9#=*' M8*H1-QR42!J<9 Y,$"I8F[1*F^S]WNY;-P*3.P8P->9X[UAZE?[OS^2J?_E3G7_V&%W?ISU$DJUF$4!+E3,Y23EU$ :V]L=D7S?.F MUW1#GVTC7/J3P65KZ?6.WNM0H_[JED+M7+9&(4'.U:5$FMC-@@)O2N;%Q635 MIHT$VW_[9E5==C(0W%\$O>YM^7@Q2W_%NATTK6T'O7OJC>;R/?%!@TSDV^20 M0\WBNYG!1D'7VI=]P/.:9BXG=RXWJBZ/\WOXOMSEK. M6%$O#"Q&$H:0,>:$VK5>A[GKV4=N?.@!_P<1^Q$ _0/EI_-)(KXO:?]C.B%6 M_QWF^0GR#7<6K1+ 8ZIMLX42UQ@9A!P+2< &Q=K<)0U,R,B]&_VJ0$M '%=, M_O'RRYJ"%$4F6_), M$)4)B@E64'QB=:,I#;UD!$]$=_-Y?6JW_,[7WQ_DW4NEO^J7EH6KY+B Q(*I M0U3LE.W75YK,L]Z\2 MF:NY];I$[9'8Z##4@6D2HD,&*)57+K)B=)LY&\\<:ER$C@2361N9]0N_U?.E MK'(IHM1QL.A ,>O %:*-XB7+-?+"5)LG.L\>:UP(#B;\S4"U@R0Z@%5U%:2C MX1P7UX_;K2_)$@'&:=(WE@O$+ T(66(L13)M2Q,H/3A*E_#917R&!'I[0R-AD;7TI>GOGX M<0M,PT-A*$Z./GXW_3F=G<\^?R#[[NK9WA?E26-T;R(.C.)-C@AA" M),XD1H<5.NI-,/'\MXQ;>&D#C0'YVH&/^16G. _GKZ;Y5?XRF4YJ%E*7&?[R MWQH.WHQF4=)PU 1[(^H66\G F6)!2O2Y")G4@Y$DP_B=C8XW[A.:=KYH>-ET M +CW%W_B_"X%,2;-L280"3FI3(K@I#4@E519">)<:3/ ]^%9QGT5TPY*>W*] M ]R\F*H^E:F^N^G]\\0ERXR%X(,"Y9P'K[T Z1)FPXN*O-$EWMYG'S?&ZJ-@ M<& $=(#YU94\YL=)7^GS64'EO' &0BD4E"+GX$26$(+4G#@KG&UC/S<[W\C% MK@.C9M9JZ/)$4 MV()%IQ0R]XWV'I_(U1=&+3A7"K1"4G0C,SA-K$S:1>1,!"':K"/YY^IK6_RV MN_K:!@0=Q B_GX=I7&'U]$L!*#(%Y*]LT@=T]Q[BH MVEV>3P!C!^:.7$]^.ZUOR"D"JB1B&S8YDE+S4443>N)+5<0^?!:&F+PZ!" MH_O'.\X-JV9M=:TB,[S=]Q7F;S+X$?5N.9XF+443@];A)8ZJWP)%B7%I,BP M[AVVX+A+D&PH/G-9V&97'0V62#6[[A_7,>_._QY <[TPC1F6BV> H9:A70@0 M"Q/@@D$3&(_%;M2J>(RKI[82V1.KI[;AW]B[A^XL39(LT3G17JU%4+)NX+#> M0#$8,R=+9])['NGIJ*\$]N7IJ&RZ.+?X[2Y,,-ZR8S"BW1<*^#Q:\% Y2 M8.A*,%FZ <7?W^JIG<6_,Q>/(0M[^68T^502+PY8K(]5M$=*#D&TKPD?TE.=[>3__>/2A0B?TC%RH'D>C M>A+ 5H Z(?=TS;4W*ZZ=:9>SB26"Y4G75PD<',H$(3,3A"E)R3:OXEM1-'*I MZ328KN8!7=F:M].K\5=G&JTFEE!477N7 M5;VOC=XXX(R,24"A9:/.ND-1.'(V=*3JU!)&/82$!^#)FS"9_SN<7^)9"H65 MNHZ%^7K/@M55A\@AVT+FAT41'LQI>#+V.^3!QWTR-':0URU$>G%/ST7!KY^* M@NL__HV+^O#XP^3SG^M1[UGVWO+:-E3GXX*2+$-D5@,W*@N>>9U>W\X7#4W. MN*N >G \HP+DR(:TU9_.EC8BK ;4#3Z.[>FO:#EX;4/"^GAG4@A3PGD+(JJZ M4=D(")YK2-%B+)E,LFA3\ASYG4=-5?GK&48J[M5<:1 M*U.,PD.GG 'O$N<8. K?9E=@&WJ.^@7*-L@>+(L8#AZ]Q#S#<.&J6'%F$EHC M8P2K=:Z;:6L)G7,(O$3++2HMN]>/*U*.]()E0'RV4YD=P+*SMGQ=IB4?+\+\ M8AB=J=[_[6)QB?GGR_E5 ;M^P;)(MSZE^I?_4I0W(5Z<.>>D$TY!5D81U^LZ M[V74:4J]6=+>ZD9)P-9G/=)+D(:H;RON[6'MKV ]Q<_51W[JV!>H0O0K2K8\ M>6-05A(?8O3@1?0I,&V\.25?T-_]Q3'Y@FW LJ!'<9.]4;#0K[U 4'O4VC0Y5 M:S\(=:M:]QOB_I@2,-;"V_J(ZR;$_7T^2;CLR'Z-GR?3*9F9]^4J+KX1G=/* ME$)>W"5AZ^S54A]B9?"J)&]M2GA0Q1J:OG&OX+M3JU'AT^7E^XX<>3?[&^=7 M?YI\F:P[\K-<*'&D_]6;(G+A/-BZR4>0U(Q4&*67X?YS_LVOW <_;H_ELW%1 M^N)E_+B0&;W -CAC_OCZ]2G&H(\F"^O)^ D%"C-90!(7.!0R:B],=+NWKPQ^ MW!Z+I2P-!YO1TZ9Z1N2UVX;EEB',F!R2OKS3)#K2T ?> MI0P-!9N3+ID.&N,HY*82(H#1*4,X'<,$O)ZM$H[@S*.\/".@]*SIP,_)I M:M) D#F1:]LU\O^#M9T;\ZMO. ^?\2[G9N?G9775'K,.+CL%:+P 94R&*&4 MPSQW+CAOW([#'TGH_.!]'+;<"W>CEP?T'?-YK>KQY_O M*5B(AH(9YT$[&9)/J>@P4D/@H'3V6*X_7OT<#X(_D,OT*)VO; D^>5 I4)HA MZPP6=%DIY-:8^U7\TW.9Q]# VX5*C@"Z$\D=7^[7?)9C @WG2F=(R3)02F5P ME8$8.)>6R4PLZU)-]Z-[W$K/$>>4!X3;"3C+M=;.9]GBDBJ,U0[/Y%A="I/ M!YL@%*D92SFSW-EFVNT(W$C=[#_J=A ]:)7NPR^>#$>^(!U)03]_*?9="F^ MRW#^">=?Q%F4+!1?'R@46^\Y%0/OK06N5>(LZZ)9PT&MAR5V(WUSIZIO'0/K M!'3OY5<,&W*.GREK485JM2)SQ#ECP&F1(!LELF"%>=EF764_/-A(4_T_FMH+ M#$] @7=A419>\EQ'%?I4YRHX"T&S#%Z'Y*3E:%%TJ:FM5/)V%\P_.GDP9/6B M?,-4LMX2)R;3Q21=#3=4/KL<16T98A94S@%"YG7A7A2!Q4"1??<%T[LD;:9( M_\R":H62$U"7E[W\J\^?Y\O!)?<89=!RI5EM'DH4E2^' 7+@)4LA611*=W0 M8XU!\F;J]L_,@[%0UHLZ#N/@[S*"GVD2D\B8P25IZSB("#&Z"-:D.@I5"Q8: M-J0UH6DSA3K920?CX^2XIM/>[I!=U-]?3NGOM!I3N\EW-9Q7NS6I?0RN38G5 MUV(<,IEFJ!?"X+S7(+Q2GD4N0Z.I>2,/KAULV9Q.0CAFZBYD23&G5QQ\3 G0 MN6 %%X[;1K?%0Y%PU.-IM\'O Y,^"@@ZB'GN+K,7Q7MG2B"'6"^@,3D(CDN( M3CF&**QE;396WCG&R/VVXT!A-I1<.@#5[HQ[9H^]5TE[%PN4:.M+YF5N7PID M*^LJ 2.5&6ERV [4C OQ/< U6#?I0)+N .VWX=XR'/R#PKW%AX]_K-8>.U_? M9&4'NJ G8IB'4!RQF!65/ 5]6K8)"IX]5N=/&IJC9M9*A/WA<46$]=P*$P,8 MKAPH&1)X)2.%2"ZIX(+QMLU;@$>/TWG+_LCXVT%D'>!NYSKCNYMU09EQH1 M M&!'('^FZ(YYS!D)(85+T2;C.UD6_VVIC>CM$=Q&T'A@!QXSY%[>\_3:;?EL6 MWM='B'.TQEEG@:&U(^A M<*LQPZXX)9PUH..R]8()\!X-\(R"^X QQ\[>?FQ+XI&JV0%P?GB5W %TQ_.J M>:@-P;$^^&:>@>*^4&P2ZS9)4;F37$ 192R=#1IHL6BZOY?,IZ21>T!N9X7\ MAO,XZ]Y!7O6!W'"&1*15,+D^<:7L-$0/+G %QHN4K"[:!GYDRGB7PB-]PWQ* MRK@'Y$Y@T=>+["'A%9RL<\AK$Y,4"5*B[$.YH"$X@\!LU,H7'Y6P1Z:4#XCL M<2KJ#Z:7^P'O1U#-^X%]1F18DH$2D8,2W$*,QD(0Q@3Z-V8;;87N*YL\\*#5 M'TPM]P'=L0_\V)PY]Q[?+ /^G\FNO F3^;(-CM]LPXD@STZ,IR38#Y8]1LWV1?6?,Q^)9BL!2JHE\JIW5 M/ F[7R27#ES?VKYZ2CRR5=ZVZE/AZ9@*RS_<%7BE]FGO6))1\I58I9UQK># M:)"BI"*E$"4[(SJ;)S0T"X[4F_]0]J EJG^H2O7+K,N>H>61#*A:/ANV 4+) M G+ADJ,LTC1J>^^&!2=?ZSX!@] 2U2>=):RJE9>$ZI>YYJ51Q!\-/FA=;_T\ M.(X9ZJ2;($GT-K9Y!=<'_2=?7#\!0] ,SR=M!;;(KR2+7@AC2$NU!R4P@=.& M@4;+9)0.4^QL.L:A:P7'7,<_ 0O0",N#W@$,/%6@4O1MB<\[A]UH2L#MWQWD MU?\31QGH%?^-Z&Z?0Z^]<>8A,J4LR,P8**DIIC.R/D5R)2&24&.;F9#/G6I? MF__89W\B;KZF_^BOLZR58U$4\!8=*%T4 9@[R%%X%;DT'-OTO#][K'$KJH-A MY+[)&DX4O4XGN5'>Y7.776:.W/^$86W*8\O 1PQK EA.2GL4;MT)HZ25P[B1ERDY!S*% M9)D5BOX%EVUFM!V+!5R^#\V.&5(#RH#"UP#LH(-W0__K[-0>^_W0>%HOEK!,93-1&, J&HZ5TOAAPC"RZ M5ZF0=4>K0YLND&>/U0D41T',4_#=6WP]87%_SMYGQVKHA XHF2B"6!T)\6$Y+I MDK#5_)/HM$N.3LX\\5H%H<'%R" ;KU$K@V1+7HA57_R23F#6!QAF+21S6G;X MW4U#L4S2F2 ],.0<5*1L,&CRSQ>+M-)U? MYMJO_$N8U]UVBS,>1"Z!1,55#J"LTQ"#*)"9YH7^T^A$7SYJ:Q+';:/_H91M M()P=L0(^[]"3BEA8YN!=3#4%II@],@0K"V8?#/>\<3_'P0/"9FWIIZE8P^'G M,'VCJU_4?\2PP/_]G_\'4$L! A0#% @ 7( I4Z$R&&9Y,C)Q,BYH=&U0 M2P$"% ,4 " !<@"E3WR)RY%H( "]*P ' @ &5" M97AH:6)I=#,Q,BUC9F\S,#)X9GDR,G$R+FAT;5!+ 0(4 Q0 ( %R *5.G M&*;;'04 "<7 < " 2D1 !E>&AI8FET,S(Q+6-E;SDP M-GAF>3(R<3(N:'1M4$L! A0#% @ 7( I4Q,_=:PO!0 8Q< !P M ( !@!8 &5X:&EB:70S,C(M8V9O.3 V>&9Y,C)Q,BYH=&U02P$" M% ,4 " !<@"E3Y= ;L#BY 0!?D1( $ @ 'I&P :'%Y M+3(P,C$P-S,Q+FAT;5!+ 0(4 Q0 ( %R *5-D#O.7U0T B' 0 M " 4_5 0!H<7DM,C R,3 W,S$N>'-D4$L! A0#% @ 7( I M4_D(Y0?[&0 [O@ !0 ( !4N,! &AQ>2TR,#(Q,#&UL4$L! A0#% @ 7( I4XIOC1%#1 ^O@" !0 M ( !?_T! &AQ>2TR,#(Q,#&UL4$L! A0#% @ 7( I4UP9 M%#2?N E]$' !0 ( !]$$" &AQ>2TR,#(Q,#&UL4$L! A0#% @ 7( I4_'P \:]:P 2TR,#(Q,#&UL4$L%!@ * H K ( +1F P ! $! end

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